



AUSTRALIAN NSP SURVEY

NATIONAL DATA REPORT 2009 - 2013

Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees

Never Stand Still

Medicine

The Kirby Institute

Directions ACT, Canberra. Albury Community Health Centre. Wagga Wagga Community Health Centre. Harm Reduction Services Ballina/Byron, Nimbin/Lismore, Murwillumbah/Tweed Coffs Harbour/Grafton. HIV/Hepatitis C Prevention Services, Blacktown, Parramatta, Mt Druitt. South Court Primary Care NSP, Nepean. Resource and Education Program for IDUs (REPIDU), Redfern. Gosford Needle and Syringe Program. Long Jetty Needle and Syringe Program. Health ConneXions, Liverpool. Kirketon Road Centre, K2, Kings Cross. St George NSP, Hunter Harm Reduction Services, ACON Hunter. First Step Program Illawarra, Nowra. NSW Users and AIDS Association (NUAA). Northern Territory AIDS Council, Alice Springs, Darwin, Palmerston. Biala Community Alcohol and Drug Services, Townsville ATODS. QUIHN Brisbane, Gold Coast, Sunshine Coast. West Moreton Sexual Health Service, Ipswich. Cairns Base Hospital, Kobi House, Toowoomba. SAVIVE, Norwood, Parks, Port Adelaide, Northern Metropolitan, Shopfront. Hindmarsh Centre. Nunkuwarrin Yunti Community Health Centre, Noarlunga Community Health Centre. Clarence Community Health Centre, Anglicare Hobart, Glenorchy. Salvation Army Launceston. Barwon Health Drug and Alcohol Services. Bendigo NSP. InnerSpace, Collingwood. Health Works, Footscray. North Richmond NSP Services. Health Information Exchange, St Kilda. Western Australia Substance Users Association (WASUA), Northbridge, South West Coast. WA AIDS Council Mobile NSP. Directions ACT, Canberra. Albury Community Health Centre. Wagga Wagga Community Health Centre. Harm Reduction Services Ballina/Byron, Nimbin/Lismore, Murwillumbah/Tweed Coffs Harbour/Grafton. HIV/Hepatitis C Prevention Services, Blacktown, Parramatta, Mt Druitt. South Court Primary Care NSP, Nepean. Resource and Education Program for IDUs (REPIDU), Redfern. Gosford Needle and Syringe Program. Long Jetty Needle and Syringe Program. Health ConneXions, Liverpool. Kirketon Road Centre, K2, Kings Cross. St George NSP, Hunter Harm Reduction Services, ACON Hunter. First Step Program Illawarra, Nowra. NSW Users and AIDS Association (NUAA). Northern Territory AIDS Council, Alice Springs, Darwin, Palmerston.



Kirby Institute

©The Kirby Institute
for infection and immunity in society

ISSN 1448-5915

This publication is available at: <http://www.kirby.unsw.edu.au>

The Kirby Institute
for infection and immunity in society
University of New South Wales
Sydney NSW 2052
Australia

Telephone: **02 9385 0900**
International prefix: **612**

Facsimile: **02 9385 0920**
Email: recept@kirby.unsw.edu.au

Suggested citation: Iversen, J. and Maher, L. Australian Needle and Syringe Program National Data Report 2008-2012. The Kirby Institute, University of New South Wales, 2013. ISBN: 1448-5915.

AUSTRALIAN NSP SURVEY
Prevalence of HIV, HCV and injecting and
sexual behaviour among NSP attendees

NATIONAL DATA REPORT
2009 - 2013

Report prepared by Jenny Iversen, Sammy Chow and Lisa Maher

The Kirby Institute
for infection and immunity in society
UNSW Australia
Sydney NSW 2052
Australia

May 2014

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Australia.

ACKNOWLEDGEMENTS

We would like to acknowledge the many people who assist in the development and conduct of the Australian NSP Survey, particularly the clients, staff and managers at participating NSP services. We also appreciate the dedication and vision of the founding members of the project, and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS until 2003.

Special thanks also go to Mr Philip Cunningham, Senior Scientist and Operations Manager and Ms Beth Catlett, DBS Coordinator from the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research (AMR). We also acknowledge the support of Ms Rachel McCleave and Ms Brenda Currie from the Kirby Institute and Mr Greg Smith and Ashwin Prekesh from Educational Assessment Australia, UNSW Global Pty Limited.

In 2013, the project received support and input from the following members of the Australian NSP Survey National Advisory Group: Ms Tammy Waters (ACT); Ms Rose Mason (NSW); Mr Damon Brogan (NT); Mr Robert Kemp (Chair, QLD); Mr Stephen Lymb and Ms Jenny Grant (SA); Ms Francine Smith (TAS); Mr Roland Jauernig (VIC); Ms Jude Bevan (WA); Ms Annie Madden (Australian Injecting and Illicit Drug Users League); Mr John Ryan (ANEX); and Ms Jenny Iversen (Secretariat), Professor John Kaldor and Professor Lisa Maher (Kirby Institute).

Ethical approvals were obtained from Institutional Ethics Committees associated with the investigators and participating NSP sites. The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Australia.

TABLE OF CONTENTS

Summary

Key Points.....	i
Introduction.....	1
Demographic characteristics	1
Injecting behaviour.....	2
Sexual behaviour.....	5
BBV testing, drug treatment and prison history.....	5
HIV antibody prevalence.....	6
HCV antibody prevalence.....	7
HCV treatment uptake.....	9

Tables

1. National.....	11
2. Australian Capital Territory.....	29
3. New South Wales.....	40
4. Northern Territory.....	59
5. Queensland.....	70
6. South Australia.....	88
7. Tasmania.....	104
8. Victoria.....	115
9. Western Australia.....	129

Appendix

Participating NSP services.....	143
Methodological notes.....	145
List of tables.....	146

SUMMARY: KEY POINTS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and associated risk behaviour among people who inject drugs.
- In 2013, 50 NSP services participated in the ANSPS and 2,407 NSP attendees completed the survey. The response rate was 44%.

Demographic characteristics:

- Over the period 2009 to 2013, the median age of survey respondents increased from 36 to 39 years and the median time since first injection increased from 15 to 18 years.
- The proportion of respondents aged less than 25 years decreased from 11% in 2009 to 8% in 2013, although the proportion of new initiates (less than 3 years since first injection) increased from 5% in 2010 to 7% in 2013. Almost half (49%) of new initiates in 2013 reported last injecting performance and image-enhancing drugs (PIEDs).

HIV and HCV antibody prevalence:

- Although the proportion of respondents testing HIV antibody positive was low in all years 2009 to 2013, HIV antibody prevalence increased from 1.2% in 2009 to 2.1% in 2013.
- HIV antibody prevalence was consistently higher among homosexual male respondents than among bisexual or heterosexual male respondents or female respondents in all years 2009 to 2013.
- HCV antibody prevalence increased significantly from 50% in 2009 to 54% in 2013.
- HCV antibody prevalence was highest among respondents aged 35 years or more and among those who first initiated injecting drugs more than ten years prior to survey participation in all years 2009 to 2013.

Injecting behaviour:

- Over the period 2009 to 2013, the proportion of respondents reporting daily or more frequent injection in the month prior to the survey decreased from 50% in 2009 to 44% in 2013.
- The proportion of respondents reporting heroin as the last drug injected declined from 34% in 2009 to 29% in 2013, while the proportion of respondents reporting methamphetamine as the last drug injected increased from 24% in 2009 to 29% in 2013.
- After heroin and methamphetamine, pharmaceutical opioids were the third most commonly reported class of drugs last injected in all years 2009 to 2013, with prevalence declining from 16% in 2009 to 14% in 2013.
- While relatively small proportions of survey respondents reported last injecting PIEDs, prevalence increased from 2% in 2009 to 7% in 2012 and 2013.
- Over the period 2009 to 2013, prevalence of re-use of needles and syringes (including reuse of one's own syringes), receptive sharing of needles and syringes and receptive sharing of ancillary equipment remained stable. In 2013, 24% of respondents reported re-use of needles and syringes, 16% reported receptive sharing of needles and syringes and 33% reported receptive sharing of ancillary equipment.

Introduction

The Australian Needle and Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibodies and sexual and injecting behavioural risk among people who inject drugs (PWID) in Australia. Conducted annually over a one-two week period in October, all clients attending participating Needle and Syringe Programs (NSPs) are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV antibody testing. Further details about the survey design and implementation are provided in the methodological notes to this report (page 145). This report presents national and state/territory data for the period 2009 to 2013.

In 2013, 50 NSPs participated in the ANSPS (see page 141), with one South Australian NSP participating for the first time in 2013. Over the period 2009 to 2013, the number of ANSPS respondents ranged from 2,395 to 2,697 and the annual response rate ranged from 39% to 46% (Table 1.1.1). Of the 2,407 ANSPS respondents in 2013, the vast majority (95%) were recruited from the 46 NSPs that participated in the ANSPS in all years 2009 to 2013.

Demographic Characteristics

The male to female ratio was approximately 2:1 for all survey years with less than one percent of respondents identifying as transgender. The majority of respondents identified as heterosexual, with 8% identifying as bisexual and 4% as homosexual in 2013.

The proportion of respondents from an Indigenous Australian background was stable at 11% to 13% over the period 2009 to 2013. The majority of respondents were born in Australia (86%), with the United Kingdom and Ireland (4%) and New Zealand (3%) the predominant countries of birth outside Australia in 2013. The majority of respondents also reported that their parents spoke English at home (range 93% to 95% over the period 2009 to 2013).


The proportion of respondents reporting incarceration in the 12 months prior to survey participation was also stable ranging from 9% to 13% over the period 2009 to 2013. Among those reporting recent incarceration, approximately one in three reported injecting in prison in all years 2009 to 2013 (Table 1.1.1).

The median age at survey completion increased from 36 years in 2009 to 39 years in 2013 and there was a concurrent decrease in the proportion of young injectors (aged <25 years) from 11% to 8% over the period 2009 to 2013 (χ^2 trend $p < 0.001$). The median time since first injection increased from 15 years in 2009 to 18 years in 2013, although the proportion of new injectors (injecting for less than 3 years) increased from 5% to 7% (χ^2 trend $p = 0.009$). The median age at first drug injection remained stable at 18 or 19 years over the period 2009 and 2013 (Table 1.1.1).

Injecting behaviour

Heroin remained the most commonly reported drug last injected nationally in all years 2009 to 2013, although prevalence declined from 34% in 2009 to 29% in 2013 (χ^2 trend $p=0.026$, Figure 1). In 2013, heroin was the most commonly injected drug in the Australian Capital Territory (54%) and Victoria (56%). Methamphetamine was the second most commonly reported drug last injected nationally in all years 2009 to 2013, with an increase in prevalence observed over the period 2009 to 2013 (χ^2 trend $p=0.009$). In 2013, methamphetamine was the most commonly reported drug last injected in New South Wales (32%), Queensland (29%), South Australia (38%) and Western Australia (36%).

Figure 1. Proportion of respondents (%) reporting last injecting heroin, methamphetamine and all other drugs, 2009–2013




The third most commonly reported class of drugs last injected nationally was pharmaceutical opioids (including morphine and oxycodone), with a decline in prevalence observed over the period 2009 to 2013 (χ^2 trend $p=0.032$, Figure 2). As in previous years, pharmaceutical opioids were the drug most commonly injected in the Northern Territory (61%) and Tasmania (33%) in 2013.

Methadone was reported as the last drug injected by less than ten percent of ANSPS respondents in all years 2009 to 2013, and prevalence declined from 9% to 7% over the period 2009 to 2013 (χ^2 trend $p=0.011$). Methadone was the second most commonly reported drug last injected in Tasmania (27%) in 2013. Buprenorphine and buprenorphine-naloxone injection were reported as the last drug injected by a minority of survey respondents in all survey years, with prevalence of 3% and 2% respectively in 2013.


One percent of survey respondents reported cocaine as the last drug injected and, as in previous years, the majority of reports in 2013 occurred in New South Wales (Table 3.1.2). A significant increase in the prevalence of PIEDs as the last drug injected occurred over the period 2009 to 2013 (χ^2 trend $p < 0.001$, Figure 2), although as in previous years, the increase was confined to NSW (4% to 11%, χ^2 trend $p < 0.001$, Table 3.1.2) and QLD (1% to 13%, χ^2 trend $p < 0.001$, Table 5.1.2). Prevalence of PIEDs injection was 2% or less in all other jurisdictions in all years 2009 to 2013. PIEDs were the most commonly reported drugs last injected among new initiates to injecting (less than 3 years since first injection), with more than half (55%) of new initiates reporting last injecting PIEDs in 2013.

Figure 2. Proportion of respondents (%) reporting last injecting pharmaceutical opioids, methadone and performance and image enhancing drugs, 2009–2013




In 2013, ANSPS respondents were asked to report all drugs injected in the previous 12 months (Table 1.1.7). More than half of respondents reported injecting methamphetamine (60%) or heroin (52%) and one in three (33%) reported injection of pharmaceutical opioids in the previous 12 months (Figure 3). Although more than half (54%) of respondents who last injected methamphetamine did not inject any other drugs in the previous 12 months, substantial proportions of respondents who last injected opioids (43% heroin, 44% methadone, 48% pharmaceutical opioids, and 65% buprenorphine/ buprenorphine-naloxone) had also injected methamphetamine in the previous 12 months. Among respondents who last injected PIEDs, 12% reported injection of other drugs in the last 12 months. Although cocaine was reported as the last drug injected by a minority (1%, $n=31$) of ANSPS respondents, 11% ($n=260$) of respondents reported injection of cocaine in the previous 12 months, with reports of cocaine injection occurring in all jurisdictions.

Figure 3. Proportion of respondents (%) by last drug injected and all drugs injected in the last 12 months, 2013



The proportion of ANSPS respondents who reported daily or more frequent injection in the month prior to survey participation declined from 50% in 2009 to 44% in 2013 (χ^2 trend $p=0.044$, Table 1.1.1). Prevalence of at least one public injection (injection in a car, beach, park, street or squat) in the month prior to survey completion also declined, from 45% in 2009 to 39% in 2013 (χ^2 trend $p=0.005$). In 2013, 14% of respondents reported being present when someone injected for the first time in the last 12 months.

Figure 4. Proportion of respondents (%) reporting reuse and receptive sharing of a needle and syringe and receptive sharing of ancillary equipment in the last month, 2009–2013



The proportion of respondents reporting reuse of needles and syringes (including one's own) in the month preceding the survey was stable at between 21% and 24% over the period 2009 to 2013 (χ^2 trend $p=0.244$, Figure 4). Prevalence of receptive sharing of needles and syringes (range 12% to 16%, χ^2 trend $p=0.606$) and prevalence of receptive sharing of ancillary equipment (range 25% to 33%, χ^2 trend $p=0.7867$) were also stable over the period 2009 to 2013. As in previous years, spoons and water were the most commonly identified receptively shared ancillary items in 2013 (Table 1.1.2).

Sexual behaviour

In each of the past five years, just under half of respondents reported sex with a regular sex partner in the month prior to survey completion (range 45% to 49%). Of these, a majority (69% to 72%) reported that they did not use condoms with their regular sex partner. A smaller proportion of respondents (14% to 15%) reported sex with other sex partners in the month preceding survey participation, although condom use was higher among this group, with around one third (range 32% to 25%) reporting that they did not use condoms. The proportion of respondents reporting commercial sex work in the month prior to the survey remained low and stable at 4% to 5% over the last five years, while use of condoms at last commercial sex was high at between 78% and 85% in all years between 2009 and 2013 (Table 1.1.3).

BBV testing, drug treatment and prison history

ANSPS respondents reported high rates of lifetime HIV and HCV testing in all of the last five years. In 2013, the proportion of respondents reporting previous HIV and HCV tests were similar, with half of respondents (50% and 51% respectively) reporting a test in the previous 12 months and one third (34% and 32% respectively) reporting a test more than 12 months ago (Table 1.1.5).

Respondents also reported high rates of engagement with drug treatment services, with three quarters (75%) of 2013 respondents reporting current or previous drug treatment. The proportion of respondents reporting methadone maintenance treatment at the time of survey participation remained stable at between 29% and 31% over the last five years. In 2013, 8% of survey respondents reported current buprenorphine treatment and a further 9% reported current buprenorphine-naloxone treatment (Table 1.1.4).

Around one half of respondents reported a lifetime history of imprisonment (47% to 50%) over the period 2009 to 2013, while a minority (9% to 13%) reported incarceration in the 12 months prior to survey completion. Among those reporting recent incarceration, around one third (29% to 34%) reported injecting in prison (Table 1.1.1).

HIV antibody prevalence

Although the overall proportion of respondents testing HIV antibody positive was low in all of the past five years, HIV antibody prevalence increased from 1.2% in 2009 to 2.1% in 2013 (χ^2 trend $p=0.006$, Table 1.2.1). As shown in Figure 5, HIV antibody prevalence was highest in New South Wales (3.2% in 2013) and lowest in the Australian Capital Territory and Tasmania where there were no HIV antibody positive respondents in any of the previous five years.

Figure 5. HIV antibody prevalence (%) by jurisdiction, 2009–2013





Figure 6. HIV antibody prevalence (%) by gender and sexual identity, 2009–2013




Nationally, HIV antibody prevalence was consistently higher among homosexual male respondents than among bisexual or heterosexual male respondents or female respondents in all survey years (Figure 6). Methamphetamine was the most commonly reported drug last injected among HIV antibody positive respondents in all survey years 2009 to 2013 (Table 1.2.5). In 2013, the median age of HIV antibody positive respondents was 44 years (range 24-63 years) and respondents first injected a median of 16 years prior to survey participation (range <1 to 40 years).

HCV antibody prevalence

Nationally, HCV antibody prevalence increased from 50% in 2009 to 54% in 2013 (χ^2 trend $p=0.020$, Table 1.3.1). Over the period 2009 to 2013, HCV antibody prevalence increased in Victoria (55% to 67%, χ^2 trend $p<0.001$) and declined in New South Wales (58% to 54%, χ^2 trend $p=0.021$). HCV antibody prevalence was stable in all other jurisdictions (Figure 7).

Figure 7. HCV antibody prevalence (%) by jurisdiction, 2009–2013



HCV antibody prevalence was significantly higher among respondents with longer injection histories and among older respondents in all years 2009 to 2013 (Table 1.3.3 and 1.3.4). HCV antibody prevalence was also higher among respondents reporting heroin or pharmaceutical opioids as the last drug injected compared to those reporting methamphetamine (Figure 8). HCV antibody prevalence was also consistently higher among respondents reporting imprisonment in the year prior to survey completion than among those not reporting recent imprisonment in any of the past five years (Figure 9).

Figure 8. HCV antibody prevalence (%) by drug last injected and gender, 2009–2013






Figure 9. HCV antibody prevalence (%) by imprisonment in the previous 12 months and gender, 2009–2013



HCV treatment uptake

Among respondents who self-reported a previous positive HCV test, the proportion who reported a lifetime history of HCV antiviral treatment remained stable at between 9% and 11% over the period 2009 to 2013 (χ^2 trend $p=0.246$, Figure 10). Similarly, the proportion of respondents who reported current HCV antiviral treatment was also stable at between 1% and 2% over the same period (χ^2 trend $p=0.372$).

Figure 10. Proportion of respondents (%) reporting lifetime and current antiviral treatment among those self-reporting HCV antibody positive serostatus, 2009–2013



* Current treatment is defined as within the previous 12 months from 2013

Among respondents who reported a lifetime history of HCV antiviral treatment in 2013 ($n=140$), the vast majority (61%) received treatment within a hospital setting with other treatment settings including prisons (13%), opioid substitution therapy clinics (6%), primary health care facilities (3%) and general practice (3%). Among respondents who self-reported a previous positive HCV test and who had no history of HCV treatment ($n=1,090$), more than one third (38%) reported being definitely willing to receive treatment, with a further one in five (20%) being somewhat willing to receive treatment in the future.

National

Table 1.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2009	2010	2011	2012	2013
Number of sites	51	52	52	52	50
N° surveyed	N=2697	N=2396	N=2395	N=2391	N=2407
Response (%)	45%	39%	41%	46%	44%
Gender (%)					
Male	1756 (65)	1611 (67)	1602 (67)	1623 (68)	1636 (68)
Female	924 (34)	771 (32)	780 (33)	753 (31)	754 (31)
Transgender	9 (<1)	8 (<1)	10 (<1)	11 (<1)	13 (<1)
Not reported	8 (<1)	6 (<1)	3 (<1)	4 (<1)	4 (<1)
Sexual identity (%)					
Heterosexual	2236 (83)	1987 (83)	1982 (83)	1949 (82)	1934 (80)
Bisexual	236 (9)	195 (8)	208 (9)	210 (9)	180 (7)
Homosexual	89 (3)	88 (4)	96 (4)	82 (3)	108 (4)
Not reported	136 (5)	126 (5)	109 (5)	150 (6)	185 (8)
Age and duration of injection (years)					
<i>Median age</i>	36	37	37	38	39
<i>Age range</i>	15-66	15-73	16-65	16-71	15-67
<i>Age group (%)</i>					
<25 years	285 (11)	203 (8)	182 (8)	176 (7)	181 (8)
25+ years	2411 (89)	2191 (91)	2205 (92)	2212 (93)	2217 (92)
Not reported	1 (<1)	2 (<1)	1 (<1)	3 (<1)	9 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	19
<i>Age range</i>	10-58	10-63	10-56	10-70	10-61
<i>N° not reported</i>	67	51	62	67	91
<i>Median years IDU</i>	15	16	17	17	18
<i>Range</i>	<1-46	<1-60	<1-41	<1-53	<1-51
<i>Duration of drug injection (%)</i>					
<3 years	162 (6)	131 (5)	168 (7)	173 (7)	177 (7)
3+ years	2468 (92)	2213 (92)	2162 (90)	2150 (90)	2139 (89)
Not reported	67 (2)	52 (2)	65 (3)	68 (3)	91 (4)
Aboriginal and Torres Strait Islander origin (%)					
No	2296 (85)	2071 (86)	2065 (86)	2056 (86)	2003 (83)
Yes	323 (12)	275 (11)	276 (12)	294 (12)	324 (13)
Not reported	78 (3)	50 (2)	54 (2)	41 (2)	80 (3)
Region/Country of birth					
Australia	2333 (87)	2088 (87)	2046 (85)	2070 (87)	2070 (86)
Other Oceania	85 (3)	76 (3)	80 (3)	86 (4)	74 (3)
Asia	25 (1)	29 (1)	31 (1)	26 (1)	35 (1)
UK & Ireland	120 (4)	94 (4)	111 (5)	105 (4)	108 (4)
Other	89 (3)	69 (3)	101 (4)	85 (4)	109 (5)
Not reported	45 (2)	40 (2)	26 (1)	19 (<1)	11 (<1)
Main language spoke at home by parents					
English speaking	2548 (94)	2275 (95)	2237 (93)	2252 (94)	2239 (93)
Non-English speaking	113 (4)	90 (4)	134 (6)	129 (5)	159 (7)
Not reported	36 (1)	31 (1)	24 (1)	10 (<1)	9 (<1)
Imprisonment last year (%)					
No	2238 (83)	1762 (74)	2049 (86)	2037 (87)	1990 (83)
Yes	339 (13)	226 (9)	238 (10)	261 (11)	252 (10)
Not reported	120 (4)	408 (17)	108 (5)	56 (2)	165 (7)
Injected in prison last year (%)	N=339	N=226	N=238	N=261	N=252
Yes	113 (33)	69 (31)	75 (32)	90 (34)	74 (29)
Frequency of injection last month (%)					
Not last month	270 (10)	259 (11)	250 (10)	235 (10)	223 (9)
Less than weekly	418 (15)	423 (18)	387 (16)	444 (19)	451 (19)
Weekly not daily	618 (23)	563 (24)	563 (24)	554 (23)	590 (25)
Daily or more	1361 (50)	1119 (47)	1159 (48)	1130 (47)	1070 (44)
Not reported	30 (1)	32 (1)	36 (2)	28 (1)	73 (3)

Table 1.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2009	2010	2011	2012	2013
Last drug injected (%)	N=2697	N=2396	N=2395	N=2391	N=2407
Cocaine	66 (2)	31 (1)	23 (1)	21 (1)	31 (1)
Heroin	917 (34)	808 (34)	802 (33)	799 (33)	709 (29)
Methadone	232 (9)	177 (7)	173 (7)	159 (7)	163 (7)
Methamphetamine	657 (24)	628 (26)	649 (27)	621 (26)	703 (29)
Performance/Image-enhancing drugs	43 (2)	57 (2)	109 (5)	162 (7)	157 (7)
Pharmaceutical opioids	426 (16)	382 (16)	358 (15)	341 (14)	332 (14)
Suboxone®	35 (1)	46 (2)	43 (2)	46 (2)	46 (2)
Subutex®/Buprenorphine	134 (5)	100 (4)	94 (4)	84 (4)	78 (3)
More than one	86 (3)	118 (5)	106 (4)	121 (5)	156 (6)
Other drug	34 (1)	37 (2)	33 (1)	22 (1)	19 (1)
Not reported	67 (2)	12 (<1)	5 (<1)	15 (1)	13 (1)
N° Injected last month	N=2397	N=2109	N=2109	N=2128	N=2111
Places injected last month (%)					
Any public	1079 (45)	887 (42)	882 (42)	836 (39)	828 (39)
All private	1298 (54)	1069 (51)	1154 (55)	1222 (57)	1262 (60)
Not reported	20 (1)	153 (7)	73 (3)	70 (3)	21 (1)
Use of sterile needles & syringes last month (%)					
All injections	1783 (74)	1477 (70)	1569 (74)	1593 (75)	1586 (75)
Most of the time	503 (21)	398 (19)	383 (18)	366 (17)	420 (20)
Half of the time	39 (2)	38 (2)	41 (2)	36 (2)	34 (2)
Some of the time	35 (1)	28 (1)	26 (1)	21 (1)	31 (1)
Not last month	8 (<1)	8 (<1)	4 (<1)	15 (<1)	9 (<1)
Not reported	29 (1)	160 (8)	86 (4)	97 (5)	31 (1)
Re-used someone else's used needle & syringe last month (%)					
None	1963 (82)	1595 (76)	1663 (79)	1713 (81)	1770 (84)
Once	124 (5)	87 (4)	104 (5)	148 (7)	105 (5)
Twice	93 (4)	70 (3)	80 (4)	60 (3)	79 (4)
3-5 times	86 (4)	58 (3)	74 (4)	61 (3)	63 (3)
>5 times	73 (3)	47 (2)	58 (3)	67 (3)	67 (3)
Not reported	58 (2)	252 (12)	130 (6)	79 (4)	27 (1)
Number of people needle & syringe was re-used after last month (%)					
None	1963 (82)	1595 (76)	1663 (79)	1713 (81)	1770 (84)
One	185 (8)	127 (6)	166 (8)	158 (7)	139 (7)
Two	26 (1)	21 (1)	23 (1)	23 (1)	31 (1)
Three to five	15 (<1)	25 (1)	14 (<1)	11 (<1)	13 (1)
More than five	10 (<1)	19 (1)	14 (<1)	22 (1)	19 (1)
Don't know	58 (2)	41 (2)	64 (3)	48 (2)	69 (3)
Not reported	140 (6)	281 (13)	165 (8)	153 (7)	70 (3)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	151 (6)	177 (8)	196 (9)	113 (5)	131 (6)
Casual sex partner	4 (<1)	16 (<1)	9 (<1)	8 (<1)	19 (1)
Close friend	86 (4)	105 (5)	125 (6)	96 (5)	88 (4)
Acquaintance	32 (1)	38 (2)	59 (3)	44 (2)	54 (3)
Other	29 (1)	38 (2)	48 (2)	21 (1)	32 (2)
Equipment used after someone else last month (%)*					
Spoon	541 (25)	446 (21)	481 (22)	450 (21)	511 (24)
Water	358 (16)	316 (15)	310 (15)	311 (15)	373 (18)
Filter	273 (12)	212 (10)	222 (11)	226 (11)	241 (11)
Drug mix	202 (9)	177 (8)	174 (8)	190 (9)	189 (9)
None	1409 (64)	1319 (63)	1387 (66)	1421 (67)	1436 (68)
Injected by someone after that person injected themselves or others last month (%)					
No	1958 (82)	1639 (78)	1731 (82)	1745 (82)	1754 (83)
Yes	387 (16)	242 (11)	283 (13)	284 (13)	278 (13)
Not reported	52 (2)	228 (11)	95 (5)	99 (5)	79 (4)
Present when someone injected for the first time in the last 12 months (%)**					
Yes	--	--	--	320 (15)	290 (14)
Overdosed in the last 12 months **					
Yes	--	--	--	--	279 (12)

* More than one option could be selected ** New question in 2012 or 2013

Table 1.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2009	2010	2011	2012	2013
N° surveyed	N=2697	N=2396	N=2395	N=2391	N=2407
Sex with a regular partner last month (%)					
No	1215 (45)	1082 (45)	1105 (46)	1173 (49)	1176 (49)
Yes	1382 (51)	1210 (51)	1135 (47)	1152 (48)	1151 (48)
Not reported	100 (4)	104 (4)	157 (7)	66 (3)	80 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=1382	N=1210	N=1135	N=1152	N=1151
Never	999 (72)	840 (69)	800 (71)	815 (71)	801 (70)
Sometimes	179 (13)	154 (13)	133 (12)	147 (13)	166 (14)
Every time	135 (10)	145 (12)	141 (12)	127 (11)	113 (10)
Not reported	69 (5)	71 (6)	59 (5)	63 (5)	71 (6)
Sex with other partner/s last month (%)					
No	2186 (81)	1923 (80)	1966 (82)	1953 (82)	1929 (80)
Yes	378 (14)	327 (14)	330 (14)	336 (14)	364 (15)
Not reported	133 (5)	146 (6)	99 (4)	102 (4)	114 (5)
Condom used with other partner/s last month (%)					
N° surveyed	N=378	N=327	N=330	N=336	N=364
Never	129 (34)	116 (35)	108 (33)	115 (34)	117 (32)
Sometimes	96 (25)	72 (22)	80 (24)	92 (27)	103 (28)
Every time	148 (39)	124 (38)	127 (38)	109 (32)	128 (35)
Not reported	5 (1)	15 (5)	15 (5)	20 (6)	16 (4)
Sex work last month (%)					
No	2458 (91)	2092 (87)	2169 (91)	2195 (92)	2141 (89)
Yes	130 (5)	128 (5)	114 (5)	119 (5)	98 (4)
Not reported	109 (4)	176 (7)	112 (5)	77 (3)	168 (7)
Condom used at last sex work last month (%)					
Yes	106 (84)	95 (78)	88 (85)	98 (84)	72 (83)

Table 1.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2009	2010	2011	2012	2013
N° surveyed	N=2697	N=2396	N=2395	N=2391	N=2407
Any treatment/therapy for drug use (%)					
No	509 (19)	425 (18)	489 (20)	539 (23)	575 (24)
Yes	2144 (80)	1910 (80)	1842 (77)	1826 (76)	1800 (75)
Not reported	44 (2)	61 (3)	64 (3)	26 (1)	32 (1)
History of methadone maintenance treatment (%)					
Currently	823 (31)	725 (30)	693 (29)	712 (30)	718 (29)
Previously	645 (24)	600 (25)	586 (24)	622 (26)	559 (23)
Never	1167 (43)	946 (39)	1006 (42)	1041 (44)	1112 (46)
Not reported	62 (2)	125 (5)	110 (5)	16 (1)	18 (1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	339 (13)	267 (11)	231 (10)	241 (10)	193 (8)
Previously	679 (25)	637 (27)	641 (27)	665 (28)	694 (29)
Never	1621 (60)	1461 (61)	1426 (60)	1456 (61)	1475 (61)
Not reported	58 (2)	31 (1)	97 (4)	29 (1)	45 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	211 (8)	200 (8)	224 (9)	245 (10)	219 (9)
Previously	411 (15)	413 (17)	438 (18)	469 (20)	529 (22)
Never	2003 (74)	1737 (73)	1640 (68)	1639 (69)	1602 (67)
Not reported	72 (3)	46 (2)	93 (4)	38 (2)	57 (2)

Table 1.1.5 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

	2009	2010	2011	2012	2013
N° surveyed	N=2697	N=2396	N=2395	N=2391	N=2407
Previous HIV test (%)					
Yes, last year	1360 (50)	1141 (48)	1172 (49)	1157 (48)	1205 (50)
> 1 year ago	922 (34)	819 (34)	849 (35)	840 (35)	812 (34)
Never tested	310 (11)	282 (12)	287 (12)	299 (13)	320 (13)
Not reported	105 (4)	154 (6)	87 (4)	95 (4)	70 (3)
Previous HCV test (%)					
Yes, last year	1549 (57)	1280 (53)	1289 (54)	1305 (55)	1235 (51)
> 1 year ago	855 (32)	750 (31)	794 (33)	781 (33)	778 (32)
Never tested	196 (7)	190 (8)	169 (7)	181 (8)	196 (8)
Not reported	97 (4)	176 (7)	143 (6)	124 (5)	198 (8)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=1383	N=1274	N=1267	N=1269	N=1230
Interferon/Interferon+Ribavirin	126 (9)	136 (11)	121 (10)	122 (10)	129 (10)
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	11 (1)
Other	17 (1)	17 (1)	18 (1)	14 (1)	16 (1)
No treatment	1174 (85)	1072 (84)	1054 (83)	1078 (85)	1017 (83)
Not reported	66 (5)	49 (4)	74 (6)	55 (4)	57 (5)
Current treatment for HCV**	N=25	N=32	N=36	N=27	N=39
Interferon/Interferon+Ribavirin	21	26	28	18	24
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	9
Other	4	6	8	9	6

* New treatment options added ** 'Current treatment' defined as within the previous 12 months from 2013

Table 1.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month by survey year

Source of needles/syringes (%)*	2009	2010	2011	2012	2013
N° Injected last month	N=2397	N=2109	N=2109	N=2128	N=2111
Needle Syringe Program	1569 (65)	2063 (86)	1917 (91)	1888 (89)	1952 (92)
Chemist/Pharmacy	601 (25)	450 (19)	415 (20)	503 (24)	436 (21)
Personal sources	418 (17)	256 (11)	184 (9)	248 (12)	197 (9)
Dispensing/Vending Machine	222 (9)	181 (8)	205 (10)	255 (12)	240 (11)
Other sources	69 (3)	77 (3)	35 (2)	18 (1)	42 (2)

* More than one option could be selected

Table 1.1.7 Number (percentage) of respondents by last drug injected and all drugs injected in the last 12 months (2013)

Last drug injected	N° (%)	Drugs injected in last 12 months*							
		Cocaine	Heroin	Methadone	Methamphetamine	PIEDs	Pharm. Opioids	Subutex/Suboxone	No other drugs
Cocaine	31 (1)	31 (100)	9 (29)	4 (13)	10 (32)	1 (3)	4 (13)	1 (3)	13 (42)
Heroin	709 (29)	80 (11)	709 (100)	104 (15)	305 (43)	7 (1)	177 (25)	79 (11)	284 (40)
Methadone	163 (7)	8 (5)	59 (36)	163 (100)	71 (44)	4 (2)	45 (28)	10 (6)	55 (34)
Methamphetamine	703 (29)	79 (11)	194 (28)	87 (12)	703 (100)	14 (2)	123 (18)	96 (14)	378 (54)
PIEDs	157 (7)	0 (0)	1 (<1)	0 (0)	2 (1)	157 (100)	2 (1)	4 (3)	138 (88)
Pharm. opioids	332 (14)	26 (8)	140 (42)	83 (25)	161 (48)	16 (5)	332 (100)	50 (15)	0 (0)
Subutex/Suboxone	124 (5)	8 (6)	51 (41)	17 (14)	77 (62)	3 (2)	39 (31)	124 (100)	28 (23)
Other/Not reported	188 (8)	28 (15)	96 (51)	60 (32)	123 (65)	12 (6)	76 (40)	51 (27)	22 (12)
Total	2407	260 (11)	1259 (52)	518 (22)	1452 (60)	214 (9)	798 (33)	415 (17)	919 (38)

* More than one option could be selected

HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009	1725	28 (1.6)	915	2 (0.2)	2657	31 (1.2)
2010	1579	21 (1.3)	759	2 (0.3)	2352	23 (1.0)
2011	1560	21 (1.4)	764	7 (0.9)	2337	29 (1.2)
2012	1546	18 (1.2)	718	9 (1.3)	2279	28 (1.2)
2013	1563	41 (2.6)	727	6 (0.8)	2307	48 (2.1)
X ² trend p value		0.074		0.015		0.006

* Totals include people whose gender was not reported or reported as transgender

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Heterosexual	1510	7 (0.5)	682	2 (0.3)	2207	9 (0.4)
Bisexual	78	2 (2.5)	146	0 (0.0)	229	3 (1.3)
Homosexual	30	18 (37.5)	37	0 (0.0)	87	18 (20.7)
p value		<0.001		1.000		<0.001
2010						
Heterosexual	1390	4 (0.3)	558	2 (0.4)	1954	6 (0.3)
Bisexual	61	3 (4.9)	124	0 (0.0)	188	3 (1.6)
Homosexual	48	14 (29.2)	36	0 (0.0)	85	14 (16.5)
p value		<0.001		1.000		<0.001
2011						
Heterosexual	1393	6 (0.4)	547	5 (0.9)	1943	11 (0.6)
Bisexual	57	3 (5.3)	141	2 (1.4)	203	6 (3.0)
Homosexual	51	12 (23.5)	38	0 (0.0)	91	12 (13.2)
p value		<0.001		0.751		<0.001
2012						
Heterosexual	1350	4 (0.3)	506	8 (1.5)	1859	12 (0.7)
Bisexual	69	2 (2.9)	127	0 (0.0)	200	3 (1.5)
Homosexual	42	9 (21.4)	31	0 (0.0)	77	9 (11.7)
p value		<0.001		0.570		<0.001
2013						
Heterosexual	1322	9 (0.7)	519	6 (1.2)	1848	15 (0.8)
Bisexual	59	6 (10.2)	114	0 (0.0)	175	7 (4.0)
Homosexual	73	24 (32.9)	26	0 (0.0)	105	24 (22.9)
p value		<0.001		0.684		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.3 HIV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
< 25 years	156	1 (0.6)	117	0 (0.0)	275	1 (0.4)
25 – 34	575	7 (1.2)	346	0 (0.0)	925	7 (0.8)
35+ years	984	20 (1.6)	446	1 (0.2)	1441	22 (1.5)
p value		0.282		0.593		0.100
2010						
< 25 years	105	1 (1.0)	90	0 (0.0)	197	1 (0.5)
25 – 34	502	3 (0.6)	263	0 (0.0)	766	3 (0.4)
35+ years	970	16 (1.7)	405	2 (0.5)	1386	18 (1.3)
p value		0.226		0.629		0.089
2011						
< 25 years	118	1 (0.9)	56	2 (3.6)	176	3 (1.7)
25 – 34	457	1 (0.2)	287	1 (0.4)	748	2 (0.3)
35+ years	979	19 (1.9)	419	4 (1.0)	1404	24 (1.3)
p value		0.015		0.116		0.005
2012						
< 25 years	130	0 (0.0)	38	0 (0.0)	169	0 (0.0)
25 – 34	412	0 (0.0)	241	3 (1.2)	657	5 (0.8)
35+ years	1003	16 (1.6)	438	6 (1.4)	1451	23 (1.6)
p value		0.134		1.000		0.113
2013						
< 25 years	110	2 (1.8)	60	0 (0.0)	170	2 (1.2)
25 – 34	394	6 (1.5)	215	2 (0.9)	616	9 (1.5)
35+ years	1052	33 (3.1)	451	4 (0.9)	1512	37 (2.5)
p value		0.229		1.000		0.304

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.4 HIV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
<3 years	90	2 (2.2)	67	0 (0.0)	158	2 (1.3)
3 to 10 years	317	5 (1.6)	237	0 (0.0)	558	5 (0.9)
11 + years	1279	21 (1.6)	585	1 (0.2)	1875	23 (1.2)
p value		0.909		0.771		0.807
2010						
<3 years	87	2 (2.3)	36	0 (0.0)	124	2 (1.6)
3 to 10 years	253	3 (1.2)	181	0 (0.0)	435	3 (0.7)
11 + years	1202	15 (1.3)	527	2 (0.4)	1740	17 (1.0)
p value		0.562		1.000		0.560
2011						
<3 years	114	2 (1.8)	48	0 (0.0)	163	2 (1.2)
3 to 10 years	251	4 (1.6)	152	2 (1.3)	404	6 (1.5)
11 + years	1148	15 (1.3)	549	5 (0.9)	1707	21 (1.2)
p value		0.731		0.780		0.845
2012						
<3 years	126	1 (0.8)	35	0 (0.0)	162	1 (0.6)
3 to 10 years	242	3 (1.2)	129	3 (2.3)	373	6 (1.6)
11 + years	1134	14 (1.2)	535	6 (1.1)	1680	21 (1.3)
p value		1.000		0.615		0.701
2013						
<3 years	120	5 (4.2)	38	0 (0.0)	160	5 (3.1)
3 to 10 years	228	10 (4.4)	140	0 (0.0)	369	10 (2.7)
11 + years	1150	25 (2.2)	527	6 (1.1)	1689	32 (1.9)
p value		0.079		0.536		0.323

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.5 HIV antibody prevalence by last drug injected, gender and survey year

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Heroin	591	5 (0.9)	311	1 (0.3)	907	6 (0.7)
Methamphetamine	402	15 (3.7)	243	1 (0.4)	649	16 (2.5)
Other	687	8 (1.2)	337	0 (0.0)	1032	9 (0.9)
p value		0.001		0.507		0.002
2010						
Heroin	522	6 (1.2)	272	2 (0.7)	797	8 (1.0)
Methamphetamine	396	10 (2.5)	210	0 (0.0)	612	10 (1.6)
Other	652	4 (0.6)	273	0 (0.0)	930	4 (0.4)
p value		0.028		0.207		0.052
2011						
Heroin	513	2 (0.4)	267	4 (1.5)	783	7 (0.9)
Methamphetamine	382	12 (3.1)	247	1 (0.4)	632	13 (2.1)
Other	662	7 (1.1)	248	2 (0.8)	917	9 (1.0)
p value		0.002		0.518		0.122
2012						
Heroin	507	2 (0.4)	262	6 (2.3)	773	9 (1.2)
Methamphetamine	355	8 (2.3)	216	2 (0.9)	577	10 (1.7)
Other	673	8 (1.2)	236	1 (0.4)	914	9 (1.0)
p value		0.045		0.167		0.467
2013						
Heroin	449	5 (1.1)	230	4 (1.7)	683	9 (1.3)
Methamphetamine	413	24 (5.8)	249	2 (0.8)	668	26 (3.9)
Other	692	12 (1.7)	245	0 (0.0)	943	13 (1.4)
p value		<0.001		0.088		0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Less than daily	645	12 (1.9)	371	2 (0.5)	1023	14 (1.4)
Daily or more	896	12 (1.3)	434	0 (0.0)	1339	13 (1.0)
Not last month	169	4 (2.4)	96	0 (0.0)	266	4 (1.5)
p value		0.535		0.239		0.591
2010						
Less than daily	696	9 (1.3)	351	2 (0.6)	1053	11 (1.0)
Daily or more	705	4 (0.6)	309	0 (0.0)	1018	4 (0.4)
Not last month	156	7 (4.5)	92	0 (0.0)	252	7 (2.8)
p value		0.002		0.616		0.004
2011						
Less than daily	619	11 (1.8)	306	3 (1.0)	929	15 (1.6)
Daily or more	752	5 (0.7)	369	4 (1.1)	1127	9 (0.8)
Not last month	161	4 (2.5)	83	0 (0.0)	246	4 (1.6)
p value		0.047		1.000		0.179
2012						
Less than daily	632	8 (1.3)	312	6 (1.9)	953	15 (1.6)
Daily or more	748	6 (0.8)	324	3 (0.9)	1076	9 (0.8)
Not last month	146	4 (2.7)	78	0 (0.0)	225	4 (1.8)
p value		0.111		0.483		0.209
2013						
Less than daily	662	20 (3.0)	334	5 (1.5)	1001	25 (2.5)
Daily or more	713	13 (1.8)	310	1 (0.3)	1031	15 (1.5)
Not last month	146	6 (4.1)	61	0 (0.0)	208	6 (2.9)
p value		0.172		0.339		0.171

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No receptive sharing	1268	24 (1.9)	653	2 (0.3)	1936	27 (1.4)
Receptive sharing	238	0 (0.0)	133	0 (0.0)	372	0 (0.0)
p value		0.023		1.000		0.015
2010						
No receptive sharing	1066	14 (1.3)	499	1 (0.2)	1570	15 (1.0)
Receptive sharing	167	1 (0.6)	89	1 (1.1)	257	2 (0.8)
p value		0.708		0.028		1.000
2011						
No receptive sharing	1093	15 (1.4)	529	7 (1.3)	1627	22 (1.4)
Receptive sharing	198	1 (0.5)	105	0 (0.0)	306	1 (0.3)
p value		0.491		0.607		0.158
2012						
No receptive sharing	1117	12 (1.1)	506	9 (1.8)	1634	22 (1.4)
Receptive sharing	220	0 (0.0)	100	0 (0.0)	320	0 (0.0)
p value		0.234		0.368		0.037
2013						
No receptive sharing	1155	27 (2.3)	534	6 (1.1)	1701	33 (1.9)
Receptive sharing	207	4 (1.9)	98	0 (0.0)	306	5 (1.6)
p value		1.000		0.597		1.000

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No imprisonment	1402	27 (1.9)	794	2 (0.3)	2213	30 (1.4)
Imprisonment	245	1 (0.4)	88	0 (0.0)	333	1 (0.3)
p value		0.108		1.000		0.172
2010						
No imprisonment	1119	18 (1.6)	605	2 (0.3)	1737	20 (1.1)
Imprisonment	167	1 (0.6)	52	0 (0.0)	219	1 (0.5)
p value		0.497		1.000		0.502
2011						
No imprisonment	1303	21 (1.6)	683	6 (0.9)	1997	28 (1.4)
Imprisonment	176	0 (0.0)	56	1 (1.8)	233	1 (0.4)
p value		0.163		0.425		0.356
2012						
No imprisonment	1289	17 (1.3)	639	9 (1.4)	1942	27 (1.4)
Imprisonment	199	1 (0.5)	47	0 (0.0)	247	1 (0.4)
p value		0.496		1.000		0.360
2013						
No imprisonment	1266	36 (2.8)	634	6 (1.0)	1912	43 (2.3)
Imprisonment	189	4 (2.1)	50	0 (0.0)	241	4 (1.7)
p value		0.811		1.000		0.814

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No condom use	671	4 (0.6)	483	1 (0.2)	1162	5 (0.4)
Condom use	91	4 (4.4)	41	0 (0.0)	132	4 (3.0)
p value		0.009		1.000		0.009
2010						
No condom use	506	6 (1.2)	313	0 (0.0)	823	6 (0.7)
Condom use	188	2 (1.1)	102	2 (2.0)	292	4 (1.4)
p value		1.000		0.060		0.299
2011						
No condom use	475	6 (1.3)	308	3 (1.0)	784	9 (1.2)
Condom use	179	4 (2.2)	82	1 (1.2)	263	5 (1.9)
p value		0.473		1.000		0.359
2012						
No condom use	475	2 (0.4)	287	2 (0.7)	767	4 (0.5)
Condom use	173	7 (4.1)	90	2 (2.2)	263	9 (3.4)
p value		0.002		0.242		0.001
2013						
No condom use	448	6 (1.3)	319	1 (0.3)	770	7 (0.9)
Condom use	187	8 (4.3)	76	2 (2.6)	268	11 (4.1)
p value		0.022		0.096		0.001

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 1.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No sex work	1612	26 (1.6)	790	2 (0.3)	2425	29 (1.2)
Sex work	36	2 (5.6)	90	0 (0.0)	129	2 (1.6)
p value		0.122		1.000		0.668
2010						
No sex work	1427	18 (1.3)	619	2 (0.3)	2057	20 (1.0)
Sex work	42	2 (4.8)	84	0 (0.0)	127	2 (1.6)
p value		0.110		1.000		0.369
2011						
No sex work	1452	19 (1.3)	666	6 (0.9)	2125	25 (1.2)
Sex work	29	0 (0.0)	75	1 (1.3)	108	2 (1.9)
p value		1.000		0.528		0.378
2012						
No sex work	1451	17 (1.2)	629	8 (1.3)	2090	25 (1.2)
Sex work	37	1 (2.7)	72	1 (1.4)	114	3 (2.6)
p value		0.366		1.000		0.174
2013						
No sex work	1415	35 (2.5)	624	6 (1.0)	2052	41 (2.0)
Sex work	36	4 (11.1)	56	0 (0.0)	94	5 (5.3)
p value		0.014		1.000		0.048

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Non Indigenous	1503	26 (1.7)	752	2 (0.3)	2269	28 (1.2)
Indigenous	166	1 (0.6)	145	0 (0.0)	313	2 (0.6)
p value		0.511		1.000		0.571
2010						
Non Indigenous	1388	19 (1.4)	633	2 (0.3)	2033	21 (1.0)
Indigenous	159	2 (1.3)	112	0 (0.0)	273	2 (0.7)
p value		1.000		1.000		1.000
2011						
Non Indigenous	1366	20 (1.5)	641	5 (0.8)	2016	25 (1.2)
Indigenous	158	1 (0.6)	111	2 (1.8)	271	4 (1.5)
p value		0.716		0.277		0.770
2012						
Non Indigenous	1349	18 (1.3)	598	8 (1.3)	1959	26 (1.3)
Indigenous	172	0 (0.0)	106	0 (0.0)	281	1 (0.4)
p value		0.251		0.614		0.242
2013						
Non Indigenous	1322	34 (2.6)	587	6 (1.0)	1920	41 (2.1)
Indigenous	184	4 (2.2)	124	0 (0.0)	312	4 (1.3)
p value		1.000		0.597		0.391

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
English speaking	1628	27 (1.7)	869	2 (0.2)	2513	30 (1.2)
Non-English speaking	72	1 (1.4)	38	0 (0.0)	111	1 (0.9)
p value		1.000		1.000		1.000
2010						
English speaking	1485	21 (1.4)	736	2 (0.3)	2234	23 (1.0)
Non-English speaking	75	0 (0.0)	15	0 (0.0)	90	0 (0.0)
p value		0.621		1.000		1.000
2011						
English speaking	1444	20 (1.4)	731	7 (1.0)	2187	28 (1.3)
Non-English speaking	100	1 (1.0)	28	0 (0.0)	129	1 (0.8)
p value		1.000		1.000		1.000
2012						
English speaking	1446	15 (1.0)	685	9 (1.3)	2143	25 (1.2)
Non-English speaking	96	3 (3.1)	27	0 (0.0)	126	3 (2.4)
p value		0.097		1.000		0.201
2013						
English speaking	1441	37 (2.6)	689	6 (0.9)	2145	44 (2.1)
Non-English speaking	114	4 (3.5)	38	0 (0.0)	153	4 (2.6)
p value		0.537		1.000		0.557

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Australia	1480	27 (1.8)	805	2 (0.3)	2298	30 (1.3)
Other Oceania	54	0 (0.0)	30	0 (0.0)	84	0 (0.0)
Asia	19	1 (5.3)	5	0 (0.0)	25	1 (4.0)
UK & Ireland	82	0 (0.0)	37	0 (0.0)	120	0 (0.0)
Other	57	0 (0.0)	30	0 (0.0)	89	0 (0.0)
p value		0.331		1.000		0.312
2010						
Australia	1366	19 (1.4)	673	2 (0.3)	2050	21 (1.0)
Other Oceania	47	1 (2.1)	28	0 (0.0)	76	1 (1.3)
Asia	22	0 (0.0)	5	0 (0.0)	27	0 (0.0)
UK & Ireland	64	0 (0.0)	29	0 (0.0)	93	0 (0.0)
Other	60	1 (1.7)	16	0 (0.0)	76	1 (1.3)
p value		0.834		0.994		0.846
2011						
Australia	1322	20 (1.5)	665	7 (1.1)	1999	28 (1.4)
Other Oceania	46	0 (0.0)	34	0 (0.0)	80	0 (0.0)
Asia	24	1 (4.2)	7	0 (0.0)	31	1 (3.2)
UK & Ireland	73	0 (0.0)	34	0 (0.0)	108	0 (0.0)
Other	77	0 (0.0)	20	0 (0.0)	97	0 (0.0)
p value		0.448		1.000		0.362
2012						
Australia	1328	12 (0.9)	630	9 (1.4)	1972	22 (1.1)
Other Oceania	49	2 (4.1)	32	0 (0.0)	81	2 (2.5)
Asia	22	0 (0.0)	3	0 (0.0)	26	0 (0.0)
UK & Ireland	73	1 (1.4)	26	0 (0.0)	99	1 (1.0)
Other	58	3 (5.2)	24	0 (0.0)	82	3 (3.7)
p value		0 (0.0)		1.000		0.179
2013						
Australia	1329	32 (2.4)	642	6 (0.9)	1983	38 (1.9)
Other Oceania	50	2 (4.0)	20	0 (0.0)	71	3 (4.2)
Asia	30	3 (10.0)	5	0 (0.0)	35	3 (8.6)
UK & Ireland	70	1 (1.4)	31	0 (0.0)	102	1 (1.0)
Other	76	3 (4.0)	27	0 (0.0)	105	3 (2.9)
p value		0.088		1.000		0.048

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 1.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009	1712	840 (49)	912	471 (52)	2641	1318 (50)
2010	1567	838 (53)	756	398 (53)	2337	1244 (53)
2011	1530	826 (54)	748	386 (52)	2290	1216 (53)
2012	1524	794 (52)	713	384 (54)	2252	1184 (53)
2013	1554	831 (53)	726	396 (55)	2296	1235 (54)
X ² trend p value		0.047		0.217		0.020

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heterosexual	1506	751 (50)	681	335 (49)	2193	1090 (50)
Bisexual	79	36 (46)	146	97 (66)	228	133 (58)
Homosexual	48	13 (27)	37	15 (41)	87	28 (32)
p value		0.006		<0.001		<0.001
2010						
Heterosexual	1378	755 (55)	556	293 (53)	1940	1052 (54)
Bisexual	60	33 (55)	123	69 (56)	186	104 (56)
Homosexual	49	11 (22)	36	10 (28)	86	21 (24)
p value		<0.001		0.009		<0.001
2011						
Heterosexual	1369	750 (55)	531	273 (51)	1903	1024 (54)
Bisexual	55	24 (44)	140	71 (51)	200	96 (48)
Homosexual	51	20 (39)	37	15 (41)	90	36 (40)
p value		0.028		0.441		0.014
2012						
Heterosexual	1329	703 (53)	501	270 (54)	1833	974 (53)
Bisexual	70	33 (47)	127	71 (56)	201	105 (52)
Homosexual	41	12 (29)	31	14 (45)	76	27 (36)
p value		0.008		0.560		0.011
2013						
Heterosexual	1316	717 (54)	518	283 (55)	1841	1005 (55)
Bisexual	58	29 (50)	114	61 (54)	173	90 (52)
Homosexual	72	19 (26)	26	12 (46)	104	33 (32)
p value		<0.001		0.692		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
< 25 years	157	32 (20)	117	42 (36)	276	74 (27)
25 – 34	572	246 (43)	348	184 (53)	924	431 (47)
35+ years	983	563 (57)	446	243 (54)	1440	812 (56)
p value		<0.001		0.001		<0.001
2010						
< 25 years	103	17 (17)	90	33 (37)	195	50 (26)
25 – 34	498	228 (46)	262	130 (50)	761	359 (47)
35+ years	965	593 (61)	403	235 (58)	1379	835 (61)
p value		<0.001		<0.001		<0.001
2011						
< 25 years	118	18 (15)	56	16 (29)	176	34 (19)
25 – 34	447	206 (46)	279	136 (49)	730	343 (47)
35+ years	959	599 (62)	411	234 (57)	1375	835 (61)
p value		<0.001		<0.001		<0.001
2012						
< 25 years	129	12 (9)	38	12 (32)	168	24 (14)
25 – 34	408	179 (44)	242	132 (55)	654	314 (48)
35+ years	986	602 (61)	432	239 (55)	1428	844 (59)
p value		<0.001		0.018		<0.001
2013						
< 25 years	109	11 (10)	60	15 (25)	169	26 (15)
25 – 34	392	155 (40)	215	105 (49)	613	263 (43)
35+ years	1046	662 (63)	450	275 (61)	1505	942 (63)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
<3 years	90	6 (7)	66	15 (23)	157	21 (13)
3 to 10 years	314	106 (34)	236	101 (43)	554	209 (38)
11 + years	1269	716 (56)	584	343 (59)	1864	1063 (57)
p value		<0.001		<0.001		<0.001
2010						
<3 years	87	9 (10)	36	9 (25)	124	18 (15)
3 to 10 years	249	86 (35)	181	77 (43)	431	163 (38)
11 + years	1197	726 (61)	524	306 (58)	1732	1039 (60)
p value		<0.001		<0.001		<0.001
2011						
<3 years	114	12 (11)	47	13 (28)	162	25 (15)
3 to 10 years	249	93 (37)	151	62 (41)	401	155 (39)
11 + years	1120	703 (63)	536	305 (57)	1665	1011 (61)
p value		<0.001		<0.001		<0.001
2012						
<3 years	125	12 (10)	35	10 (29)	161	23 (14)
3 to 10 years	238	79 (33)	126	50 (40)	366	129 (35)
11 + years	1118	681 (61)	533	313 (59)	1662	999 (60)
p value		<0.001		<0.001		<0.001
2013						
<3 years	120	5 (4)	38	9 (24)	160	15 (9)
3 to 10 years	224	58 (26)	140	62 (44)	365	120 (33)
11 + years	1145	723 (63)	526	317 (60)	1682	1046 (62)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heroin	32	9 (28)	862	512 (59)	902	524 (58)
All other opioids	43	7 (16)	740	405 (55)	807	424 (53)
Methamphetamine	51	4 (8)	585	221 (38)	648	230 (35)
Perform/Image-enhancing drugs	22	0 (0)	19	5 (26)	43	5 (12)
Other	6	1 (17)	170	102 (60)	180	104 (58)
p value		0.027		<0.001		<0.001
2010						
Heroin	28	8 (29)	746	475 (64)	792	498 (63)
All other opioids	21	6 (29)	652	385 (59)	688	396 (58)
Methamphetamine	33	3 (9)	566	228 (40)	610	237 (39)
Perform/Image-enhancing drugs	29	0 (0)	24	1 (4)	56	1 (2)
Other	12	1 (8)	160	104 (65)	179	107 (60)
p value		0.008		<0.001		<0.001
2011						
Heroin	27	8 (30)	729	452 (62)	773	470 (61)
All other opioids	24	6 (25)	600	366 (61)	634	378 (60)
Methamphetamine	29	5 (17)	577	265 (46)	620	274 (44)
Perform/Image-enhancing drugs	64	2 (3)	31	3 (10)	105	5 (5)
Other	17	4 (24)	125	78 (62)	153	87 (57)
p value		0.007		<0.001		<0.001
2012						
Heroin	24	5 (21)	727	459 (63)	768	478 (62)
All other opioids	14	6 (43)	568	344 (61)	597	358 (60)
Methamphetamine	27	9 (33)	531	234 (44)	568	249 (44)
Perform/Image-enhancing drugs	87	2 (2)	57	5 (9)	151	7 (5)
Other	8	1 (13)	8	82 (59)	153	87 (57)
p value		<0.001		<0.001		<0.001
2013						
Heroin	13	4 (31)	651	438 (67)	681	453 (67)
All other opioids	15	2 (13)	565	338 (60)	599	354 (59)
Methamphetamine	43	7 (16)	569	281 (47)	662	305 (46)
Perform/Image-enhancing drugs	75	1 (1)	63	1 (1)	141	2 (1)
Other	11	1 (9)	169	105 (62)	200	116 (58)
p value		0.004		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Less than daily	63	6 (10)	940	484 (51)	1018	496 (49)
Daily or more	69	13 (19)	1232	655 (53)	1329	683 (51)
Not last month	24	2 (8)	225	119 (53)	265	123 (46)
p value		0.213		0.734		0.220
2010						
Less than daily	57	4 (7)	978	522 (53)	1047	533 (51)
Daily or more	44	12 (27)	942	556 (59)	1010	578 (57)
Not last month	19	2 (11)	222	112 (50)	252	119 (47)
p value		0.015		0.012		0.002
2011						
Less than daily	74	9 (12)	823	431 (52)	912	442 (48)
Daily or more	59	13 (22)	1012	615 (61)	1100	645 (59)
Not last month	26	2 (8)	205	105 (51)	244	110 (45)
p value		0.148		<0.001		<0.001
2012						
Less than daily	67	12 (18)	856	478 (56)	939	501 (53)
Daily or more	52	9 (17)	985	557 (57)	1069	584 (55)
Not last month	40	2 (5)	168	83 (49)	219	88 (40)
p value		0.130		0.224		<0.001
2013						
Less than daily	89	5 (6)	872	489 (56)	996	515 (52)
Daily or more	38	7 (18)	955	554 (58)	1025	587 (57)
Not last month	30	3 (10)	165	84 (51)	208	90 (43)
p value		0.080		0.218		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No receptive sharing	109	11 (10)	1784	922 (52)	1924	948 (49)
Receptive sharing	19	7 (37)	340	194 (57)	369	205 (56)
p value		0.006		0.075		0.031
2010						
No receptive sharing	84	14 (17)	1449	779 (54)	1563	808 (52)
Receptive sharing	7	2 (29)	243	154 (63)	253	157 (62)
p value		0.602		0.005		0.002
2011						
No receptive sharing	110	15 (14)	1449	811 (56)	1593	840 (53)
Receptive sharing	15	5 (33)	276	171 (62)	297	180 (61)
p value		0.051		0.066		0.012
2012						
No receptive sharing	107	19 (18)	1480	808 (55)	1620	843 (52)
Receptive sharing	10	2 (20)	292	192 (66)	315	205 (65)
p value		1.000		<0.001		<0.001
2013						
No receptive sharing	111	8 (7)	1538	869 (57)	1694	910 (54)
Receptive sharing	14	3 (21)	270	162 (60)	303	177 (58)
p value		0.108		0.284		0.131

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 1.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No imprisonment	140	14 (10)	2006	1006 (50)	2200	1038 (47)
Imprisonment	12	6 (50)	311	206 (66)	331	216 (65)
p value		0.001		<0.001		<0.001
2010						
No imprisonment	110	12 (11)	1580	806 (51)	1730	835 (48)
Imprisonment	2	1 (50)	211	146 (69)	217	149 (69)
p value		0.220		<0.001		<0.001
2011						
No imprisonment	149	20 (13)	1717	924 (54)	1914	964 (50)
Imprisonment	7	3 (43)	210	157 (75)	226	164 (72)
p value		0.066		<0.001		<0.001
2012						
No imprisonment	152	23 (15)	1719	913 (53)	1921	962 (50)
Imprisonment	6	0 (0)	228	156 (68)	243	161 (66)
p value		0.594		<0.001		<0.001
2013						
No imprisonment	146	14 (10)	1691	913 (54)	1905	965 (51)
Imprisonment	8	0 (0)	224	166 (74)	238	171 (72)
p value		1.000		<0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 1.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No sex work	153	19 (12)	2200	1149 (52)	2409	1189 (49)
Sex work	3	2 (67)	120	75 (63)	129	79 (61)
p value		0.048		0.031		0.009
2010						
No sex work	109	13 (12)	1893	1053 (56)	2044	1086 (53)
Sex work	9	4 (44)	115	52 (45)	127	57 (45)
p value		0.024		0.033		0.082
2011						
No sex work	150	24 (16)	1886	1055 (56)	2085	1098 (53)
Sex work	2	0 (0)	94	57 (61)	103	60 (58)
p value		1.000		0.370		0.267
2012						
No sex work	150	21 (14)	1857	1024 (55)	2061	1076 (52)
Sex work	6	1 (17)	103	63 (61)	115	65 (57)
p value		1.000		0.231		0.367
2013						
No sex work	142	10 (7)	1833	1030 (56)	2045	1083 (53)
Sex work	8	3 (38)	79	46 (58)	92	53 (58)
p value		0.022		0.721		0.382

* Total includes people who did not report duration of drug injection

Table 1.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Non Indigenous	1490	721 (48)	749	388 (52)	2253	1115 (49)
Indigenous	166	87 (52)	145	76 (52)	313	163 (52)
p value		0.328		0.928		0.399
2010						
Non Indigenous	1377	743 (54)	631	343 (54)	2020	1093 (54)
Indigenous	158	77 (49)	111	50 (45)	271	128 (47)
p value		0.238		0.080		0.038
2011						
Non Indigenous	1341	712 (53)	629	321 (51)	1978	1035 (52)
Indigenous	153	90 (59)	108	58 (54)	263	149 (57)
p value		0.178		0.608		0.186
2012						
Non Indigenous	1330	679 (51)	594	321 (54)	1936	1005 (52)
Indigenous	169	101 (60)	105	54 (51)	277	156 (56)
p value		0.034		0.671		0.177
2013						
Non Indigenous	1314	689 (52)	586	305 (52)	1910	998 (52)
Indigenous	184	111 (60)	124	80 (65)	312	194 (62)
p value		0.044		0.011		0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
English speaking	1615	790 (49)	866	449 (52)	2497	1246 (50)
Non-English speaking	72	39 (54)	38	17 (45)	111	56 (50)
p value		0.401		0.411		0.923
2010						
English speaking	1474	788 (53)	734	383 (52)	2221	1178 (53)
Non-English speaking	75	37 (49)	14	8 (57)	89	45 (51)
p value		0.553		0.792		0.666
2011						
English speaking	1415	746 (53)	716	373 (52)	2142	1122 (52)
Non-English speaking	99	67 (68)	27	11 (41)	127	79 (62)
p value		0.004		0.246		0.031
2012						
English speaking	1425	738 (52)	680	365 (54)	2177	1108 (52)
Non-English speaking	95	55 (58)	27	14 (52)	125	70 (56)
p value		0.249		0.852		0.461
2013						
English speaking	1432	761 (53)	688	373 (54)	2134	1142 (54)
Non-English speaking	114	66 (58)	38	23 (61)	153	89 (58)
p value		0.328		0.447		0.265

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Australia	1467	728 (50)	802	411 (51)	2282	1144 (50)
Other Oceania	54	23 (43)	30	17 (57)	84	40 (48)
Asia	19	9 (47)	5	2 (40)	25	11 (44)
UK & Ireland	82	42 (51)	37	21 (57)	120	64 (53)
Other	57	24 (42)	30	15 (50)	89	40 (45)
p value		0.672		0.904		0.734
2010						
Australia	1357	724 (53)	670	344 (51)	2038	1075 (53)
Other Oceania	46	24 (52)	28	19 (68)	75	43 (57)
Asia	22	13 (59)	5	4 (80)	27	17 (63)
UK & Ireland	64	41 (64)	29	14 (48)	93	55 (59)
Other	58	26 (45)	16	11 (69)	74	37 (50)
p value		0.293		0.170		0.503
2011						
Australia	1296	691 (53)	652	339 (52)	1959	1034 (53)
Other Oceania	44	22 (50)	33	19 (58)	77	41 (53)
Asia	24	16 (67)	7	1 (14)	31	17 (55)
UK & Ireland	73	42 (58)	32	16 (50)	106	58 (55)
Other	76	42 (55)	20	9 (45)	96	51 (53)
p value		0.654		0.309		0.995
2012						
Australia	1307	672 (51)	627	330 (53)	1948	1008 (52)
Other Oceania	48	21 (44)	31	20 (65)	79	41 (52)
Asia	22	19 (86)	2	2 (100)	25	21 (84)
UK & Ireland	72	41 (57)	26	17 (65)	98	58 (59)
Other	59	33 (56)	24	113 (54)	83	46 (55)
p value		0.011		0.332		0.011
2013						
Australia	1322	708 (54)	641	351 (55)	1975	1067 (54)
Other Oceania	50	24 (48)	20	12 (60)	70	36 (51)
Asia	29	21 (72)	5	4 (80)	34	25 (74)
UK & Ireland	70	37 (53)	31	16 (52)	102	53 (52)
Other	75	37 (49)	27	11 (41)	104	48 (46)
p value		0.257		0.466		0.088

* Total includes people whose gender was not reported or reported as transgender

Australian Capital Territory

Table 2.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2009	2010	2011	2012	2013
Number of sites	1	1	1	1	1
N° surveyed	N=63	N=97	N=100	N=78	N=100
Response (%)	67%	83%	56%	65%	80%
Gender (%)					
Male	39 (62)	72 (74)	68 (68)	53 (68)	67 (67)
Female	24 (38)	25 (26)	32 (32)	25 (32)	32 (32)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	52 (83)	81 (83)	83 (83)	71 (91)	85 (85)
Bisexual	7 (11)	5 (5)	5 (5)	5 (6)	4 (4)
Homosexual	1 (2)	1 (1)	5 (5)	0 (0)	1 (1)
Not reported	3 (5)	10 (10)	7 (7)	2 (3)	10 (10)
Age and duration of injection (years)					
<i>Median age</i>	32	35	35	40	40
Age range	16-60	19-64	22-65	20-66	20-67
<i>Age group (%)</i>					
<25 years	15 (23)	3 (3)	4 (4)	4 (5)	4 (4)
25+ years	48 (76)	94 (97)	96 (96)	74 (95)	96 (96)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	17	18	18	18	17
Age range	12-42	10-40	10-55	12-41	10-51
Not reported	1	2	2	0	6
<i>Median years IDU</i>	13	17	18	20	20
Range	1-36	2-49	1-49	<1-51	<1-51
<i>Duration of drug injection (%)</i>					
<3 years	7 (11)	1 (1)	4 (4)	2 (3)	1(1)
3+ years	55 (87)	94 (97)	94 (94)	76 (97)	93 (93)
Not reported	1 (2)	2 (2)	2 (2)	0 (0)	6 (6)
Aboriginal and Torres Strait Islander origin (%)					
No	56 (89)	79 (81)	85 (85)	71 (91)	80 (80)
Yes	5 (8)	17 (18)	12 (12)	4 (5)	18 (18)
Not reported	2 (3)	1 (1)	3 (3)	3 (4)	2 (2)
Region/Country of birth (%)					
Australia	50 (79)	89 (92)	90 (90)	71 (91)	88 (88)
Other Oceania	2 (3)	2 (2)	4 (4)	1 (1)	0 (0)
Asia	1 (2)	0 (0)	0 (0)	1 (1)	2 (2)
UK & Ireland	8 (13)	4 (4)	0 (0)	5 (6)	5 (5)
Other	2 (3)	0 (0)	6 (6)	0 (0)	4 (4)
Not reported	0 (0)	2 (2)	0 (0)	0 (0)	1 (1)
Main language spoken at home by parents (%)					
English speaking	61 (97)	95 (98)	95 (95)	75 (96)	93 (93)
Non-English speaking	2 (3)	2 (2)	5 (5)	3 (4)	7 (7)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Imprisonment last year (%)					
No	51 (81)	67 (69)	89 (89)	67 (87)	76 (76)
Yes	9 (14)	14 (14)	6 (6)	4 (5)	16 (16)
Not reported	3 (5)	16 (16)	5 (5)	6 (8)	8 (8)
Injected in prison (%)					
Yes	1 (11)	4 (29)	2 (33)	3 (75)	4 (25)
Frequency of injection last month (%)					
Not last month	4 (6)	8 (8)	10 (10)	2 (3)	5 (5)
Less than weekly	10 (16)	15 (15)	16 (16)	10 (13)	17 (17)
Weekly not daily	12 (19)	30 (31)	22 (22)	22 (28)	28 (28)
Daily or more	37 (59)	42 (43)	50 (50)	44 (56)	47 (47)
Not reported	0 (0)	2 (2)	2 (2)	0 (0)	3 (3)

Table 2.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2009	2010	2011	2012	2013
Last drug injected (%)	N=63	N=97	N=100	N=78	N=100
Cocaine	0 (0)	4 (4)	0 (0)	1 (1)	0 (0)
Heroin	24 (38)	28 (29)	44 (44)	30 (38)	56 (56)
Methadone	2 (3)	16 (16)	12 (12)	9 (12)	6 (6)
Methamphetamine	15 (24)	26 (27)	24 (24)	23 (29)	30 (30)
Performance/Image-enhancing drugs	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Pharmaceutical opioids	6 (10)	3 (3)	3 (3)	3 (4)	4 (4)
Suboxone®	4 (6)	1 (1)	1 (1)	0 (0)	1 (1)
Subutex®/Buprenorphine	6 (10)	10 (10)	7 (7)	3 (4)	0 (0)
More than one	2 (3)	7 (7)	5 (5)	5 (6)	3 (3)
Other drug	0 (0)	2 (2)	3 (3)	3 (4)	0 (0)
Not reported	2 (3)	0 (0)	0 (0)	1 (1)	0 (0)
N° Injected last month	N=59	N=87	N=88	N=76	N=92
Places injected last month (%)*					
Any public	30 (51)	40 (56)	40 (45)	33 (43)	43 (47)
All private	28 (47)	44 (51)	47 (53)	42 (55)	49 (53)
Not reported	1 (2)	3 (3)	1 (1)	1 (1)	0 (0)
Use of new sterile needles & syringes last month (%)					
All injections	43 (73)	58 (67)	59 (67)	56 (74)	60 (65)
Most of the time	15 (25)	24 (28)	24 (27)	17 (22)	29 (32)
Half of the time	1 (2)	0 (0)	2 (2)	0 (0)	2 (2)
Some of the time	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Not last month	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	4 (5)	2 (2)	1 (1)	1 (1)
Re-used another's used needle & syringe last month (%)					
None	51 (86)	62 (71)	75 (85)	60 (79)	74 (80)
Once	1 (2)	3 (3)	4 (5)	6 (8)	9 (10)
Twice	1 (2)	7 (8)	0 (0)	1 (1)	1 (1)
3-5 times	4 (7)	3 (3)	2 (2)	1 (1)	4 (4)
>5 times	1 (2)	2 (2)	3 (3)	5 (7)	3 (3)
Not reported	1 (2)	10 (11)	4 (5)	3 (4)	1 (1)
Number of people needle & syringe was re-used after last month (%)					
None	51 (86)	62 (71)	75 (85)	60 (79)	74 (80)
One	4 (7)	8 (9)	4 (5)	4 (5)	9 (10)
Two	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)
Three to five	2 (3)	2 (2)	0 (0)	0 (0)	1 (1)
More than five	2 (3)	1 (1)	2 (2)	3 (4)	1 (1)
Don't know	0 (0)	3 (3)	3 (3)	4 (5)	3 (3)
Not reported	1 (2)	10 (11)	4 (4)	5 (7)	3 (3)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	4 (7)	8 (9)	8 (9)	2 (3)	8 (9)
Casual sex partner	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Close friend	2 (3)	5 (6)	3 (3)	3 (4)	8 (9)
Acquaintance	1 (2)	4 (5)	1 (1)	4 (5)	2 (2)
Other	0 (0)	2 (2)	2 (2)	0 (0)	0 (0)
Equipment used after someone else last month (%)*					
Spoon	20 (38)	18 (21)	12 (14)	19 (25)	33 (36)
Water	14 (26)	16 (18)	14 (16)	13 (17)	16 (17)
Filter	4 (8)	8 (9)	11 (13)	6 (8)	14 (15)
Drug mix	7 (13)	9 (10)	9 (10)	5 (7)	12 (13)
None	28 (53)	53 (61)	64 (73)	51 (67)	53 (58)
Injected by someone after that person injected themselves or others last month (%)					
No	49 (83)	66 (76)	80 (91)	69 (91)	81 (88)
Yes	10 (17)	11 (13)	6 (7)	6 (8)	9 (10)
Not reported	0 (0)	10 (11)	2 (2)	1 (1)	2 (2)
Present when someone injected for the first time in the last 12 months (%)**					
Yes	--	--	--	10 (13)	12 (13)
Overdosed in the last 12 months **					
Yes	--	--	--	--	10 (10)

* More than one option could be selected ** New question in 2012 or 2013

Table 2.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2009	2010	2011	2012	2013
N° surveyed	N=63	N=97	N=100	N=78	N=100
Sex with a regular partner last month (%)					
No	34 (54)	41 (42)	54 (54)	53 (68)	59 (59)
Yes	28 (44)	50 (52)	44 (44)	24 (31)	36 (36)
Not reported	1 (2)	6 (6)	2 (2)	1 (1)	5 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=28	N=41	N=44	N=24	N=36
Never	20 (71)	23 (56)	31 (70)	13 (54)	24 (67)
Sometimes	4 (14)	7 (17)	9 (20)	9 (38)	5 (14)
Every time	3 (11)	9 (22)	3 (7)	2 (8)	2 (6)
Not reported	1 (4)	2 (5)	1 (2)	0 (0)	5 (14)
Sex with other partner/s last month (%)					
No	59 (94)	82 (85)	91 (91)	63 (81)	86 (86)
Yes	2 (3)	6 (6)	6 (6)	11 (14)	11 (11)
Not reported	2 (3)	9 (9)	3 (3)	4 (5)	3 (3)
Condom used with other partner/s last month (%)					
N° surveyed	N=2	N=6	N=6	N=11	N=11
Never	1 (50)	2 (33)	2 (33)	2 (18)	5 (45)
Sometimes	0 (0)	2 (33)	2 (33)	3 (27)	2 (18)
Every time	1 (50)	1 (17)	2 (33)	6 (55)	4 (36)
Not reported	0 (0)	1 (17)	0 (0)	0 (0)	0 (0)
Sex work last month (%)					
No	60 (95)	85 (88)	91 (91)	72 (92)	92 (92)
Yes	0 (0)	2 (2)	2 (2)	3 (4)	2 (2)
Not reported	3 (5)	10 (10)	7 (7)	3 (4)	6 (6)
Condom used at last sex work last month (%) *					
Yes	0 (0)	2 (100)	1 (100)	2 (67)	1 (50)

Table 2.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2009	2010	2011	2012	2013
N° surveyed	N=63	N=97	N=100	N=78	N=100
Any treatment/therapy for drug use (%)					
No	10 (16)	11 (11)	14 (14)	9 (12)	5 (5)
Yes	53 (84)	84 (87)	86 (86)	69 (88)	94 (94)
Not reported	0 (0)	2 (2)	0 (0)	0 (0)	1 (1)
History of methadone maintenance treatment (%)					
Currently	23 (37)	45 (46)	43 (43)	34 (44)	47 (47)
Previously	18 (29)	16 (16)	20 (20)	27 (35)	31 (31)
Never	22 (35)	28 (29)	33 (33)	17 (22)	21 (21)
Not reported	0 (0)	8 (8)	4 (4)	0 (0)	1 (1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	4 (6)	7 (7)	7 (7)	7 (9)	10 (10)
Previously	11 (17)	25 (26)	34 (34)	20 (26)	35 (35)
Never	46 (73)	64 (66)	57 (57)	49 (63)	51 (51)
Not reported	2 (3)	1 (1)	2 (2)	2 (3)	4 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	5 (8)	4 (4)	10 (10)	5 (6)	8 (8)
Previously	4 (6)	17 (18)	21 (21)	13 (17)	27 (27)
Never	51 (81)	75 (77)	66 (66)	60 (77)	63 (63)
Not reported	3 (5)	1 (1)	3 (3)	0 (0)	2 (2)

Table 2.1.5 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2009	2010	2011	2012	2013
N° surveyed	N=63	N=97	N=100	N=78	N=100
Previous HIV test (%)					
Last year	30 (48)	50 (52)	43 (43)	42 (54)	44 (44)
> 1 year ago	25 (40)	21 (22)	40 (40)	30 (38)	44 (44)
Never tested	5 (8)	15 (15)	14 (14)	3 (4)	8 (8)
Not reported	3 (5)	11 (11)	3 (3)	3 (4)	4 (4)
Previous HCV test (%)					
Last year	34 (54)	49 (51)	53 (53)	44 (56)	41 (41)
> 1 year ago	24 (38)	27 (28)	38 (38)	29 (37)	45 (45)
Never tested	4 (6)	9 (9)	5 (5)	2 (3)	5 (5)
Not reported	1 (2)	12 (12)	4 (4)	3 (4)	9 (9)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=31	N=57	N=55	N=46	N=62
Interferon/Interferon+Ribavirin	2 (6)	4 (7)	6 (11)	1 (2)	4 (6)
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	0 (0)
Other	0 (0)	1 (2)	1 (2)	2 (4)	0 (0)
No treatment	29 (94)	52 (91)	48 (87)	42 (91)	55 (89)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	3 (5)
Current treatment for HCV**	N=0	N=3	N=1	N=0	N=6
Interferon/Interferon+Ribavirin	0	3	1	0	2
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	2
Other	0	0	0	0	2

* New treatment options added ** 'Current treatment' defined as within the previous 12 months from 2013

Table 2.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2009	2010	2011	2012	2013
N° Injected last month	N=59	N=87	N=88	N=76	N=100
Needle Syringe Program	34 (58)	82 (94)	81 (92)	70 (92)	81 (81)
Chemist/Pharmacy	30 (51)	21 (24)	17 (19)	27 (36)	30 (30)
Personal sources	21 (36)	12 (14)	8 (9)	14 (18)	19 (19)
Dispensing/Vending Machine	15 (25)	20 (23)	14 (16)	22 (29)	24 (24)
Other sources	1 (2)	4 (5)	1 (1)	0 (0)	2 (2)

* More than one option could be selected

Table 2.1.7 Number (percentage) of respondents by last drug injected and all drugs injected in the last 12 months (2013)

	N° (%)	Drugs injected in last 12 months*							
		Cocaine	Heroin	Methadone	Methamphetamine	PIEDs	Pharm. Opioids	Subutex/Suboxone	No other drugs
Last drug injected									
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Heroin	56 (56)	8 (14)	56 (100)	15 (27)	24 (43)	1 (2)	18 (32)	5 (9)	21 (38)
Methadone	6 (6)	0 (0)	4 (67)	6 (100)	5 (83)	0 (0)	3 (50)	0 (0)	0 (0)
Methamphetamine	30 (30)	4 (13)	15 (50)	8 (27)	30 (100)	0 (0)	9 (30)	8 (27)	11 (37)
PIEDs	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Pharm. opioids	4 (4)	0 (0)	1 (25)	1 (25)	1 (25)	0 (0)	4 (100)	0 (0)	0 (0)
Subutex/Suboxone	1 (1)	0 (0)	1 (100)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	0 (0)
Other/Not reported	3 (3)	0 (0)	2 (67)	1 (33)	3 (100)	0 (0)	1 (33)	1 (33)	0 (0)
Total	100	12 (12)	79 (79)	31 (31)	64 (64)	1 (1)	36 (36)	15 (15)	33 (33)

* More than one option could be selected

HIV antibody prevalence

Table 2.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009	36	0 (0.0)	22	0 (0.0)	58	0 (0.0)
2010	72	0 (0.0)	25	0 (0.0)	97	0 (0.0)
2011	64	0 (0.0)	31	0 (0.0)	95	0 (0.0)
2012	53	0 (0.0)	25	0 (0.0)	78	0 (0.0)
2013	67	0 (0.0)	32	0 (0.0)	100	0 (0.0)
X ² trend p value		--		--		--

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 2.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009	36	21 (58)	22	13 (59)	58	34 (59)
2010	70	48 (69)	25	15 (60)	95	63 (66)
2011	62	44 (71)	31	12 (39)	93	56 (60)
2012	53	34 (64)	25	16 (64)	78	50 (64)
2013	67	49 (73)	32	18 (56)	100	67 (67)
X ² trend p value		0.288		0.997		0.446

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heterosexual	32	19 (59)	18	10 (56)	50	29 (58)
Bisexual	3	1 (33)	2	1 (50)	5	2 (40)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.565		1.000		0.643
2010						
Heterosexual	61	44 (72)	18	12 (67)	79	56 (71)
Bisexual	3	2 (67)	2	0 (0)	5	2 (40)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.439		0.147		0.078
2011						
Heterosexual	56	41 (73)	22	9 (41)	78	50 (64)
Bisexual	2	1 (50)	3	2 (67)	5	3 (60)
Homosexual	3	2 (67)	2	1 (50)	5	3 (60)
p value		0.585		0.777		1.000
2012						
Heterosexual	49	31 (63)	22	13 (59)	71	44 (62)
Bisexual	2	1 (50)	3	3 (100)	5	4 (80)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.280		0.646
2013						
Heterosexual	60	44 (73)	24	11 (46)	85	55 (65)
Bisexual	1	1 (100)	3	3 (100)	4	4 (100)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		0.222		0.395

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
< 25 years	8	3 (38)	5	4 (80)	13	7 (54)
25 – 34	15	12 (80)	5	3 (60)	20	15 (75)
35+ years	13	6 (46)	12	6 (50)	25	12 (48)
p value		0.077		0.518		0.174
2010						
< 25 years	3	2 (67)	0	0 (0)	3	2 (67)
25 – 34	29	19 (66)	10	6 (60)	39	25 (64)
35+ years	38	27 (71)	15	9 (60)	53	36 (68)
p value		0.905		1.000		0.920
2011						
< 25 years	1	1 (100)	3	0 (0)	4	1 (25)
25 – 34	26	17 (65)	14	5 (36)	40	22 (55)
35+ years	35	26 (74)	14	7 (50)	49	33 (67)
p value		0.696		0.321		0.171
2012						
< 25 years	4	1 (25)	0	0 (0)	4	1 (25)
25 – 34	7	3 (43)	7	3 (43)	14	6 (43)
35+ years	42	30 (71)	18	13 (72)	60	43 (72)
p value		0.091		0.170		0.040
2013						
< 25 years	3	1 (33)	1	0 (0)	4	1 (25)
25 – 34	12	7 (58)	15	8 (53)	28	15 (54)
35+ years	52	41 (79)	16	10 (63)	68	51 (75)
p value		0.064		0.586		0.025

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
<3 years	3	0 (0)	3	2 (67)	6	2 (33)
3 to 10 years	12	9 (75)	3	2 (67)	15	11 (73)
11 + years	20	11 (55)	16	9 (56)	36	20 (56)
p value		0.061		0.907		0.220
2010						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	19	11 (58)	3	0 (0)	22	11 (50)
11 + years	48	35 (73)	22	15 (68)	70	50 (71)
p value		0.140		0.052		0.051
2011						
<3 years	5	2 (100)	2	1 (50)	4	3 (75)
3 to 10 years	11	7 (64)	7	1 (14)	18	8 (44)
11 + years	49	35 (71)	21	10 (48)	70	45 (64)
p value		0.859		0.312		0.307
2012						
<3 years	2	1 (50)	0	0 (0)	2	1 (50)
3 to 10 years	6	2 (33)	3	1 (33)	9	3 (33)
11 + years	45	31 (69)	22	15 (68)	67	46 (69)
p value		0.189		0.530		0.070
2013						
<3 years	5	3 (60)	1	1 (100)	1	1 (100)
3 to 10 years	57	43 (75)	7	1 (14)	12	4 (33)
11 + years	0	0 (0)	23	16 (70)	81	59 (73)
p value		0.597		0.025		0.016

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heroin	2	2 (100)	22	13 (59)	24	15 (63)
All other opioids	3	0 (0)	12	10 (83)	16	11 (69)
Methamphetamine	0	0 (0)	15	6 (40)	15	6 (40)
Perform/Image-enhancing drugs	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.050		0.117		0.391
2010						
Heroin	0	0 (0)	26	18 (69)	27	19 (70)
All other opioids	0	0 (0)	28	22 (79)	29	23 (79)
Methamphetamine	0	0 (0)	26	13 (50)	26	13 (50)
Perform/Image-enhancing drugs	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	1 (100)	12	8 (67)	13	8 (62)
p value		--		0.166		0.132
2011						
Heroin	0	0 (0)	40	20 (50)	41	20 (49)
All other opioids	1	1 (100)	18	15 (83)	19	16 (84)
Methamphetamine	0	0 (0)	24	14 (58)	24	14 (58)
Perform/Image-enhancing drugs	1	0 (0)	0	0 (0)	1	0 (0)
Other	2	2 (100)	6	4 (67)	8	6 (75)
p value		0.135		0.117		0.059
2012						
Heroin	0	0 (0)	30	22 (73)	30	22 (73)
All other opioids	0	0 (0)	15	11 (73)	15	11 (73)
Methamphetamine	1	1 (100)	22	12 (55)	23	13 (57)
Perform/Image-enhancing drugs	0	0 (0)	0	0 (0)	0	0 (0)
Other	1	0 (0)	8	4 (50)	9	4 (44)
p value		0.157		0.357		0.288
2013						
Heroin	0	0 (0)	54	37 (69)	56	37 (66)
All other opioids	0	0 (0)	10	8 (80)	11	9 (82)
Methamphetamine	1	1 (100)	26	16 (62)	30	19 (63)
Perform/Image-enhancing drugs	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.762		0.730

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Less than daily	1	0 (0)	19	7 (37)	20	7 (35)
Daily or more	5	2 (40)	28	21 (75)	34	24 (71)
Not last month	0	0 (0)	4	3 (75)	4	3 (75)
p value		0.439		0.026		0.029
2010						
Less than daily	1	0 (0)	47	34 (72)	49	35 (71)
Daily or more	0	0 (0)	35	24 (69)	36	25 (69)
Not last month	0	0 (0)	8	2 (25)	8	2 (25)
p value		--		0.037		0.039
2011						
Less than daily	2	1 (50)	34	22 (65)	36	23 (64)
Daily or more	1	1 (100)	45	28 (62)	45	28 (62)
Not last month	0	0 (0)	8	2 (25)	10	3 (30)
p value		1.000		0.122		0.171
2012						
Less than daily	0	0 (0)	32	20 (63)	32	20 (63)
Daily or more	1	1 (100)	43	28 (65)	44	29 (66)
Not last month	1	0 (0)	1	1 (100)	2	1 (50)
p value		1.000		1.000		0.912
2013						
Less than daily	0	0 (0)	40	29 (73)	45	31 (69)
Daily or more	0	0 (0)	46	30 (65)	47	31 (66)
Not last month	1	1 (100)	4	2 (50)	5	3 (60)
p value		--		0.546		0.883

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No receptive sharing	5	1 (20)	41	23 (56)	46	24 (52)
Receptive sharing	0	0 (0)	6	5 (83)	7	6 (86)
p value		0.123		1.000		1.000
2010						
No receptive sharing	1	0 (0)	60	39 (65)	62	40 (65)
Receptive sharing	0	0 (0)	13	12 (92)	14	13 (93)
p value		--		0.092		0.052
2011						
No receptive sharing	2	1 (50)	69	47 (68)	71	48 (68)
Receptive sharing	0	0 (0)	8	2 (25)	8	2 (25)
p value		--		0.024		0.046
2012						
No receptive sharing	1	1 (100)	59	38 (64)	60	39 (65)
Receptive sharing	0	0 (0)	13	9 (69)	13	9 (69)
p value		--		1.000		1.000
2013						
No receptive sharing	0	0 (0)	68	45 (66)	74	48 (65)
Receptive sharing	0	0 (0)	17	13 (76)	17	13 (76)
p value		--		0.564		0.408

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 2.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No imprisonment	5	2 (40)	44	27 (61)	49	29 (59)
Imprisonment	1	0 (0)	5	3 (60)	7	4 (57)
p value		1.000		1.000		1.000
2010						
No imprisonment	1	0 (0)	66	43 (65)	67	43 (64)
Imprisonment	0	0 (0)	12	9 (75)	13	10 (77)
p value		--		0.741		0.526
2011						
No imprisonment	2	1 (50)	80	47 (59)	83	48 (58)
Imprisonment	1	1 (100)	5	3 (60)	6	4 (67)
p value		1.000		1.000		1.000
2012						
No imprisonment	2	1 (50)	65	42 (65)	67	43 (64)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.617		0.620
2013						
No imprisonment	1	1 (100)	71	47 (66)	76	49 (64)
Imprisonment	0	0 (0)	16	11 (69)	16	11 (69)
p value		--		0.845		0.744

* Total includes people who did not report duration of drug injection

Table 2.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No sex work	6	2 (33)	48	30 (63)	55	33 (60)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2010						
No sex work	1	0 (0)	80	53 (66)	83	55 (66)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		1.000		1.000
2011						
No sex work	4	3 (75)	81	48 (59)	86	51 (59)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.515		0.515
2012						
No sex work	2	1 (50)	70	44 (63)	72	45 (63)
Sex work	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		0.548		0.549
2013						
No sex work	1	1 (100)	86	58 (67)	92	61 (66)
Sex work	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 2.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Non Indigenous	35	21 (60)	17	10 (59)	52	31 (60)
Indigenous	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.417		0.566		0.303
2010						
Non Indigenous	60	43 (72)	17	12 (71)	77	55 (71)
Indigenous	9	5 (56)	8	3 (38)	17	8 (47)
p value		0.439		0.194		0.085
2011						
Non Indigenous	53	37 (70)	27	11 (41)	80	48 (60)
Indigenous	8	6 (75)	3	1 (33)	11	7 (64)
p value		1.000		1.000		1.000
2012						
Non Indigenous	46	29 (63)	25	16 (64)	71	45 (63)
Indigenous	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.629		--		0.626
2013						
Non Indigenous	52	38 (73)	27	15 (56)	80	53 (66)
Indigenous	13	9 (69)	5	3 (60)	18	12 (67)
p value		0.743		1.000		0.973

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
English speaking	35	21 (60)	21	13 (62)	56	34 (61)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.417		0.409		0.167
2010						
English speaking	68	46 (68)	25	15 (60)	93	61 (66)
Non-English speaking	2	2 (100)	0	0 (0)	2	2 (100)
p value		1.000		--		0.548
2011						
English speaking	58	42 (72)	31	12 (39)	89	54 (61)
Non-English speaking	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.573		--		1.000
2012						
English speaking	52	34 (65)	23	15 (65)	75	49 (65)
Non-English speaking	1	0 (0)	2	1 (50)	3	1 (33)
p value		0.358		1.000		0.291
2013						
English speaking	63	46 (73)	29	16 (55)	93	62 (67)
Non-English speaking	4	3 (75)	3	2 (67)	7	5 (71)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Australia	27	18 (67)	18	12 (67)	45	30 (67)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	5	1 (20)	3	1 (33)	8	2 (25)
Other	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.055		0.352		0.015
2010						
Australia	65	45 (69)	23	15 (65)	88	60 (68)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	2 (100)	2	0 (0)	4	2 (50)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.124		0.071		0.168
2011						
Australia	57	41 (72)	26	11 (42)	83	52 (63)
Other Oceania	2	2 (100)	2	0 (0)	4	2 (50)
Asia	0	0 (0)	0	0 (0)	4	2 (50)
UK & Ireland	1	1 (100)	3	1 (33)	0	0 (0)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.156		0.774		0.258
2012						
Australia	49	31 (63)	22	13 (59)	71	44 (62)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	2	1 (50)	3	3 (100)	5	4 (80)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.280		0.856
2013						
Australia	61	45 (74)	27	15 (56)	88	60 (68)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	2	1 (50)	3	1 (33)	5	2 (40)
Other	2	1 (50)	1	1 (100)	4	2 (50)
p value		0.516		0.773		0.386

* Total includes people whose gender was not reported or reported as transgender

New South Wales

Table 3.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2009	2010	2011	2012	2013
Number of sites	20	21	20	20	20
N° surveyed	N=830	N=680	N=694	N=712	N=686
Response (%)	39%	40%	36%	47%	38%
Gender (%)					
Male	500 (60)	427 (63)	463 (67)	476 (67)	475 (69)
Female	322 (39)	247 (36)	228 (33)	227 (32)	206 (30)
Transgender	7 (<1)	5 (1)	3 (<1)	6 (1)	5 (<1)
Not reported	1 (<1)	1 (<1)	0 (0)	3 (<1)	0 (0)
Sexual identity (%)					
Heterosexual	669 (81)	545 (80)	563 (81)	576 (81)	548 (80)
Bisexual	77 (9)	76 (11)	61 (9)	60 (8)	50 (7)
Homosexual	40 (5)	25 (4)	38 (5)	25 (4)	45 (7)
Not reported	44 (5)	34 (5)	32 (5)	51 (7)	43 (6)
Age and duration of injection (years)					
<i>Median age</i>	38	39	38	39	39
Age range	18-64	18-69	18-63	18-64	18-65
<i>Age group (%)</i>					
<25 years	66 (8)	54 (8)	51 (7)	55 (8)	52 (8)
25+ years	764 (92)	626 (92)	640 (92)	657 (92)	634 (92)
Not reported	0 (0)	0 (0)	3 (<1)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	18	18	19	19	19
Age range	10-57	10-63	10-47	10-64	10-54
N° not reported	17	22	23	20	25
<i>Median years IDU</i>	17	18	17	18	19
Range	<1-45	<1-45	<1-46	<1-46	<1-48
<i>Duration of drug injection (%)</i>					
<3 years	47 (6)	48 (7)	64 (9)	66 (9)	61 (9)
<3+ years	766 (92)	610 (90)	606 (87)	626 (88)	600 (87)
Not reported	17 (2)	22 (3)	24 (3)	20 (3)	25 (4)
Aboriginal and Torres Strait Islander origin (%)					
No	682 (82)	565 (83)	582 (84)	609 (86)	543 (79)
Yes	122 (15)	96 (14)	91 (13)	90 (13)	124 (18)
Not reported	26 (3)	19 (3)	21 (3)	13 (2)	19 (3)
Region/Country of birth (%)					
Australia	726 (87)	581 (85)	588 (85)	621 (87)	602 (88)
Other Oceania	18 (2)	24 (4)	21 (3)	22 (3)	19 (3)
Asia	4 (<1)	10 (1)	12 (2)	8 (1)	9 (1)
UK & Ireland	37 (4)	23 (3)	27 (4)	30 (4)	22 (3)
Other	28 (3)	24 (4)	33 (5)	21 (3)	32 (5)
Not reported	17 (2)	18 (3)	13 (2)	10 (1)	2 (<1)
Main language spoken at home by parents (%)					
English speaking	787 (95)	645 (95)	643 (93)	675 (95)	636 (93)
Non-English speaking	33 (4)	23 (3)	40 (6)	32 (4)	48 (7)
Not reported	10 (1)	12 (2)	11 (2)	5 (1)	2 (<1)
Imprisonment last year (%)*					
No	684 (82)	492 (72)	567 (82)	603 (87)	569 (83)
Yes	103 (12)	77 (11)	82 (12)	75 (11)	85 (12)
Not reported	43 (5)	111 (16)	45 (2)	18 (3)	32 (5)
Injected in prison (%)					
N=103		N=77	N=82	N=75	N=85
Yes	30 (29)	20 (26)	18 (22)	27 (36)	31 (36)
Frequency of injection last month (%)					
Not last month	129 (16)	119 (18)	105 (15)	110 (15)	102 (15)
Less than weekly	150 (18)	128 (19)	119 (17)	144 (20)	150 (22)
Weekly not daily	200 (24)	134 (20)	167 (24)	178 (25)	161 (23)
Daily or more	337 (41)	284 (42)	285 (41)	271 (38)	251 (37)
Not reported	14 (2)	15 (2)	18 (3)	9 (1)	22 (3)

Table 3.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2009	2010	2011	2012	2013
Last drug injected (%)	N=830	N=680	N=694	N=712	N=686
Cocaine	51 (6)	19 (3)	12 (2)	16 (2)	22 (3)
Heroin	306 (37)	236 (35)	211 (30)	216 (30)	178 (26)
Methadone	116 (14)	59 (9)	79 (11)	69 (10)	75 (11)
Methamphetamine	181 (22)	201 (30)	198 (29)	187 (26)	218 (32)
Performance/Image-enhancing drugs	30 (4)	29 (4)	64 (9)	83 (12)	73 (11)
Pharmaceutical opioids	80 (10)	62 (9)	70 (10)	80 (11)	57 (8)
Suboxone®	6 (<1)	2 (<1)	1 (<1)	7 (1)	2 (<1)
Subutex®/Buprenorphine	16 (2)	16 (2)	16 (2)	10 (1)	11 (2)
More than one	23 (3)	36 (5)	27 (4)	33 (5)	33 (5)
Other drug	0 (0)	16 (2)	15 (2)	4 (<1)	9 (1)
Not reported	21 (3)	4 (<1)	1 (<1)	7 (1)	8 (1)
N° Injected last month	N=687	N=548	N=571	N=593	N=562
Places injected last month (%)*					
Any public	249 (36)	176 (32)	169 (30)	166 (28)	166 (30)
All private	430 (63)	331 (60)	388 (68)	412 (69)	393 (70)
Not reported	8 (1)	41 (7)	14 (2)	15 (3)	3 (<1)
Use of new sterile needles & syringes last month (%)					
All injections	500 (73)	368 (67)	439 (77)	439 (74)	445 (79)
Most of the time	157 (23)	108 (20)	95 (17)	112 (19)	87 (15)
Half of the time	10 (1)	14 (3)	9 (2)	10 (2)	11 (2)
Some of the time	9 (1)	11 (2)	7 (1)	6 (1)	11 (2)
Not last month	2 (<1)	6 (1)	1 (<1)	6 (1)	2 (<1)
Not reported	9 (1)	41 (7)	20 (4)	20 (3)	6 (1)
Re-used another's used needle & syringe last month (%)					
None	560 (82)	400 (73)	486 (85)	491 (83)	485 (86)
Once	44 (6)	33 (6)	25 (4)	35 (6)	24 (4)
Twice	33 (5)	19 (3)	16 (3)	12 (2)	27 (5)
3-5 times	18 (3)	16 (3)	12 (2)	20 (3)	11 (2)
>5 times	17 (2)	15 (3)	5 (1)	15 (3)	13 (2)
Not reported	15 (2)	65 (12)	27 (5)	20 (3)	2 (<1)
Number of people needle & syringe was re-used after last month (%)					
None	560 (82)	400 (73)	486 (85)	491 (83)	485 (86)
One	53 (8)	33 (6)	27 (5)	41 (7)	28 (5)
Two	6 (1)	7 (1)	4 (<1)	9 (2)	8 (1)
Three to five	3 (<1)	8 (1)	2 (<1)	1 (<1)	2 (<1)
More than five	2 (<1)	4 (<1)	0 (0)	4 (<1)	5 (1)
Don't know	18 (3)	11 (2)	16 (3)	9 (2)	16 (3)
Not reported	45 (7)	85 (16)	36 (6)	38 (6)	18 (3)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	39 (6)	53 (10)	48 (8)	33 (6)	26 (5)
Casual sex partner	3 (<1)	6 (1)	1 (<1)	1 (<1)	5 (1)
Close friend	16 (2)	23 (4)	21 (4)	25 (4)	22 (4)
Acquaintance	13 (2)	11 (2)	11 (2)	9 (2)	11 (2)
Other	11 (2)	13 (2)	12 (2)	0 (0)	8 (1)
Equipment used after someone else last month (%)*					
Spoon	127 (20)	93 (17)	94 (16)	95 (16)	118 (21)
Water	81 (13)	64 (12)	64 (11)	75 (13)	86 (15)
Filter	52 (8)	36 (7)	39 (7)	47 (8)	51 (9)
Drug mix	52 (8)	29 (5)	35 (6)	34 (6)	47 (8)
None	420 (68)	370 (68)	432 (76)	428 (72)	418 (74)
Injected by someone after that person injected themselves or others last month (%)					
No	592 (86)	432 (79)	484 (85)	486 (82)	487 (87)
Yes	76 (11)	52 (9)	66 (12)	80 (13)	61 (11)
Not reported	19 (3)	64 (12)	21 (4)	27 (5)	14 (2)
Present when someone injected for the first time in the last 12 months (%)**					
Yes	--	--	--	81 (14)	89 (16)
Overdosed in the last 12 months **					
Yes	--	--	--	--	63 (9)

* More than one option could be selected ** New question in 2012

Table 3.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2009	2010	2011	2012	2013
N° surveyed	N=830	N=680	N=694	N=712	N=686
Sex with a regular partner last month (%)					
No	369 (44)	280 (41)	307 (44)	324 (46)	320 (47)
Yes	439 (53)	370 (54)	334 (48)	360 (51)	348 (51)
Not reported	22 (3)	30 (4)	53 (8)	28 (4)	18 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=439	N=370	N=334	N=360	N=348
Never	378 (86)	273 (74)	238 (71)	254 (71)	232 (67)
Sometimes	43 (10)	42 (11)	32 (10)	47 (13)	62 (18)
Every time	2 (<1)	35 (9)	46 (14)	39 (11)	42 (12)
Not reported	16 (4)	20 (5)	18 (5)	20 (6)	12 (3)
Sex with other partner/s last month (%)					
No	665 (80)	532 (78)	557 (80)	584 (82)	540 (79)
Yes	126 (15)	103 (15)	102 (15)	94 (13)	120 (17)
Not reported	39 (5)	45 (7)	35 (5)	34 (5)	26 (4)
Condom used with other partner/s last month (%)					
N° surveyed	N=126	N=103	N=102	N=94	N=120
Never	47 (37)	44 (43)	27 (26)	28 (30)	38 (32)
Sometimes	22 (17)	17 (17)	28 (27)	29 (31)	35 (29)
Every time	55 (44)	39 (38)	46 (45)	32 (34)	40 (33)
Not reported	2 (2)	3 (3)	1 (1)	5 (5)	7 (6)
Sex work last month (%)					
No	740 (89)	568 (84)	618 (89)	637 (89)	607 (88)
Yes	57 (7)	51 (8)	38 (5)	42 (6)	33 (5)
Not reported	33 (4)	61 (9)	38 (5)	33 (5)	46 (7)
Condom used at last sex work last month (%)					
Yes	52 (91)	39 (80)	30 (83)	35 (85)	27 (93)

Table 3.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2009	2010	2011	2012	2013
N° surveyed	N=830	N=680	N=694	N=712	N=686
Any treatment/therapy for drug use (%)					
No	112 (13)	111 (16)	525 (76)	526 (74)	512 (75)
Yes	704 (85)	551 (81)	138 (20)	174 (24)	162 (24)
Not reported	14 (2)	18 (3)	31 (4)	12 (2)	12 (2)
History of methadone maintenance treatment (%)					
Currently	396 (48)	279 (41)	273 (39)	289 (41)	263 (38)
Previously	177 (21)	143 (21)	128 (18)	143 (20)	146 (21)
Never	236 (28)	218 (32)	245 (35)	275 (39)	269 (39)
Not reported	21 (3)	40 (6)	48 (7)	5 (<1)	8 (1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	91 (11)	60 (9)	60 (9)	53 (7)	42 (6)
Previously	213 (26)	176 (26)	156 (22)	182 (26)	164 (24)
Never	500 (60)	435 (64)	443 (64)	466 (65)	468 (68)
Not reported	26 (3)	7 (1)	35 (5)	11 (2)	12 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	37 (4)	30 (4)	39 (6)	66 (9)	36 (5)
Previously	76 (9)	68 (10)	82 (12)	89 (13)	119 (17)
Never	687 (87)	567 (83)	535 (77)	542 (76)	513 (75)
Not reported	1 (1)	15 (2)	38 (5)	15 (2)	18 (3)

Table 3.1.5 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2009	2010	2011	2012	2013
N° surveyed	N=830	N=680	N=694	N=712	N=686
Previous HIV test (%)					
Yes, last year	423 (51)	337 (50)	331 (48)	310 (44)	336 (49)
> 1 year ago	304 (37)	227 (33)	244 (35)	272 (38)	240 (35)
Never tested	69 (8)	69 (10)	92 (13)	96 (13)	100 (15)
Not reported	34 (4)	47 (7)	27 (4)	34 (5)	10 (1)
Previous HCV test (%)					
Yes, last year	497 (60)	357 (53)	354 (51)	364 (51)	342 (50)
> 1 year ago	265 (32)	216 (32)	229 (33)	243 (34)	229 (33)
Never tested	39 (5)	59 (9)	67 (10)	64 (9)	62 (9)
Not reported	29 (3)	48 (7)	44 (6)	41 (6)	53 (8)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=508	N=368	N=364	N=375	N=364
Interferon/Interferon+Ribavirin	50 (10)	47 (13)	36 (10)	46 (12)	39 (11)
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	3 (1)
Other	3 (<1)	5 (1)	4 (1)	3 (1)	8 (2)
No treatment	432 (85)	301 (82)	296 (81)	304 (81)	299 (82)
Not reported	23 (5)	15 (4)	28 (8)	22 (6)	15 (4)
Current treatment for HCV**	N=6	N=14	N=13	N=7	N=7
Interferon/Interferon+Ribavirin	5	11	7	5	3
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	2
Other	1	3	3	2	2

* New treatment options added ** 'Current treatment' defined as within the previous 12 months from 2013

Table 3.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2009	2010	2011	2012	2013
N° Injected last month	N=687	N=548	N=571	N=593	N=562
Needle Syringe Program	474 (69)	491 (69)	521 (91)	527 (89)	518 (92)
Chemist/Pharmacy	139 (20)	139 (20)	96 (17)	101 (17)	96 (17)
Personal sources	79 (12)	79 (12)	39 (7)	56 (9)	55 (10)
Dispensing/Vending Machine	129 (19)	129 (19)	95 (17)	120 (20)	136 (24)
Other sources	22 (3)	22 (3)	18 (3)	3 (<1)	17 (3)

* More than one option could be selected

Table 3.1.7 Number (percentage) of respondents by last drug injected and all drugs injected in the last 12 months (2013)

	Drugs injected in last 12 months*								
	N° (%)	Cocaine	Heroin	Methadone	Methamphetamine	PIEDs	Pharm. Opioids	Subutex/Suboxone	No other drugs
Last drug injected									
Cocaine	22 (3)	22 (100)	6 (27)	2 (9)	6 (27)	1 (5)	1 (5)	0 (0)	11 (50)
Heroin	178 (26)	36 (20)	178 (100)	35 (20)	65 (37)	5 (3)	50 (28)	18 (10)	71 (40)
Methadone	75 (11)	7 (9)	25 (33)	75 (100)	27 (36)	2 (3)	13 (17)	1 (1)	31 (41)
Methamphetamine	218 (32)	34 (16)	67 (31)	36 (17)	218 (100)	6 (3)	32 (15)	15 (7)	115 (53)
PIEDs	73 (11)	0 (0)	1 (1)	0 (0)	0 (0)	73 (100)	1 (1)	1 (1)	69 (95)
Pharm. opioids	57 (8)	7 (12)	21 (37)	13 (23)	24 (42)	4 (7)	57 (100)	6 (11)	0 (0)
Subutex/Suboxone	13 (2)	3 (23)	5 (38)	0 (0)	7 (54)	1 (8)	2 (15)	13 (100)	3 (23)
Other/Not reported	3 (3)	11 (22)	27 (54)	21 (42)	25 (50)	2 (4)	16 (32)	7 (14)	12 (24)
Total	686	120 (17)	330 (48)	182 (27)	372 (54)	94 (14)	172 (25)	61 (9)	312 (45)

* More than one option could be selected

HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009	488	12 (2.5)	320	0 (0.0)	816	13 (1.6)
2010	422	8 (1.9)	243	0 (0.0)	671	8 (1.2)
2011	455	5 (1.1)	224	1 (0.5)	682	7 (1.0)
2012	465	7 (1.5)	223	0 (0.0)	697	8 (1.2)
2013	456	20 (4.4)	204	0 (0.0)	665	21 (3.2)
X ² trend p value		0.128		0.885		0.057

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Heterosexual	424	2 (0.5)	232	0 (0.0)	658	2 (0.3)
Bisexual	21	0 (0.0)	53	0 (0.0)	76	1 (1.3)
Homosexual	22	10 (45.5)	15	0 (0.0)	39	10 (25.6)
p value		<0.001		---		<0.001
2010						
Heterosexual	371	1 (0.3)	166	0 (0.0)	539	1 (0.2)
Bisexual	14	0 (0.0)	58	0 (0.0)	74	0 (0.0)
Homosexual	15	7 (46.7)	8	0 (0.0)	24	7 (29.2)
p value		<0.001		--		<0.001
2011						
Heterosexual	397	1 (0.3)	158	0 (0.0)	555	1 (0.2)
Bisexual	17	1 (5.6)	40	1 (2.5)	59	3 (5.1)
Homosexual	21	3 (14.3)	15	0 (0.0)	37	3 (8.1)
p value		<0.001		0.258		<0.001
2012						
Heterosexual	410	1 (0.2)	153	0 (0.0)	565	1 (0.2)
Bisexual	14	0 (0.0)	42	0 (0.0)	58	1 (1.7)
Homosexual	15	5 (33.3)	7	0 (0.0)	24	5 (20.8)
p value		0.001		--		<0.001
2013						
Heterosexual	384	2 (0.5)	143	0 (0.0)	528	2 (0.4)
Bisexual	21	1 (4.8)	28	0 (0.0)	50	2 (4.0)
Homosexual	31	16 (51.6)	11	0 (0.0)	45	16 (35.6)
p value		<0.001		--		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.3 HIV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
< 25 years	26	0 (0.0)	38	0 (0.0)	64	0 (0.0)
25 – 34	135	2 (1.5)	109	0 (0.0)	244	2 (0.8)
35+ years	324	10 (3.1)	173	0 (0.0)	505	11 (2.2)
p value		0.425		--		0.217
2010						
< 25 years	27	1 (3.7)	25	0 (0.0)	53	1 (1.9)
25 – 34	107	1 (0.9)	85	0 (0.0)	192	1 (0.5)
35+ years	286	4 (1.4)	133	0 (0.0)	424	4 (0.9)
p value		0.556		--		0.504
2011						
< 25 years	40	1 (2.5)	10	0 (0.0)	50	1 (2.0)
25 – 34	123	0 (0.0)	88	1 (1.1)	212	1 (0.5)
35+ years	290	3 (8.1)	125	0 (0.0)	417	5 (1.2)
p value		<0.001		0.439		0.444
2012						
< 25 years	42	0 (0.0)	10	0 (0.0)	53	0 (0.0)
25 – 34	117	0 (0.0)	65	0 (0.0)	184	0 (0.0)
35+ years	306	7 (2.3)	148	0 (0.0)	460	8 (1.7)
p value		0.296		--		0.249
2013						
< 25 years	38	1 (2.6)	11	0 (0.0)	49	1 (2.0)
25 – 34	105	3 (2.9)	50	0 (0.0)	157	4 (2.6)
35+ years	313	16 (5.1)	143	0 (0.0)	459	16 (3.5)
p value		0.697		--		0.931

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.4 HIV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
<3 years	30	2 (6.7)	16	0 (0.0)	46	2 (4.4)
3 to 10 years	66	2 (3.0)	68	0 (0.0)	135	2 (1.5)
11 + years	382	8 (2.1)	229	0 (0.0)	618	9 (1.5)
p value		0.292		--		0.323
2010						
<3 years	30	1 (3.3)	16	0 (0.0)	47	1 (2.1)
3 to 10 years	59	0 (0.0)	50	0 (0.0)	109	0 (0.0)
11 + years	317	5 (1.6)	170	0 (0.0)	492	5 (1.0)
p value		0.521		--		0.290
2011						
<3 years	51	0 (0.0)	10	0 (0.0)	61	0 (0.0)
3 to 10 years	78	3 (3.9)	34	0 (0.0)	112	2 (2.7)
11 + years	306	2 (0.7)	177	1 (0.6)	486	4 (0.8)
p value		0.064		1.000		0.224
2012						
<3 years	52	1 (1.9)	11	0 (0.0)	64	1 (1.6)
3 to 10 years	75	1 (1.3)	43	0 (0.0)	119	1 (0.8)
11 + years	324	5 (1.5)	164	0 (0.0)	494	6 (1.2)
p value		0.840		--		0.845
2013						
<3 years	53	4 (7.6)	4	0 (0.0)	57	4 (7.0)
3 to 10 years	61	6 (9.8)	42	0 (0.0)	103	6 (5.8)
11 + years	324	9 (2.8)	151	0 (0.0)	480	10 (2.1)
p value		0.015		--		0.017

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.5 HIV antibody prevalence by last drug injected, gender and survey year

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Heroin	180	2 (1.1)	119	0 (0.0)	302	2 (0.7)
Methamphetamine	98	7 (7.1)	79	0 (0.0)	178	7 (3.9)
Other	198	3 (1.5)	113	0 (0.0)	315	4 (1.3)
p value		0.004		--		0.016
2010						
Heroin	136	1 (0.7)	93	0 (0.0)	231	1 (0.4)
Methamphetamine	120	3 (2.5)	75	0 (0.0)	197	3 (1.5)
Other	162	2 (1.2)	73	0 (0.0)	237	2 (0.8)
p value		0.589		--		0.523
2011						
Heroin	123	0 (0.0)	82	0 (0.0)	207	1 (0.5)
Methamphetamine	118	4 (3.4)	76	0 (0.0)	195	4 (2.1)
Other	213	1 (0.5)	66	1 (1.5)	279	2 (0.7)
p value		0.026		0.295		0.308
2012						
Heroin	144	0 (0.0)	67	0 (0.0)	214	1 (0.5)
Methamphetamine	103	4 (3.9)	74	0 (0.0)	181	4 (2.2)
Other	214	3 (1.4)	79	0 (0.0)	295	3 (1.0)
p value		0.034		--		0.308
2013						
Heroin	109	2 (1.8)	61	0 (0.0)	171	2 (1.2)
Methamphetamine	137	10 (7.3)	71	0 (0.0)	211	10 (4.7)
Other	204	8 (3.9)	70	0 (0.0)	275	9 (3.3)
p value		0.131		--		0.126

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Less than daily	194	5 (2.6)	146	0 (0.0)	341	5 (1.5)
Daily or more	207	4 (1.9)	121	0 (0.0)	332	5 (1.5)
Not last month	78	3 (3.9)	48	0 (0.0)	127	3 (2.4)
p value		0.652		--		0.770
2010						
Less than daily	179	3 (1.7)	100	0 (0.0)	281	3 (1.1)
Daily or more	171	3 (1.8)	84	0 (0.0)	257	3 (1.2)
Not last month	59	0 (0.0)	56	0 (0.0)	117	0 (0)
p value		0.871		--		0.749
2011						
Less than daily	192	2 (1.0)	87	0 (0.0)	281	3 (1.1)
Daily or more	188	1 (0.5)	91	1 (1.1)	280	2 (0.7)
Not last month	60	1 (1.7)	43	0 (0.0)	103	1 (1.0)
p value		0.513		1.000		1.000
2012						
Less than daily	201	3 (1.5)	106	0 (0.0)	313	4 (1.3)
Daily or more	187	2 (1.1)	78	0 (0.0)	268	2 (0.8)
Not last month	70	2 (2.9)	37	0 (0.0)	107	2 (1.9)
p value		0.518		--		0.571
2013						
Less than daily	211	11 (5.2)	92	0 (0.0)	305	11 (3.6)
Daily or more	168	5 (3.0)	71	0 (0.0)	242	6 (2.5)
Not last month	66	3 (4.6)	33	0 (0.0)	99	3 (3.0)
p value		0.592		--		0.750

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.7 HIV antibody prevalence by re-use of someone else's used needle & syringe last month, gender and survey year

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No receptive sharing	337	9 (2.7)	210	0 (0.0)	554	10 (1.8)
Receptive sharing	56	0 (0.0)	53	0 (0.0)	109	0 (0.0)
p value		0.370		---		0.381
2010						
No receptive sharing	259	8 (3.1)	133	0 (0.0)	394	8 (2.0)
Receptive sharing	50	0 (0.0)	32	0 (0.0)	83	0 (0.0)
p value		0.363		--		0.361
2011						
No receptive sharing	322	2 (0.6)	154	1 (0.7)	477	3 (0.6)
Receptive sharing	39	1 (2.6)	19	0 (0.0)	58	1 (1.7)
p value		0.291		1.000		0.369
2012						
No receptive sharing	327	4 (1.2)	146	0 (0.0)	481	5 (1.0)
Receptive sharing	48	0 (0.0)	32	0 (0.0)	80	0 (0.0)
p value		1.000		--		1.000
2013						
No receptive sharing	328	13 (4.0)	141	0 (0.0)	473	13 (2.8)
Receptive sharing	50	2 (4.0)	21	0 (0.0)	72	3 (4.2)
p value		1.000		--		0.456

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no injection last month

Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No imprisonment	394	12 (3.1)	273	0 (0.0)	675	13 (1.9)
Imprisonment	70	0 (0.0)	32	0 (0.0)	102	0 (0.0)
p value		0.228		---		0.236
2010						
No imprisonment	291	7 (2.4)	190	0 (0.0)	486	7 (1.4)
Imprisonment	54	0 (0.0)	22	0 (0.0)	76	0 (0.0)
p value		0.602		--		0.602
2011						
No imprisonment	385	5 (1.3)	185	0 (0.0)	572	6 (1.1)
Imprisonment	53	0 (0.0)	26	1 (3.9)	80	1 (1.3)
p value		1.000		0.123		0.602
2012						
No imprisonment	397	7 (1.8)	188	0 (0.0)	593	8 (1.4)
Imprisonment	46	0 (0.0)	24	0 (0.0)	71	0 (0.0)
p value		1.000		--		1.000
2013						
No imprisonment	378	17 (4.5)	172	0 (0.0)	553	18 (3.3)
Imprisonment	57	2 (3.5)	22	0 (0.0)	81	2 (2.5)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.9 HIV antibody prevalence by condom use at last sex, gender and survey year

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No condom use	197	1 (0.5)	175	0 (0.0)	374	1 (0.3)
Condom use	31	2 (6.5)	10	0 (0.0)	41	2 (4.9)
p value		0.049		---		0.027
2010						
No condom use	163	3 (1.8)	106	0 (0.0)	270	3 (1.1)
Condom use	48	0 (0.0)	27	0 (0.0)	76	0 (0.0)
p value		1.000		--		1.000
2011						
No condom use	152	3 (2.0)	83	0 (0.0)	235	3 (1.3)
Condom use	51	2 (3.9)	24	1 (4.2)	76	3 (4.0)
p value		0.601		0.224		0.159
2012						
No condom use	145	2 (1.4)	102	0 (0.0)	250	2 (0.8)
Condom use	60	2 (3.3)	22	0 (0.0)	82	2 (2.4)
p value		0.582		--		0.256
2013						
No condom use	138	3 (2.2)	87	0 (0.0)	226	3 (1.3)
Condom use	72	2 (2.8)	26	0 (0.0)	101	3 (3.0)
p value		1.000		--		0.378

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 3.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No sex work	462	10 (2.2)	261	0 (0.0)	729	11 (1.5)
Sex work	7	2 (28.6)	48	0 (0.0)	57	2 (3.5)
p value		0.012		---		0.243
2010						
No sex work	374	6 (1.6)	183	0 (0.0)	561	6 (1.1)
Sex work	9	1 (11.1)	41	0 (0.0)	51	1 (2.0)
p value		0.154		--		0.458
2011						
No sex work	416	4 (1.0)	192	0 (0.0)	609	4 (0.7)
Sex work	6	0 (0.0)	28	1 (3.6)	36	2 (5.6)
p value		1.000		0.127		0.039
2012						
No sex work	432	6 (1.4)	188	0 (0.0)	625	6 (1.0)
Sex work	10	1 (10)	26	0 (0.0)	40	2 (5.0)
p value		0.149		--		0.078
2013						
No sex work	411	15 (3.7)	173	0 (0.0)	588	15 (2.6)
Sex work	12	3 (25.0)	20	0 (0.0)	33	4 (12.1)
p value		0.011		--		0.015

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Non Indigenous	422	11 (2.6)	245	0 (0.0)	672	11 (1.6)
Indigenous	48	1 (2.1)	70	0 (0.0)	120	2 (1.7)
p value		1.000		---		1.000
2010						
Non Indigenous	357	7 (2.0)	197	0 (0.0)	558	5 (1.3)
Indigenous	52	1 (1.9)	42	0 (0.0)	96	1 (1.0)
p value		1.000		--		1.000
2011						
Non Indigenous	395	5 (1.3)	178	0 (0.0)	574	5 (0.9)
Indigenous	47	0 (0.0)	40	1 (2.5)	88	2 (2.3)
p value		1.000		0.183		0.236
2012						
Non Indigenous	413	7 (1.7)	177	0 (0.0)	597	7 (1.2)
Indigenous	45	0 (0.0)	41	0 (0.0)	88	1 (1.1)
p value		1.000		--		1.000
2013						
Non Indigenous	376	17 (4.5)	147	0 (0.0)	526	18 (3.4)
Indigenous	68	1 (1.5)	51	0 (0.0)	121	1 (0.8)
p value		0.332		--		0.226

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
English speaking	461	12 (2.6)	307	0 (0.0)	776	13 (1.7)
Non-English speaking	21	0 (0.0)	11	0 (0.0)	32	0 (0.0)
p value		1.000		---		1.000
2010						
English speaking	398	8 (2.0)	234	0 (0.0)	638	8 (1.3)
Non-English speaking	17	0 (0.0)	6	0 (0.0)	23	0 (0.0)
p value		1.000		--		1.000
2011						
English speaking	67	0 (0.0)	23	0 (0.0)	91	0 (0.0)
Non-English speaking	378	5 (1.3)	199	1 (0.5)	579	7 (1.2)
p value		1.000		1.000		0.602
2012						
English speaking	440	6 (1.4)	213	0 (0.0)	660	7 (1.1)
Non-English speaking	23	1 (4.4)	7	0 (0.0)	32	1 (3.1)
p value		0.302		--		0.317
2013						
English speaking	419	19 (4.5)	193	0 (0.0)	616	20 (3.3)
Non-English speaking	35	1 (2.9)	11	0 (0.0)	47	1 (2.1)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Australia	417	12 (2.9)	292	0 (0.0)	714	13 (1.8)
Other Oceania	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)
Asia	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
UK & Ireland	28	0 (0.0)	8	0 (0.0)	37	0 (0.0)
Other	17	0 (0.0)	9	0 (0.0)	28	0 (0.0)
p value		1.000		---		1.000
2010						
Australia	355	7 (2.0)	216	0 (0.0)	575	7 (1.2)
Other Oceania	12	1 (8.3)	11	0 (0.0)	24	1 (4.2)
Asia	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)
UK & Ireland	14	0 (0.0)	8	0 (0.0)	22	0 (0.0)
Other	22	0 (0.0)	4	0 (0.0)	26	0 (0.0)
p value		0.483		--		0.654
2011						
Australia	378	5 (1.3)	199	1 (0.5)	579	7 (1.2)
Other Oceania	10	0 (0.0)	11	0 (0.0)	21	0 (0.0)
Asia	10	0 (0.0)	2	0 (0.0)	12	0 (0.0)
UK & Ireland	19	0 (0.0)	6	0 (0.0)	26	0 (0.0)
Other	28	0 (0.0)	4	0 (0.0)	32	0 (0.0)
p value		1.000		1.000		1.000
2012						
Australia	402	3 (0.8)	196	0 (0.0)	606	4 (0.7)
Other Oceania	14	2 (14.2)	8	0 (0.0)	22	2 (9.1)
Asia	7	0 (0.0)	0	0 (0.0)	8	0 (0.0)
UK & Ireland	23	0 (0.0)	7	0 (0.0)	30	0 (0.0)
Other	12	2 (16.7)	9	0 (0.0)	21	2 (9.5)
p value		0.001		--		0.003
2013						
Australia	392	15 (3.8)	188	0 (0.0)	582	15 (2.6)
Other Oceania	12	1 (8.3)	6	0 (0.0)	19	2 (10.5)
Asia	8	1 (12.5)	1	0 (0.0)	9	1 (11.1)
UK & Ireland	14	1 (7.1)	7	0 (0.0)	22	1 (4.6)
Other	28	2 (7.1)	2	0 (0.0)	31	2 (6.5)
p value		0.602		--		0.131

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 3.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009	485	272 (56)	320	193 (60)	813	468 (58)
2010	422	228 (54)	243	135 (56)	671	365 (54)
2011	448	220 (49)	219	129 (59)	670	350 (52)
2012	453	213 (47)	220	121 (55)	682	338 (50)
2013	453	232 (51)	204	120 (59)	661	354 (54)
X ² trend p value		0.022		0.616		0.021

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heterosexual	421	238 (57)	232	134 (58)	655	373 (57)
Bisexual	21	13 (62)	53	41 (77)	76	54 (71)
Homosexual	22	5 (23)	15	7 (47)	39	12 (31)
p value		0.004		0.012		<0.001
2010						
Heterosexual	371	209 (56)	166	91 (55)	539	301 (56)
Bisexual	14	8 (57)	58	35 (60)	74	44 (59)
Homosexual	15	2 (13)	8	3 (38)	24	5 (21)
p value		0.003		0.422		0.002
2011						
Heterosexual	391	192 (49)	154	91 (59)	545	283 (52)
Bisexual	17	9 (53)	40	23 (58)	59	32 (54)
Homosexual	21	7 (33)	14	8 (57)	36	16 (44)
p value		0.340		0.969		0.641
2012						
Heterosexual	339	195 (49)	152	85 (56)	553	281 (51)
Bisexual	14	4 (29)	41	23 (56)	57	27 (47)
Homosexual	15	3 (20)	6	1 (17)	23	5 (22)
p value		0.033		0.163		0.021
2013						
Heterosexual	383	206 (54)	143	84 (59)	527	291 (55)
Bisexual	21	11 (52)	28	17 (61)	49	28 (57)
Homosexual	30	6 (20)	11	5 (45)	44	12 (27)
p value		0.002		0.720		0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
< 25 years	26	2 (8)	38	17 (45)	64	19 (30)
25 – 34	135	66 (49)	109	66 (61)	244	132 (54)
35+ years	324	202 (62)	173	109 (63)	505	314 (62)
p value		<0.001		0.109		<0.001
2010						
< 25 years	27	4 (15)	25	16 (64)	53	20 (38)
25 – 34	107	49 (46)	85	39 (46)	192	88 (46)
35+ years	288	175 (61)	133	80 (60)	426	257 (60)
p value		<0.001		0.078		<0.001
2011						
< 25 years	40	4 (10)	10	5 (50)	50	9 (18)
25 – 34	120	49 (41)	86	46 (53)	207	95 (46)
35+ years	286	167 (58)	122	78 (64)	410	246 (60)
p value		<0.001		0.261		<0.001
2012						
< 25 years	41	0 (0)	10	5 (50)	52	5 (10)
25 – 34	114	34 (30)	65	38 (58)	181	74 (41)
35+ years	298	179 (60)	145	78 (54)	449	259 (58)
p value		<0.001		0.778		<0.001
2013						
< 25 years	38	2 (5)	11	4 (36)	49	6 (12)
25 – 34	105	38 (36)	50	25 (50)	156	64 (41)
35+ years	310	192 (62)	143	91 (64)	456	284 (62)
p value		0.000		0.069		0.000

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
<3 years	30	1 (3)	16	6 (38)	46	7 (15)
3 to 10 years	65	20 (31)	68	37 (54)	134	58 (43)
11 + years	380	249 (66)	229	147 (64)	616	398 (65)
p value		<0.001		0.052		<0.001
2010						
<3 years	30	3 (10)	16	5 (31)	47	8 (17)
3 to 10 years	59	20 (34)	50	28 (56)	109	48 (44)
11 + years	319	200 (63)	170	100 (59)	494	302 (61)
p value		<0.001		0.114		<0.001
2011						
<3 years	51	5 (10)	10	3 (30)	61	8 (13)
3 to 10 years	78	27 (35)	33	19 (58)	111	46 (41)
11 + years	299	183 (61)	173	107 (62)	475	291 (61)
p value		<0.001		0.156		<0.001
2012						
<3 years	51	3 (6)	11	3 (27)	63	7 (11)
3 to 10 years	73	18 (25)	43	26 (60)	117	44 (38)
11 + years	315	187 (59)	161	91 (57)	482	281 (58)
p value		<0.001		0.134		<0.001
2013						
<3 years	53	0 (0)	4	2 (50)	57	2 (4)
3 to 10 years	61	14 (23)	42	21 (50)	103	35 (34)
11 + years	321	207 (65)	151	94 (62)	476	303 (64)
p value		0.000		0.334		0.000

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heroin	10	3 (30)	289	187 (65)	301	190 (63)
All other opioids	8	1 (13)	201	130 (65)	214	133 (62)
Methamphetamine	10	3 (30)	164	85 (52)	177	90 (51)
Perform/Image-enhancing drugs	18	3 (30)	11	1 (9)	30	1 (3)
Other	0	0 (0)	71	43 (61)	72	43 (60)
p value		0.083		<0.001		<0.001
2010						
Heroin	10	3 (30)	214	137 (64)	231	144 (62)
All other opioids	6	2 (33)	128	79 (62)	138	81 (59)
Methamphetamine	11	2 (18)	184	89 (48)	198	93 (47)
Perform/Image-enhancing drugs	16	0 (0)	10	0 (0)	29	0 (0)
Other	4	1 (25)	63	43 (68)	71	45 (63)
p value		0.251		<0.001		<0.001
2011						
Heroin	5	3 (60)	196	104 (53)	206	109 (53)
All other opioids	6	1 (17)	151	103 (68)	156	105 (66)
Methamphetamine	7	2 (29)	178	98 (55)	190	100 (53)
Perform/Image-enhancing drugs	36	1 (3)	21	2 (10)	62	3 (5)
Other	6	1 (17)	40	30 (75)	52	33 (63)
p value		0.006		<0.001		<0.001
2012						
Heroin	10	2 (20)	198	114 (58)	211	118 (56)
All other opioids	4	2 (50)	156	99 (63)	160	101 (63)
Methamphetamine	7	2 (29)	165	86 (52)	177	91 (51)
Perform/Image-enhancing drugs	39	1 (3)	35	1 (3)	80	2 (3)
Other	3	0 (0)	43	24 (56)	47	25 (53)
p value		0.015		<0.001		<0.001
2013						
Heroin	3	1 (33)	163	116 (71)	171	119 (70)
All other opioids	4	0 (0)	137	85 (62)	143	87 (61)
Methamphetamine	8	1 (13)	198	107 (54)	209	111 (53)
Perform/Image-enhancing drugs	36	0 (0)	30	1 (3)	68	1 (2)
Other	3	0 (0)	50	28 (56)	62	34 (55)
p value		0.029		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Less than daily	17	3 (18)	321	196 (61)	342	200 (58)
Daily or more	20	2 (10)	305	184 (60)	330	190 (58)
Not last month	8	2 (25)	115	69 (60)	127	71 (56)
p value		0.586		0.973		0.880
2010						
Less than daily	25	2 (8)	253	135 (53)	282	138 (49)
Daily or more	13	4 (31)	235	149 (63)	258	155 (60)
Not last month	7	2 (29)	105	59 (56)	117	64 (55)
p value		0.131		0.073		0.033
2011						
Less than daily	28	4 (14)	242	127 (52)	275	132 (48)
Daily or more	18	3 (17)	247	155 (63)	275	160 (58)
Not last month	15	1 (7)	84	47 (56)	103	48 (47)
p value		0.793		0.069		0.029
2012						
Less than daily	27	5 (19)	275	162 (59)	309	170 (55)
Daily or more	23	2 (9)	231	116 (50)	261	121 (46)
Not last month	12	0 (0)	87	44 (51)	103	44 (43)
p value		0.291		0.112		0.036
2013						
Less than daily	28	1 (4)	268	144 (54)	302	150 (50)
Daily or more	11	1 (9)	222	139 (63)	241	145 (60)
Not last month	16	0 (0)	75	44 (59)	99	46 (46)
p value		0.444		0.139		0.018

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No receptive sharing	34	3 (9)	510	307 (60)	551	314 (57)
Receptive sharing	3	2 (67)	105	66 (63)	109	68 (62)
p value		0.042		0.742		0.341
2010						
No receptive sharing	30	5 (17)	352	195 (55)	394	203 (52)
Receptive sharing	4	1 (25)	78	52 (67)	83	53 (64)
p value		0.559		0.077		0.052
2011						
No receptive sharing	42	6 (14)	414	234 (57)	468	243 (52)
Receptive sharing	1	1 (100)	55	41 (75)	56	42 (75)
p value		0.163		0.013		0.001
2012						
No receptive sharing	45	6 (13)	417	228 (55)	474	238 (50)
Receptive sharing	5	1 (20)	71	42 (59)	77	44 (57)
p value		0.546		0.520		0.271
2013						
No receptive sharing	33	1 (3)	430	249 (58)	472	256 (54)
Receptive sharing	5	0 (0)	59	34 (58)	69	38 (55)
p value		1.000		0.967		0.896

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 3.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No imprisonment	41	4 (10)	615	360 (59)	673	369 (55)
Imprisonment	3	2 (67)	98	70 (71)	101	72 (71)
p value		0.045		0.020		0.002
2010						
No imprisonment	41	5 (12)	427	228 (53)	486	238 (49)
Imprisonment	1	0 (0)	74	55 (74)	76	56 (74)
p value		1.000		0.001		<0.001
2011						
No imprisonment	59	7 (12)	475	260 (55)	550	269 (49)
Imprisonment	1	1 (100)	73	55 (75)	77	58 (75)
p value		0.133		0.001		<0.001
2012						
No imprisonment	61	7 (11)	504	263 (52)	581	274 (47)
Imprisonment	1	0 (0)	66	40 (61)	69	41 (59)
p value		1.000		0.197		0.057
2013						
No imprisonment	52	1 (2)	479	261 (54)	550	272 (49)
Imprisonment	4	0 (0)	74	56 (76)	80	58 (73)
p value		1.000		0.001		0.000

* Total includes people who did not report duration of drug injection

Table 3.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No sex work	45	6 (13)	666	399 (60)	726	410 (56)
Sex work	1	1 (100)	55	40 (73)	57	41 (72)
p value		0.152		0.084		0.036
2010						
No sex work	39	4 (10)	504	293 (58)	561	303 (54)
Sex work	5	3 (60)	45	23 (51)	51	26 (51)
p value		0.023		0.432		0.770
2011						
No sex work	55	7 (13)	527	305 (58)	600	315 (53)
Sex work	0	0 (0)	32	18 (56)	34	19 (56)
p value		--		0.856		0.728
2012						
No sex work	56	5 (9)	537	290 (54)	610	301 (49)
Sex work	3	1 (33)	35	18 (51)	40	19 (48)
p value		0.279		0.767		0.821
2013						
No sex work	53	1 (2)	514	296 (58)	586	308 (53)
Sex work	1	0 (0)	29	18 (62)	32	20 (63)
p value		1.000		0.634		0.273

* Total includes people who did not report duration of drug injection

Table 3.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Non-Indigenous	419	231 (55)	245	152 (62)	669	385 (58)
Indigenous	48	27 (56)	70	37 (53)	120	64 (53)
p value		1.000		0.269		0.484
2010						
Non-Indigenous	357	191 (54)	197	113 (57)	558	305 (55)
Indigenous	52	31 (60)	42	21 (50)	96	53 (55)
p value		0.458		0.397		1.000
2011						
Non-Indigenous	390	187 (48)	174	102 (59)	565	289 (51)
Indigenous	45	21 (47)	39	24 (62)	85	45 (53)
p value		1.000		0.857		0.816
2012						
Non-Indigenous	401	189 (47)	175	95 (54)	583	287 (49)
Indigenous	45	21 (47)	40	24 (60)	87	46 (53)
p value		1.00		0.598		0.566
2013						
Non-Indigenous	373	186 (50)	147	83 (56)	522	269 (52)
Indigenous	68	41 (60)	51	33 (65)	121	76 (63)
p value		0.114		0.303		0.025

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
English speaking	458	258 (56)	307	183 (60)	773	444 (57)
Non-English speaking	21	10 (48)	11	8 (73)	32	18 (56)
p value		0.823		0.536		1.000
2010						
English speaking	398	220 (55)	234	128 (55)	638	350 (55)
Non-English speaking	17	6 (35)	6	4 (67)	23	10 (43)
p value		0.136		0.693		0.295
2011						
English speaking	413	197 (48)	206	125 (61)	622	323 (52)
Non-English speaking	28	17 (61)	10	4 (40)	38	21 (55)
p value		0.241		0.207		0.740
2012						
English speaking	428	197 (46)	210	118 (56)	645	318 (49)
Non-English speaking	23	15 (65)	7	1 (14)	32	17 (53)
p value		0.087		0.048		0.720
2013						
English speaking	416	216 (52)	193	112 (58)	612	330 (54)
Non-English speaking	35	15 (43)	11	8 (73)	47	23 (49)
p value		0.303		0.531		0.509

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Australia	414	234 (57)	292	171 (59)	711	406 (57)
Other Oceania	11	8 (73)	7	5 (71)	18	13 (72)
Asia	3	1 (33)	1	1 (100)	4	2 (50)
UK & Ireland	28	16 (57)	8	6 (75)	37	23 (62)
Other	17	9 (53)	9	8 (89)	28	18 (64)
p value		0.771		0.280		0.649
2010						
Australia	355	195 (55)	216	119 (55)	575	316 (55)
Other Oceania	12	8 (67)	11	8 (73)	24	16 (67)
Asia	9	4 (44)	1	1 (100)	10	5 (50)
UK & Ireland	14	10 (71)	8	2 (25)	22	12 (55)
Other	22	7 (32)	4	3 (75)	26	10 (38)
p value		0.122		0.217		0.372
2011						
Australia	373	177 (47)	194	118 (61)	569	296 (52)
Other Oceania	8	6 (75)	11	7 (64)	19	13 (68)
Asia	10	6 (60)	2	0 (0)	12	6 (50)
UK & Ireland	20	10 (50)	6	2 (33)	27	12 (44)
Other	28	14 (50)	4	2 (50)	32	16 (50)
p value		0.571		0.296		0.609
2012						
Australia	392	183 (47)	194	105 (54)	594	292 (49)
Other Oceania	13	5 (38)	7	6 (86)	20	11 (55)
Asia	7	5 (71)	0	0 (0)	8	5 (63)
UK & Ireland	22	14 (64)	7	3 (43)	29	17 (59)
Other	12	3 (25)	9	5 (56)	21	8 (38)
p value		0.149		0.361		0.584
2013						
Australia	390	204 (52)	188	110 (59)	580	316 (54)
Other Oceania	12	6 (50)	6	4 (67)	18	10 (56)
Asia	8	3 (38)	1	0 (0)	9	3 (33)
UK & Ireland	14	8 (57)	7	4 (57)	22	12 (55)
Other	27	11 (41)	2	2 (100)	30	13 (43)
p value		0.711		0.724		0.566

* Total includes people whose gender was not reported or reported as transgender

Northern Territory

Table 4.1.1 Number (percentage) of respondents by graphic characteristics and survey year

Demographic characteristics	2009	2010	2011	2012	2013
Number of sites	3	3	3	3	3
N° surveyed	N=77	N=83	N=70	N=50	N=70
Response (%)	29%	31%	33%	21%	33%
Gender (%)					
Male	52 (68)	59 (71)	46 (66)	33 (66)	49 (70)
Female	25 (32)	24 (29)	23 (33)	16 (32)	21 (30)
Transgender	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	66 (86)	67 (81)	56 (80)	39 (78)	61 (87)
Bisexual	5 (6)	10 (12)	12 (17)	8 (16)	5 (7)
Homosexual	2 (3)	5 (6)	1 (1)	2 (4)	1 (1)
Not reported	4 (5)	1 (1)	1 (1)	1 (2)	3 (4)
Age and duration of injection (years)					
<i>Median age</i>	40	41	40	39	42
Age range	22-60	17-63	17-64	20-59	19-62
<i>Age group (%)</i>					
<25 years	4 (5)	6 (7)	4 (6)	2 (4)	2 (3)
25+ years	73 (95)	77 (93)	66 (94)	48 (96)	68 (97)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	18	18	19	18	20
Age range	12-42	12-46	12-44	12-40	13-40
Not reported	4	0	3	3	2
<i>Median years IDU</i>	18	19	16	17	21
Range	1-37	<1-43	1-46	1-41	3-46
<i>Duration of drug injection (%)</i>					
<3 years	4 (5)	7 (8)	7 (10)	3 (6)	0 (0)
3+ years	69 (90)	76 (92)	60 (86)	44 (88)	68 (97)
Not reported	4 (5)	0 (0)	3 (4)	3 (6)	2 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	65 (84)	64 (77)	56 (80)	37 (74)	55 (79)
Yes	10 (13)	18 (22)	13 (19)	12 (24)	13 (19)
Not reported	2 (3)	1 (1)	1 (1)	1 (2)	2 (3)
Region/Country of birth (%)					
Australia	65 (84)	71 (86)	60 (86)	44 (88)	59 (84)
Other Oceania	2 (3)	3 (4)	0 (0)	1 (2)	1 (1)
Asia	2 (3)	0 (0)	2 (3)	0 (0)	0 (0)
UK & Ireland	2 (3)	6 (7)	8 (11)	2 (4)	7 (10)
Other	4 (5)	2 (2)	0 (0)	3 (6)	3 (4)
Not reported	2 (3)	1 (1)	0 (0)	0 (0)	0 (0)
Main language spoken at home by parents (%)					
English speaking	70 (91)	77 (93)	65 (93)	48 (96)	68 (97)
Non-English speaking	6 (7)	6 (7)	5 (7)	2 (4)	2 (3)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Imprisonment last year (%)					
No	72 (94)	65 (78)	65 (93)	45 (90)	62 (89)
Yes	2 (3)	2 (2)	3 (4)	4 (8)	7 (14)
Not reported	3 (4)	16 (19)	2 (3)	1 (2)	1 (1)
Injected in prison (%)					
Yes	N=2 1 (50)	N=2 1 (50)	N=3 1 (33)	N=4 0 (0)	N=7 1 (14)
Frequency of injection last month (%)					
Not last month	7 (9)	10 (12)	10 (14)	5 (10)	8 (11)
Less than weekly	13 (17)	13 (16)	7 (10)	3 (6)	11 (16)
Weekly not daily	15 (19)	13 (16)	7 (10)	10 (20)	12 (17)
Daily or more	42 (55)	45 (54)	46 (66)	32 (64)	39 (56)
Not reported	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)

Table 4.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2009	2010	2011	2012	2013
Last drug injected (%)	N=77	N=83	N=70	N=50	N=70
Cocaine	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)
Heroin	2 (3)	3 (4)	2 (3)	2 (4)	7 (10)
Methadone	7 (9)	3 (4)	2 (3)	1 (2)	1 (1)
Methamphetamine	20 (26)	21 (25)	16 (23)	9 (18)	8 (11)
Performance/Image-enhancing drugs	1 (1)	1 (1)	1 (1)	1 (2)	3 (4)
Pharmaceutical opioids	38 (49)	50 (60)	44 (63)	35 (70)	43 (61)
Suboxone®	1 (1)	4 (5)	2 (3)	1 (2)	0 (0)
Subutex®/Buprenorphine	1 (1)	1 (1)	0 (0)	0 (0)	1 (1)
More than one	1 (1)	0 (0)	1 (1)	1 (2)	5 (7)
Other drug	1 (1)	0 (0)	2 (3)	0 (0)	1 (1)
Not reported	4 (5)	0 (0)	0 (0)	0 (0)	0 (0)
N° Injected last month	N=70	N=71	N=60	N=45	N=62
Places injected last month (%)*					
Any public	28 (40)	26 (37)	18 (30)	16 (36)	18 (29)
All private	42 (60)	42 (59)	39 (65)	29 (64)	43 (69)
Not reported	0 (0)	3 (4)	3 (5)	0 (0)	1 (2)
Use of new sterile needles & syringes last month (%)					
All injections	59 (84)	57 (80)	49 (82)	33 (73)	51 (82)
Most of the time	9 (13)	10 (14)	9 (15)	9 (20)	9 (15)
Half of the time	1 (1)	2 (3)	0 (0)	0 (0)	0 (0)
Some of the time	1 (1)	0 (0)	0 (0)	1 (2)	1 (2)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	2 (3)	2 (3)	2 (4)	1 (2)
Re-used another's used needle & syringe last month (%)					
None	62 (89)	62 (87)	48 (80)	39 (87)	55 (89)
Once	5 (7)	1 (1)	3 (5)	1 (2)	3 (5)
Twice	0 (0)	1 (1)	4 (7)	4 (9)	2 (3)
3-5 times	1 (1)	1 (1)	1 (2)	1 (2)	0 (0)
>5 times	1 (1)	0 (0)	1 (2)	0 (0)	1 (2)
Not reported	1 (1)	6 (8)	3 (5)	0 (0)	1 (2)
Number of people needle & syringe was re-used after last month (%)					
None	62 (89)	62 (87)	48 (80)	39 (87)	55 (89)
One	2 (3)	2 (3)	6 (10)	4 (9)	1 (2)
Two	0 (0)	1 (1)	1 (2)	0 (0)	0 (0)
Three to five	0 (0)	0 (0)	1 (1)	2 (4)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	2 (3)	0 (0)	2 (5)	0 (0)	2 (3)
Not reported	4 (6)	6 (8)	2 (5)	0 (0)	4 (6)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	1 (1)	1 (1)	8 (13)	5 (11)	1 (2)
Casual sex partner	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Close friend	0 (0)	2 (3)	5 (8)	1 (2)	0 (0)
Acquaintance	0 (0)	0 (0)	2 (3)	0 (0)	1 (2)
Other	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)
Equipment used after someone else last month (%)*					
Spoon	12 (18)	19 (27)	17 (28)	10 (22)	22 (35)
Water	4 (6)	4 (6)	8 (13)	3 (7)	7 (11)
Filter	8 (12)	7 (10)	4 (7)	4 (9)	7 (11)
Drug mix	4 (6)	8 (11)	4 (7)	3 (7)	3 (5)
None	47 (71)	45 (63)	38 (63)	32 (71)	39 (63)
Injected by someone after that person injected themselves or others last month (%)					
No	58 (83)	61 (86)	54 (90)	36 (80)	58 (94)
Yes	11 (16)	4 (6)	4 (6)	9 (20)	2 (3)
Not reported	1 (1)	6 (8)	2 (3)	0 (0)	2 (3)
Present when someone injected for the first time in the last 12 months (%)**					
Yes	--	--	--	10 (22)	4 (6)
Overdosed in the last 12 months **					
Yes	--	--	--	--	10 (14)

* More than one option could be selected ** New question in 2012 or 2013

Table 4.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2009	2010	2011	2012	2013
N° surveyed	N=77	N=83	N=70	N=50	N=70
Sex with a regular partner last month (%)					
No	47 (61)	53 (64)	35 (50)	30 (60)	43 (61)
Yes	26 (34)	26 (31)	34 (49)	19 (38)	26 (37)
Not reported	4 (5)	4 (5)	1 (1)	1 (2)	1 (1)
Condom used with regular partner last month (%)					
N° surveyed	N=26	N=26	N=34	N=19	N=26
Never	19 (73)	20 (77)	23 (68)	12 (63)	24 (92)
Sometimes	1 (4)	0 (0)	0 (0)	1 (5)	0 (0)
Every time	3 (12)	4 (15)	8 (24)	5 (26)	1 (4)
Not reported	3 (12)	2 (8)	3 (9)	1 (5)	1 (4)
Sex with other partner/s last month (%)					
No	65 (84)	65 (78)	64 (91)	40 (80)	57 (81)
Yes	6 (8)	12 (14)	6 (9)	10 (20)	13 (19)
Not reported	6 (8)	6 (7)	0 (0)	0 (0)	0 (0)
Condom used with other partner/s last month (%)					
N° surveyed	N=6	N=12	N=6	N=10	N=13
Never	2 (33)	5 (42)	1 (17)	5 (50)	5 (38)
Sometimes	1 (17)	2 (17)	1 (17)	2 (20)	2 (15)
Every time	3 (50)	4 (33)	3 (50)	3 (30)	5 (38)
Not reported	0 (0)	1 (8)	1 (17)	0 (0)	1 (8)
Sex work last month (%)					
No	71 (92)	72 (87)	66 (94)	46 (92)	64 (91)
Yes	3 (4)	5 (6)	4 (6)	4 (8)	3 (4)
Not reported	3 (4)	6 (7)	0 (0)	0 (0)	3 (4)
Condom used at last sex work last month (%)					
Yes	3 (100)	4 (80)	4 (100)	3 (75)	2 (67)

Table 4.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2009	2010	2011	2012	2013
N° surveyed	N=77	N=83	N=70	N=50	N=70
Any treatment/therapy for drug use (%)					
No	21 (27)	24 (29)	22 (31)	14 (28)	29 (41)
Yes	55 (71)	56 (67)	47 (67)	36 (72)	41 (59)
Not reported	1 (1)	3 (4)	1 (1)	0 (0)	0 (0)
History of methadone maintenance treatment					
Currently	12 (16)	7 (8)	7 (10)	6 (12)	11 (16)
Previously	14 (18)	25 (30)	22 (31)	11 (22)	18 (26)
Never	49 (64)	46 (55)	39 (56)	32 (64)	41 (59)
Not reported	2 (3)	5 (6)	2 (3)	1 (2)	0 (0)
History of buprenorphine (Subutex®) treatment (%)					
Currently	3 (4)	5 (6)	3 (4)	6 (12)	3 (4)
Previously	18 (23)	17 (20)	21 (30)	18 (36)	16 (23)
Never	55 (71)	59 (71)	45 (64)	26 (52)	50 (71)
Not reported	1 (1)	2 (2)	1 (1)	0 (0)	1 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	3 (9)	9 (11)	6 (9)	6 (12)	9 (13)
Previously	6 (8)	9 (11)	13 (19)	6 (12)	11 (16)
Never	67 (87)	64 (77)	51 (73)	38 (76)	48 (69)
Not reported	1 (1)	1 (1)	0 (0)	0 (0)	2 (3)

Table 4.1.5 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2009	2010	2011	2012	2013
N° surveyed	N=77	N=83	N=70	N=50	N=70
Previous HIV test (%)					
Yes, last year	32 (42)	38 (46)	32 (46)	29 (58)	35 (50)
> 1 year ago	33 (43)	28 (34)	32 (46)	15 (30)	25 (36)
Never tested	9 (12)	12 (14)	6 (9)	5 (10)	10 (14)
Not reported	3 (4)	5 (6)	0 (0)	1 (2)	0 (0)
Previous HCV test (%)					
Yes, last year	40 (52)	46 (55)	37 (53)	30 (60)	36 (51)
> 1 year ago	32 (42)	23 (28)	30 (43)	16 (32)	24 (34)
Never tested	3 (4)	8 (10)	2 (3)	3 (6)	7 (10)
Not reported	2 (3)	6 (7)	1 (1)	1 (2)	3 (4)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=32	N=46	N=33	N=24	N=36
Interferon/Interferon+Ribavirin	2 (6)	2 (4)	1 (3)	1 (4)	2 (6)
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	0 (0)
Other	0 (0)	1 (2)	2 (6)	0 (0)	0 (0)
No treatment	30 (94)	44 (96)	29 (88)	22 (92)	33 (92)
Not reported	0 (0)	0 (0)	1 (3)	1 (4)	1 (3)
Current treatment for HCV**	N=0	N=2	N=1	N=0	N=1
Interferon/Interferon+Ribavirin	0	1	0	0	1
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	0
Other	0	1	1	0	0

* New treatment options added ** 'Current treatment' defined as within the previous 12 months from 2013

Table 4.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2009	2010	2011	2012	2013
N° Injected last month	N=70	N=71	N=60	N=45	N=62
Needle Syringe Program	46 (66)	59 (83)	58 (97)	43 (96)	58 (94)
Chemist/Pharmacy	7 (10)	9 (13)	8 (13)	9 (20)	6 (10)
Personal sources	21 (30)	14 (19)	8 (13)	12 (27)	7 (11)
Dispensing/Vending Machine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other sources	0 (0)	4 (6)	0 (0)	0 (0)	0 (0)

* More than one option could be selected

Table 4.1.7 Number (percentage) of respondents by last drug injected and all drugs injected in the last 12 months (2013)

	N° (%)	Drugs injected in last 12 months*							
		Cocaine	Heroin	Methadone	Methamphetamine	PIEDs	Pharm. Opioids	Subutex/Suboxone	No other drugs
Last drug injected									
Cocaine	1 (1)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Heroin	7 (10)	1 (14)	7 (100)	2 (29)	5 (71)	0 (0)	3 (43)	2 (29)	1 (14)
Methadone	1 (1)	0 (0)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)
Methamphetamine	8 (11)	2 (25)	2 (25)	0 (0)	8 (100)	1 (13)	3 (38)	1 (13)	3 (38)
PIEDs	3 (4)	0 (0)	0 (0)	0 (0)	1 (33)	3 (100)	0 (0)	0 (0)	1 (33)
Pharm. opioids	43 (61)	6 (14)	12 (28)	13 (30)	21 (49)	1 (2)	43 (100)	12 (28)	0 (0)
Subutex/Suboxone	1 (1)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	1 (100)	1 (100)	0 (0)
Other/Not reported	6 (9)	1 (17)	0 (0)	2 (33)	3 (50)	0 (0)	5 (83)	2 (33)	0 (0)
Total	70	11 (16)	22 (31)	18 (26)	40 (57)	5 (7)	56 (80)	18 (26)	5 (7)

* More than one option could be selected

HIV antibody prevalence

Table 4.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009	51	0 (0.0)	25	0 (0.0)	76	0 (0.0)
2010	55	0 (0.0)	23	0 (0.0)	78	0 (0.0)
2011	46	1 (2.2)	21	0 (0.0)	68	1 (1.5)
2012	30	1 (3.3)	15	0 (0.0)	46	1 (2.2)
2013	47	2 (4.3)	19	0 (0.0)	66	2 (3.0)
X ² trend p value		0.050		--		0.048

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 4.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009	50	20 (40)	25	9 (36)	75	29 (39)
2010	55	29 (53)	23	8 (35)	78	37 (47)
2011	40	22 (50)	21	10 (48)	61	32 (52)
2012	30	11 (37)	15	5 (33)	46	16 (35)
2013	46	21 (46)	19	12 (63)	65	33 (51)
X ² trend p value		0.954		0.107		0.416

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heterosexual	46	19 (41)	18	7 (39)	64	26 (41)
Bisexual	2	1 (50)	3	1 (33)	5	2 (40)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		1.000		0.826
2010						
Heterosexual	48	28 (58)	15	7 (47)	63	35 (56)
Bisexual	5	1 (20)	4	1 (25)	9	2 (22)
Homosexual	1	0 (0)	4	0 (0)	5	0 (0)
p value		0.104		0.320		0.007
2011						
Heterosexual	35	21 (60)	14	7 (50)	49	28 (57)
Bisexual	4	1 (25)	7	3 (43)	11	4 (36)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.195		1.000		0.247
2012						
Heterosexual	26	11 (42)	10	4 (40)	37	15 (41)
Bisexual	3	0 (0)	3	1 (33)	6	1 (17)
Homosexual	0	0 (0)	2	0 (0)	2	0 (0)
p value		0.268		0.760		0.355
2013						
Heterosexual	40	21 (53)	17	12 (71)	57	33 (58)
Bisexual	4	0 (0)	0	0 (0)	4	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.075		--		0.018

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
< 25 years	2	0 (0)	2	1 (50)	4	1 (25)
25 – 34	7	1 (14)	7	2 (29)	14	3 (21)
35+ years	41	19 (46)	16	6 (38)	57	25 (44)
p value		0.139		0.838		0.257
2010						
< 25 years	4	1 (25)	2	0 (0)	6	1 (17)
25 – 34	5	0 (0)	7	2 (29)	12	2 (17)
35+ years	46	28 (61)	14	6 (43)	60	34 (57)
p value		0.009		0.543		0.011
2011						
< 25 years	1	1 (100)	2	0 (0)	3	1 (33)
25 – 34	9	3 (33)	7	4 (57)	16	7 (44)
35+ years	30	18 (60)	12	6 (50)	42	24 (57)
p value		0.253		0.565		0.478
2012						
< 25 years	2	1 (50)	0	0 (0)	2	1 (50)
25 – 34	5	0 (0)	6	2 (33)	11	2 (18)
35+ years	23	10 (43.5)	9	3 (33)	33	13 (39)
p value		0.147		1.000		0.363
2013						
< 25 years	1	0 (0)	1	0 (0)	2	0 (0)
25 – 34	9	4 (44)	3	0 (0)	12	4 (33)
35+ years	36	17 (47)	15	12 (80)	51	29 (57)
p value		1.000		0.009		0.105

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
<3 years	2	0 (0)	2	1 (50)	4	1 (25)
3 to 10 years	4	1 (25)	5	1 (20)	9	2 (22)
11 + years	42	19 (45)	16	7 (44)	58	26 (45)
p value		0.349		0.603		0.352
2010						
<3 years	4	0 (0)	3	0 (0)	7	0 (0)
3 to 10 years	7	3 (43)	3	3 (100)	10	6 (60)
11 + years	44	26 (59)	17	5 (29)	61	31 (51)
p value		0.042		0.034		0.020
2011						
<3 years	5	1 (20)	1	0 (0)	6	1 (17)
3 to 10 years	3	3 (100)	4	3 (75)	7	6 (86)
11 + years	30	16 (53)	15	6 (40)	45	22 (49)
p value		0.117		0.285		0.050
2012						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3 to 10 years	3	1 (33)	0	0 (0)	3	1 (33)
11 + years	24	10 (42)	12	4 (33)	37	14 (38)
p value		0.773		1.000		0.788
2013						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	6	0 (0)	3	0 (0)	9	0 (0)
11 + years	39	20 (51)	15	12 (80)	54	32 (59)
p value		0.027		0.025		0.001

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heroin	0	0 (0)	2	0 (0)	2	0 (0)
All other opioids	2	1 (50)	43	21 (49)	46	22 (48)
Methamphetamine	2	0 (0)	17	3 (18)	19	3 (16)
Perform/Image-enhancing drugs	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	2	2 (100)	3	2 (67)
p value		0.248		0.041		0.068
2010						
Heroin	0	0 (0)	3	2 (67)	3	2 (67)
All other opioids	3	0 (0)	53	28 (53)	56	28 (50)
Methamphetamine	3	0 (0)	15	7 (47)	18	7 (39)
Perform/Image-enhancing drugs	1	0 (0)	0	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.801		0.568
2011						
Heroin	1	0 (0)	1	0 (0)	2	0 (0)
All other opioids	2	1 (50)	36	23 (64)	40	26 (65)
Methamphetamine	2	0 (0)	13	5 (38)	15	5 (33)
Perform/Image-enhancing drugs	1	0 (0)	0	0 (0)	1	0 (0)
Other	0	0 (0)	2	0 (0)	3	1 (33)
p value		0.494		0.102		0.076
2012						
Heroin	0	0 (0)	2	1 (50)	2	1 (50)
All other opioids	1	0 (0)	32	13 (41)	35	13 (37)
Methamphetamine	1	0 (0)	5	1 (20)	7	2 (29)
Perform/Image-enhancing drugs	0	0 (0)	0	0 (0)	1	0 (0)
Other	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.678		0.831
2013						
Heroin	0	0 (0)	5	1 (20)	5	1 (20)
All other opioids	1	0 (0)	45	26 (58)	45	26 (58)
Methamphetamine	1	0 (0)	6	2 (33)	6	2 (33)
Perform/Image-enhancing drugs	1	0 (0)	2	0 (0)	3	0 (0)
Other	0	0 (0)	5	3 (60)	6	4 (67)
p value		--		0.219		0.125

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Less than daily	1	0 (0)	26	14 (54)	28	14 (50)
Daily or more	2	1 (50)	38	14 (37)	41	15 (37)
Not last month	1	0 (0)	3	0 (0)	6	0 (0)
p value		0.513		0.129		0.068
2010						
Less than daily	2	0 (0)	26	15 (58)	28	15 (54)
Daily or more	3	0 (0)	37	18 (49)	40	18 (45)
Not last month	2	0 (0)	6	2 (33)	8	2 (25)
p value		--		0.549		0.377
2011						
Less than daily	3	0 (0)	10	3 (30)	13	3 (28)
Daily or more	2	1 (50)	36	21 (58)	40	24 (60)
Not last month	1	0 (0)	6	4 (67)	8	5 (63)
p value		0.500		0.239		0.062
2012						
Less than daily	0	0 (0)	12	6 (50)	12	6 (50)
Daily or more	1	0 (0)	25	9 (36)	29	10 (34)
Not last month	2	0 (0)	3	0 (0)	5	0 (0)
p value		--		0.299		0.170
2013						
Less than daily	0	0 (0)	20	14 (70)	20	14 (70)
Daily or more	0	0 (0)	36	17 (47)	37	18 (49)
Not last month	0	0 (0)	7	1 (14)	8	1 (13)
p value		--		0.037		0.020

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No receptive sharing	3	1 (33)	57	23 (40)	61	24 (39)
Receptive sharing	0	0 (0)	6	4 (67)	7	4 (57)
p value		--		0.388		0.435
2010						
No receptive sharing	3	0 (0)	56	30 (54)	59	30 (51)
Receptive sharing	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		0.112		0.238
2011						
No receptive sharing	4	0 (0)	35	19 (54)	41	21 (51)
Receptive sharing	1	1 (100)	8	2 (25)	9	3 (33)
p value		0.200		0.240		0.467
2012						
No receptive sharing	1	0 (0)	32	13 (41)	35	13 (37)
Receptive sharing	0	0 (0)	5	2 (40)	6	3 (50)
p value		--		1.000		0.662
2013						
No receptive sharing	0	0 (0)	49	27 (55)	50	28 (56)
Receptive sharing	0	0 (0)	6	4 (67)	6	4 (67)
p value		--		0.686		0.691

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 4.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No imprisonment	4	1 (25)	62	24 (39)	70	25 (36)
Imprisonment	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		0.161		0.137
2010						
No imprisonment	5	0 (0)	57	30 (53)	62	30 (48)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.237		0.494
2011						
No imprisonment	5	0 (0)	49	26 (53)	57	29 (51)
Imprisonment	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.167		1.000		1.000
2012						
No imprisonment	3	0 (0)	35	13 (37)	41	14 (34)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.631		0.608
2013						
No imprisonment	0	0 (0)	55	25 (45)	57	26 (46)
Imprisonment	0	0 (0)	7	7 (100)	7	7 (100)
p value		--		0.011		0.011

* Total includes people who did not report duration of drug injection

Table 4.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No sex work	4	1 (25)	61	26 (43)	69	27 (39)
Sex work	0	0 (0)	3	0 (0)	3	0 (0)
p value		---		0.265		0.287
2010						
No sex work	5	0 (0)	63	35 (56)	68	35 (51)
Sex work	0	0 (0)	5	0 (0)	5	0 (0)
p value		--		0.023		0.055
2011						
No sex work	5	1 (20)	49	27 (55)	57	31 (54)
Sex work	1	0 (0)	3	1 (33)	4	1 (25)
p value		1.000		0.590		0.338
2012						
No sex work	3	0 (0)	36	14 (39)	42	15 (36)
Sex work	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		1.000		1.000
2013						
No sex work	0	0 (0)	58	29 (50)	60	30 (50)
Sex work	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.492		0.492

* Total includes people who did not report duration of drug injection

Table 4.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Non Indigenous	40	17 (43)	23	9 (39)	63	26 (41)
Indigenous	8	1 (13)	2	0 (0)	10	1 (10)
p value		0.229		0.520		0.080
2010						
Non Indigenous	43	24 (56)	18	6 (33)	61	30 (49)
Indigenous	12	5 (42)	5	2 (40)	17	7 (41)
p value		0.517		1.000		0.595
2011						
Non Indigenous	32	18 (56)	16	7 (44)	48	25 (52)
Indigenous	7	3 (43)	5	3 (60)	12	6 (50)
p value		0.682		0.635		1.000
2012						
Non Indigenous	26	9 (35)	10	3 (30)	36	12 (33)
Indigenous	4	2 (50)	4	1 (25)	9	3 (33)
p value		0.611		1.000		1.000
2013						
Non Indigenous	39	18 (46)	11	5 (45)	50	23 (46)
Indigenous	5	2 (40)	8	7 (88)	13	9 (69)
p value		1.000		0.147		0.213

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
English speaking	44	16 (36)	24	9 (38)	68	25 (37)
Non-English speaking	5	3 (60)	1	0 (0)	6	3 (50)
p value		0.363		1.000		0.667
2010						
English speaking	49	27 (55)	23	8 (35)	72	35 (49)
Non-English speaking	6	2 (33)	0	0 (0)	6	2 (33)
p value		0.406		--		0.678
2011						
English speaking	36	19 (53)	20	10 (50)	56	29 (52)
Non-English speaking	4	3 (75)	1	0 (0)	5	3 (60)
p value		0.613		1.000		1.000
2012						
English speaking	30	11 (37)	13	5 (38)	44	16 (36)
Non-English speaking	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.524		0.536
2013						
English speaking	44	20 (45)	19	12 (63)	63	32 (51)
Non-English speaking	2	1 (50)	0	0 (0)	2	1 (50)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Australia	40	14 (35)	23	8 (35)	63	22 (35)
Other Oceania	1	1 (100)	1	1 (100)	2	2 (100)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	4	3 (75)	0	0 (0)	4	3 (75)
p value		0.283		0.600		0.109
2010						
Australia	46	24 (52)	20	6 (30)	66	30 (45)
Other Oceania	2	1 (50)	1	1 (100)	3	2 (67)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	5	3 (60)	1	1 (100)	6	4 (67)
Other	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.802		0.214		0.698
2011						
Australia	35	18 (51)	18	9 (50)	53	27 (50)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	2	0 (0)	2	2 (100)
UK & Ireland	5	4 (80)	1	1 (100)	6	5 (83)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.355		0.476		0.111
2012						
Australia	25	9 (36)	14	5 (36)	40	14 (35)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	2	1 (50)	1	0 (0)	3	1 (33)
p value		1.000		1.000		1.000
2013						
Australia	41	20 (49)	15	10 (67)	56	30 (54)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	3	1 (33)	2	2 (100)	5	3 (60)
Other	1	0 (0)	2	0 (0)	3	0 (0)
p value		1.000		0.237		0.196

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 5.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2009	2010	2011	2012	2013
Number of sites	8	8	8	8	8
N° surveyed	N=801	N=550	N=552	N=624	N=565
Response (%)	59%	34%	40%	45%	45%
Gender (%)					
Male	585 (73)	419 (76)	394 (71)	454 (73)	397 (70)
Female	211 (26)	126 (23)	154 (28)	168 (27)	167 (30)
Transgender	1 (<1)	1 (<1)	2 (<1)	1 (<1)	1 (<1)
Not reported	4 (<1)	4 (<1)	2 (<1)	1 (<1)	0 (0)
Sexual identity (%)					
Heterosexual	868 (86)	457 (83)	467 (85)	529 (85)	471 (83)
Bisexual	63 (8)	39 (7)	44 (8)	49 (8)	42 (7)
Homosexual	10 (1)	28 (5)	20 (4)	18 (3)	19 (3)
Not reported	42 (5)	26 (5)	21 (4)	28 (4)	33 (6)
Age and duration of injection (years)					
<i>Median age</i>	34	35	35	36	37
Age range	15-66	15-73	17-62	16-71	16-65
<i>Age group (%)</i>					
<25 years	117 (15)	61 (11)	59 (11)	73 (12)	68 (12)
25+ years	684 (85)	487 (86)	492 (89)	551 (88)	495 (88)
Not reported	0 (0)	2 (<1)	1 (<1)	0 (0)	2 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	19
Age range	10-58	10-59	11-56	10-70	11-61
Not reported	19	13	12	15	15
<i>Median years IDU</i>	14	15	15	16	15
Range	<1-46	<1-60	<1-47	<1-53	<1-46
<i>Duration of drug injection</i>					
<3 years	58 (7)	40 (7)	55 (10)	71 (11)	68 (12)
3+ years	724 (90)	496 (90)	486 (88)	538 (86)	482 (85)
Not reported	19 (2)	14 (3)	11 (2)	15 (2)	15 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	675 (84)	479 (87)	481 (87)	537 (86)	493 (87)
Yes	105 (13)	62 (11)	55 (10)	78 (13)	58 (10)
Not reported	21 (3)	9 (2)	16 (3)	9 (1)	14 (2)
Region/Country of birth (%)					
Australia	698 (87)	490 (89)	465 (84)	549 (88)	504 (89)
Other Oceania	40 (5)	20 (4)	29 (5)	35 (6)	29 (5)
Asia	5 (<1)	5 (1)	4 (1)	1 (<1)	0 (0)
UK & Ireland	24 (3)	17 (3)	22 (4)	22 (4)	13 (2)
Other	21 (3)	15 (3)	22 (4)	14 (2)	17 (3)
Not reported	13 (2)	3 (<1)	10 (2)	3 (<1)	2 (<1)
Main language spoken at home by parents (%)					
English speaking	768 (96)	535 (97)	530 (96)	606 (97)	544 (96)
Non-English speaking	24 (3)	9 (2)	15 (3)	16 (3)	19 (3)
Not reported	9 (1)	6 (1)	7 (1)	2 (<1)	2 (<1)
Imprisonment last year (%)					
No	656 (82)	410 (75)	474 (86)	543 (88)	497 (88)
Yes	111 (14)	51 (9)	49 (9)	64 (10)	45 (8)
Not reported	34 (4)	89 (16)	29 (5)	11 (2)	23 (4)
Injected in prison (%)	N=111	N=51	N=49	N=64	N=45
Yes	51 (46)	25 (49)	26 (53)	30 (47)	17 (38)
Frequency of injection last month (%)					
Not last month	74 (9)	59 (11)	51 (9)	67 (11)	41 (7)
Less than weekly	123 (15)	103 (19)	99 (18)	112 (18)	107 (19)
21)Weekly not daily	173 (22)	131 (24)	136 (25)	133 (21)	153 (27)
Daily or more	426 (53)	252 (46)	260 (47)	305 (49)	254 (45)
Not reported	5 (<1)	5 (1)	6 (1)	7 (1)	10 (2)

Table 5.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2009	2010	2011	2012	2013
Last drug injected (%)	N=801	N=550	N=552	N=624	N=565
Cocaine	7 (<1)	2 (<1)	6 (1)	3 (<1)	3 (<1)
Heroin	218 (27)	123 (22)	112 (20)	129 (21)	91 (16)
Methadone	38 (5)	36 (7)	22 (4)	45 (7)	36 (6)
Methamphetamine	232 (29)	149 (27)	162 (29)	165 (26)	162 (29)
Performance/Image-enhancing drugs	9 (1)	24 (4)	41 (7)	70 (11)	71 (13)
Pharmaceutical opioids	177 (22)	141 (26)	130 (24)	124 (20)	117 (21)
Suboxone®	10 (1)	13 (2)	10 (2)	17 (3)	16 (3)
Subutex®/Buprenorphine	53 (7)	32 (6)	39 (7)	41 (7)	32 (6)
More than one	30 (4)	19 (3)	24 (4)	20 (3)	35 (6)
Other drug	10 (1)	9 (2)	6 (1)	8 (1)	1 (<1)
Not reported	17 (2)	2 (<1)	0 (0)	2 (<1)	1 (<1)
N° Injected last month	N=722	N=487	N=495	N=550	N=514
Places injected last month (%)*					
Any public	347 (48)	174 (36)	174 (35)	193 (35)	163 (32)
All private	367 (51)	280 (57)	303 (61)	347 (63)	347 (68)
Not reported	8 (1)	33 (7)	18 (4)	10 (2)	4 (1)
Use of new sterile needles & syringes last month (%)					
All injections	532 (74)	348 (71)	368 (74)	426 (77)	391 (76)
Most of the time	151 (21)	91 (19)	92 (19)	85 (15)	101 (20)
Half of the time	10 (1)	8 (2)	12 (2)	12 (2)	12 (2)
Some of the time	14 (2)	5 (1)	6 (1)	2 (<1)	5 (1)
Not last month	5 (<1)	1 (<1)	2 (<1)	4 (<1)	1 (<1)
Not reported	10 (1)	34 (7)	15 (3)	21 (4)	4 (1)
Re-used another's used needle & syringe last month (%)					
None	579 (80)	377 (77)	379 (77)	463 (84)	437 (85)
Once	37 (5)	13 (3)	29 (6)	31 (6)	21 (4)
Twice	23 (5)	9 (2)	15 (3)	12 (2)	18 (4)
3-5 times	32 (4)	11 (2)	19 (4)	12 (2)	13 (3)
>5 times	31 (4)	10 (2)	18 (4)	21 (4)	19 (4)
Not reported	20 (3)	67 (14)	35 (7)	11 (2)	6 (1)
Number of people needle & syringe was re-used after last month (%)					
None	579 (80)	377 (77)	379 (77)	463 (84)	437 (85)
One	63 (9)	26 (5)	43 (9)	36 (7)	39 (8)
Two	11 (2)	1 (<1)	6 (1)	4 (<1)	7 (1)
Three to five	7 (1)	7 (1)	3 (<1)	1 (<1)	3 (<1)
More than five	5 (<1)	3 (<1)	4 (1)	6 (1)	2 (<1)
Don't know	16 (2)	10 (2)	9 (2)	10 (2)	15 (3)
Not reported	41 (6)	63 (13)	51 (10)	30 (5)	11 (2)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	52 (7)	29 (6)	45 (9)	27 (5)	33 (6)
Casual sex partner	1 (<1)	1 (<1)	2 (<1)	1 (<1)	4 (1)
Close friend	43 (6)	17 (3)	28 (6)	19 (3)	20 (4)
Acquaintance	8 (1)	7 (1)	11 (2)	8 (1)	12 (2)
Other	6 (<1)	6 (1)	10 (2)	7 (1)	6 (1)
Equipment used after someone else last month (%)*					
Spoon	187 (28)	97 (20)	111 (22)	114 (21)	104 (20)
Water	132 (20)	74 (15)	77 (16)	73 (13)	85 (17)
Filter	100 (15)	56 (12)	54 (11)	58 (11)	55 (11)
Drug mix	65 (10)	41 (8)	42 (8)	51 (9)	45 (9)
None	389 (59)	317 (65)	318 (64)	387 (70)	379 (74)
Injected by someone after that person injected themselves or others last month (%)					
No	575 (80)	382 (78)	404 (82)	466 (85)	438 (85)
Yes	133 (18)	49 (10)	69 (14)	73 (13)	65 (13)
Not reported	14 (2)	56 (12)	22 (4)	11 (2)	11 (2)
Present when someone injected for the first time in the last 12 months (%)**					
Yes	--	--	--	98 (18)	78 (15)
Overdosed in the last 12 months **					
Yes	--	--	--	--	65 (12)

* More than one option could be selected ** New question in 2012 or 2013

Table 5.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2009	2010	2011	2012	2013
N° surveyed	N=801	N=487	N=552	N=624	N=565
Sex with a regular partner last month (%)					
No	358 (45)	241 (44)	250 (45)	280 (45)	255 (45)
Yes	414 (52)	284 (52)	280 (51)	334 (54)	304 (54)
Not reported	29 (4)	25 (5)	22 (4)	10 (2)	6 (1)
Condom used with regular partner last month (%)					
N° surveyed	N=414	N=284	N=280	N=334	N=304
Never	293 (71)	194 (68)	199 (71)	256 (77)	221 (73)
Sometimes	58 (14)	42 (15)	34 (12)	39 (12)	40 (13)
Every time	41 (10)	33 (12)	30 (11)	31 (9)	27 (9)
Not reported	22 (5)	15 (5)	17 (6)	8 (2)	16 (5)
Sex with other partner/s last month (%)					
No	653 (82)	440 (80)	449 (81)	526 (84)	461 (82)
Yes	117 (15)	79 (14)	81 (15)	77 (12)	83 (15)
Not reported	31 (4)	31 (6)	22 (4)	21 (3)	21 (4)
Condom used with other partner/s last month (%)					
N° surveyed	N=117	N=79	N=81	N=77	N=83
Never	40 (34)	25 (32)	30 (37)	24 (31)	26 (31)
Sometimes	40 (34)	20 (25)	20 (25)	20 (26)	22 (37)
Every time	36 (31)	31 (39)	24 (30)	23 (30)	34 (41)
Not reported	1 (<1)	3 (4)	7 (9)	10 (13)	1 (1)
Sex work last month (%)					
No	740 (92)	489 (89)	509 (92)	593 (95)	525 (93)
Yes	30 (4)	14 (3)	19 (3)	17 (3)	9 (2)
Not reported	31 (4)	47 (9)	24 (4)	14 (2)	31 (5)
Condom used at last sex work last month (%)					
Yes	18 (69)	10 (83)	12 (80)	13 (76)	6 (86)

Table 5.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2009	2010	2011	2012	2013
N° surveyed	N=801	N=550	N=552	N=624	N=565
Any treatment/therapy for drug use (%)					
No	182 (23)	119 (22)	152 (28)	176 (28)	188 (33)
Yes	606 (76)	410 (75)	380 (69)	442 (71)	373 (66)
Not reported	13 (2)	21 (4)	20 (4)	6 (1)	4 (1)
History of methadone maintenance treatment (%)					
Currently	143 (18)	98 (18)	92 (17)	106 (17)	95 (17)
Previously	189 (24)	133 (24)	121 (22)	151 (24)	114 (20)
Never	453 (57)	292 (53)	322 (58)	362 (58)	354 (63)
Not reported	16 (2)	27 (5)	17 (3)	5 (1)	2 (1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	115 (14)	77 (14)	67 (12)	74 (12)	51 (9)
Previously	173 (22)	121 (22)	120 (22)	144 (23)	149 (26)
Never	497 (62)	345 (63)	343 (62)	401 (64)	358 (63)
Not reported	16 (2)	7 (1)	22 (4)	5 (1)	7 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	70 (9)	47 (9)	46 (8)	60 (10)	56 (10)
Previously	153 (19)	109 (20)	110 (20)	132 (21)	110 (19)
Never	560 (70)	379 (69)	376 (68)	427 (68)	389 (70)
Not reported	18 (2)	15 (3)	20 (4)	5 (1)	10 (2)

Table 5.1.5 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2009	2010	2011	2012	2013
N° surveyed	N=801	N=550	N=552	N=624	N=565
Previous HIV test (%)					
Yes, last year	410 (51)	239 (43)	281 (51)	291 (47)	277 (49)
> 1 year ago	239 (30)	205 (37)	193 (35)	226 (36)	200 (35)
Never tested	126 (16)	73 (13)	63 (11)	87 (14)	82 (15)
Not reported	26 (3)	33 (6)	15 (3)	20 (3)	6 (1)
Previous HCV test (%)					
Yes, last year	446 (56)	281 (51)	290 (53)	328 (53)	269 (48)
> 1 year ago	249 (31)	187 (34)	182 (33)	205 (33)	197 (35)
Never tested	85 (11)	44 (8)	47 (9)	60 (10)	56 (10)
Not reported	21 (9)	38 (7)	33 (6)	31 (5)	43 (8)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=351	N=263	N=255	N=289	N=257
Interferon/Interferon+Ribavirin	18 (5)	27 (10)	20 (8)	24 (8)	25 (10)
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	5 (2)
Other	6 (2)	2 (1)	5 (2)	1 (<1)	1 (<1)
No treatment	300 (85)	222 (84)	217 (85)	257 (89)	218 (85)
Not reported	20 (6)	12 (5)	13 (5)	7 (2)	8 (3)
Current treatment for HCV**	N=8	N=2	N=4	N=6	N=6
Interferon/Interferon+Ribavirin	6	2	2	6	3
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	3
Other	2	0	2	0	0

* New treatment options added ** 'Current treatment' defined as within the previous 12 months from 2013

Table 5.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2009	2010	2011	2012	2013
N° Injected last month	N=722	N=487	N=495	N=550	N=514
Needle Syringe Program	461 (64)	430 (88)	444 (90)	500 (91)	487 (95)
Chemist/Pharmacy	234 (32)	112 (23)	118 (24)	159 (29)	109 (21)
Personal sources	133 (18)	47 (10)	38 (7)	50 (9)	34 (7)
Dispensing/Vending Machine	71 (10)	56 (12)	72 (15)	78 (14)	52 (10)
Other sources	18 (2)	4 (6)	5 (1)	6 (1)	3 (1)

* More than one option could be selected

Table 5.1.7 Number (percentage) of respondents by last drug injected and all drugs injected in the last 12 months (2013)

Last drug injected	N° (%)	Drugs injected in last 12 months*							
		Cocaine	Heroin	Methadone	Methamphetamine	PIEDs	Pharm. Opioids	Subutex/Suboxone	No other drugs
Cocaine	3 (<1)	3 (100)	2 (67)	1 (33)	2 (67)	0 (0)	1 (33)	1 (33)	0 (0)
Heroin	91 (16)	8 (9)	91 (100)	9 (10)	35 (38)	0 (0)	23 (25)	17 (19)	36 (40)
Methadone	36 (6)	0 (0)	16 (44)	36 (100)	16 (44)	0 (0)	13 (36)	5 (14)	10 (28)
Methamphetamine	162 (29)	16 (10)	30 (19)	14 (9)	162 (100)	1 (1)	29 (18)	26 (16)	104 (64)
PIEDs	71 (13)	0 (0)	0 (0)	0 (0)	1 (1)	71 (100)	1 (1)	3 (4)	60 (85)
Pharm. opioids	117 (21)	7 (6)	56 (48)	21 (18)	61 (52)	5 (4)	117 (100)	17 (15)	0 (0)
Subutex/Suboxone	48 (9)	4 (8)	22 (46)	10 (21)	29 (60)	1 (2)	18 (38)	48 (100)	9 (19)
Other/Not reported	37 (7)	6 (16)	15 (41)	16 (43)	26 (70)	6 (16)	21 (57)	16 (43)	0 (0)
Total	565	44 (8)	232 (41)	107 (19)	332 (59)	84 (15)	223 (39)	133 (24)	219 (39)

* More than one option could be selected

HIV antibody prevalence

Table 5.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009	581	10 (1.7)	209	0 (0.0)	795	10 (1.3)
2010	407	11 (2.1)	123	0 (0.0)	535	11 (2.1)
2011	376	8 (2.1)	148	0 (0.0)	528	8 (1.5)
2012	415	7 (1.7)	153	2 (1.3)	570	9 (1.6)
2013	372	7 (1.9)	160	0 (0.0)	533	7 (1.3)
X ² trend p value		0.849		0.300		0.949

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Heterosexual	519	1 (0.2)	162	0 (0.0)	682	1 (0.2)
Bisexual	24	2 (8.3)	37	0 (0.0)	62	2 (3.2)
Homosexual	9	6 (67.0)	1	0 (0.0)	10	6 (60.0)
p value		<0.001		---		<0.001
2010						
Heterosexual	345	2 (0.6)	97	0 (0.0)	445	2 (0.5)
Bisexual	21	2 (9.5)	16	0 (0.0)	37	2 (5.4)
Homosexual	21	7 (33)	6	0 (0.0)	27	87(25.9)
p value		<0.001		---		<0.001
2011						
Heterosexual	340	2 (0.6)	109	0 (0.0)	451	2 (0.4)
Bisexual	13	0 (0.0)	29	0 (0.0)	43	0 (0.0)
Homosexual	11	6 (54.6)	6	0 (0.0)	17	6 (35.3)
p value		<0.001		---		<0.001
2012						
Heterosexual	368	1 (0.3)	112	2 (1.8)	480	3 (0.6)
Bisexual	20	2 (10.0)	27	0 (0.0)	48	2 (4.2)
Homosexual	11	2 (18.2)	6	0 (0.0)	17	2 (11.8)
p value		<0.001		1.000		0.002
2013						
Heterosexual	322	1 (0.3)	119	0 (0.0)	442	1 (0.2)
Bisexual	13	1 (7.7)	28	0 (0.0)	41	1 (2.4)
Homosexual	17	5 (29.4)	2	0 (0.0)	19	5 (26.3)
p value		<0.001		--		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.3 HIV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
< 25 years	75	0 (0.0)	39	0 (0.0)	116	0 (0.0)
25 – 34	220	3 (1.4)	82	0 (0.0)	304	3 (1.0)
35+ years	283	7 (2.5)	85	0 (0.0)	369	7 (1.9)
p value		0.305		--		0.242
2010						
< 25 years	44	0 (0.0)	13	0 (0.0)	58	0 (0.0)
25 – 34	155	2 (1.3)	50	0 (0.0)	205	2 (1.0)
35+ years	208	10 (4.8)	59	0 (0.0)	271	10 (3.7)
p value		0.090		--		0.092
2011						
< 25 years	45	0 (0.0)	9	0 (0.0)	56	0 (0.0)
25 – 34	129	0 (0.0)	67	0 (0.0)	197	0 (0.0)
35+ years	201	8 (4.0)	72	0 (0.0)	274	8 (2.9)
p value		0.039		---		0.023
2012						
< 25 years	56	0 (0.0)	13	0 (0.0)	69	0 (0.0)
25 – 34	128	1 (0.8)	63	0 (0.0)	192	1 (0.5)
35+ years	231	2 (2.6)	77	2 (2.6)	309	8 (2.6)
p value		0.408		0.583		0.181
2013						
< 25 years	43	0 (0.0)	20	0 (0.0)	63	0 (0.0)
25 – 34	111	0 (0.0)	49	0 (0.0)	160	0 (0.0)
35+ years	216	7 (3.2)	91	0 (0.0)	308	7 (2.3)
p value		0.112		--		0.115

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.4 HIV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
<3 years	36	0 (0.0)	20	0 (0.0)	57	0 (0.0)
3 to 10 years	128	1 (0.8)	67	0 (0.0)	197	1 (0.5)
11 + years	404	9 (2.2)	116	0 (0.0)	522	9 (1.7)
p value		0.394		--		0.291
2010						
<3 years	29	0 (0.0)	7	0 (0.0)	36	0 (0.0)
3 to 10 years	82	3 (3.7)	28	0 (0.0)	111	3 (2.7)
11 + years	288	9 (3.1)	83	0 (0.0)	375	9 (2.4)
p value		0.782		--		0.891
2011						
<3 years	41	1 (2.4)	12	0 (0.0)	84	1 (1.9)
3 to 10 years	71	1 (1.4)	36	0 (0.0)	108	1 (0.9)
11 + years	254	6 (2.4)	99	0 (0.0)	355	6 (1.7)
p value		1.000		---		1.000
2012						
<3 years	52	0 (0.0)	11	0 (0.0)	63	0 (0.0)
3 to 10 years	77	1 (1.3)	31	0 (0.0)	108	1 (0.9)
11 + years	275	6 (2.2)	109	2 (1.8)	386	8 (2.1)
p value		0.847		1.000		0.653
2013						
<3 years	51	1 (2.0)	10	0 (0.0)	61	1 (1.6)
3 to 10 years	74	1 (1.4)	34	0 (0.0)	108	1 (0.9)
11 + years	237	5 (2.1)	113	0 (0.0)	351	5 (1.4)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.5 HIV antibody prevalence by last drug injected, gender and survey year

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Heroin	158	1 (0.6)	57	0 (0.0)	216	1 (0.5)
Methamphetamine	169	7 (4.1)	60	0 (0.0)	231	7 (3.0)
Other	242	2 (0.8)	84	0 (0.0)	328	2 (0.6)
p value		0.016		--		0.016
2010						
Heroin	93	3 (3.2)	30	0 (0.0)	123	3 (2.4)
Methamphetamine	107	7 (6.6)	33	0 (0.0)	143	7 (4.9)
Other	207	2 (1.0)	59	0 (0.0)	268	2 (0.8)
p value		0.014		--		0.019
2011						
Heroin	75	0 (0.0)	32	0 (0.0)	107	0 (0.0)
Methamphetamine	102	4 (3.9)	54	0 (0.0)	156	4 (2.6)
Other	199	4 (2.0)	62	0 (0.0)	265	4 (1.5)
p value		0.267		--		0.284
2012						
Heroin	70	0 (0.0)	48	1 (2.1)	118	1 (0.9)
Methamphetamine	103	2 (1.9)	46	0 (0.0)	149	2 (1.3)
Other	240	5 (2.1)	59	1 (1.7)	301	6 (2.0)
p value		0.666		1.000		0.905
2013						
Heroin	58	0 (0.0)	30	0 (0.0)	88	0 (0.0)
Methamphetamine	91	6 (6.6)	62	0 (0.0)	153	6 (3.9)
Other	222	1 (0.5)	68	0 (0.0)	291	1 (0.3)
p value		0.004		--		0.007

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Less than daily	218	6 (2.8)	76	0 (0.0)	296	6 (2.0)
Daily or more	305	3 (1.0)	112	0 (0.0)	420	3 (0.7)
Not last month	56	1 (1.8)	18	0 (0.0)	74	1 (1.4)
p value		0.310		--		0.301
2010						
Less than daily	181	4 (2.2)	58	0 (0.0)	242	4 (1.7)
Daily or more	174	1 (0.6)	57	0 (0.0)	232	1 (0.4)
Not last month	49	7 (14.3)	8	0 (0.0)	58	7 (12.1)
p value		<0.001		--		<0.001
2011						
Less than daily	162	4 (2.5)	61	0 (0.0)	224	4 (1.8)
Daily or more	169	2 (1.2)	76	0 (0.0)	247	2 (0.8)
Not last month	41	2 (4.9)	10	0 (0.0)	51	2 (3.9)
p value		0.196		---		0.176
2012						
Less than daily	163	2 (1.2)	60	0 (0.0)	224	2 (0.9)
Daily or more	201	4 (2.0)	78	2 (2.6)	279	6 (2.2)
Not last month	47	1 (2.1)	14	0 (0.0)	61	1 (1.6)
p value		0.756		0.592		0.484
2013						
Less than daily	173	3 (1.7)	75	0 (0.0)	249	3 (1.2)
Daily or more	164	2 (1.2)	78	0 (0.0)	242	2 (0.8)
Not last month	27	1 (3.7)	6	0 (0.0)	33	1 (3.0)
p value		0.508		--		0.470

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No receptive sharing	418	9 (2.2)	152	0 (0.0)	574	9 (1.6)
Receptive sharing	94	0 (0.0)	28	0 (0.0)	123	0 (0.0)
p value		0.377		---		0.373
2010						
No receptive sharing	279	4 (1.4)	88	0 (0.0)	369	4 (1.1)
Receptive sharing	28	1 (2.6)	13	0 (0.0)	41	1 (2.4)
p value		0.382		--		0.411
2011						
No receptive sharing	260	6 (2.3)	101	0 (0.0)	363	6 (1.7)
Receptive sharing	48	0 (0.0)	28	0 (0.0)	77	0 (0.0)
p value		0.595		---		0.596
2012						
No receptive sharing	307	6 (2.0)	115	2 (1.7)	422	8 (1.9)
Receptive sharing	52	0 (0.0)	19	0 (0.0)	71	0 (0.0)
p value		0.599		1.000		0.609
2013						
No receptive sharing	289	2 (0.7)	124	0 (0.0)	414	2 (0.5)
Receptive sharing	45	2 (4.4)	26	0 (0.0)	71	2 (2.8)
p value		0.089		--		0.104

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No imprisonment	465	10 (2.2)	182	0 (0.0)	652	10 (1.5)
Imprisonment	86	0 (0.0)	24	0 (0.0)	110	0 (0.0)
p value		0.375		---		0.372
2010						
No imprisonment	302	10 (3.3)	94	0 (0.0)	401	10 (2.5)
Imprisonment	38	0 (0.0)	10	0 (0.0)	48	0 (0.0)
p value		0.610		---		0.609
2011						
No imprisonment	325	8 (2.5)	135	0 (0.0)	463	8 (1.7)
Imprisonment	40	0 (0.0)	8	0 (0.0)	48	0 (0.0)
p value		0.606		---		1.000
2012						
No imprisonment	350	6 (1.7)	141	2 (1.4)	493	8 (1.6)
Imprisonment	52	1 (1.9)	9	0 (0.0)	61	1 (1.6)
p value		1.000		1.000		1.000
2013						
No imprisonment	319	7 (2.2)	150	0 (0.0)	470	7 (1.5)
Imprisonment	37	0 (0.0)	6	0 (0.0)	43	0 (0.0)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.9 HIV antibody prevalence by condom use at last sex, gender and survey year

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No condom use	224	3 (1.3)	118	0 (0.0)	347	3 (0.9)
Condom use	33	2 (6.1)	8	0 (0.0)	41	2 (4.9)
p value		0.125		---		0.089
2010						
No condom use	131	3 (2.3)	56	0 (0.0)	189	3 (1.6)
Condom use	56	2 (3.8)	15	0 (0.0)	71	2 (2.8)
p value		0.637		--		0.616
2011						
No condom use	121	2 (1.7)	70	0 (0.0)	192	2 (1.0)
Condom use	44	1 (2.3)	14	0 (0.0)	59	1 (1.7)
p value		1.000		---		0.554
2012						
No condom use	155	0 (0.0)	73	0 (0.0)	229	0 (0.0)
Condom use	48	3 (6.3)	18	1 (5.6)	66	4 (6.1)
p value		0.013		0.198		0.002
2013						
No condom use	132	2 (1.5)	76	0 (0.0)	208	2 (1.0)
Condom use	47	3 (6.4)	15	0 (0.0)	62	3 (4.8)
p value		0.114		--		0.081

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 5.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
No sex work	545	10 (1.8)	188	0 (0.0)	737	10 (1.4)
Sex work	13	0 (0.0)	16	0 (0.0)	30	0 (0.0)
p value		1.000		---		1.000
2010						
No sex work	370	11 (3.0)	103	0 (0.0)	477	11 (2.3)
Sex work	4	0 (0.0)	9	0 (0.0)	13	0 (0.0)
p value		1.000		--		1.000
2011						
No sex work	355	7 (2.0)	135	0 (0.0)	492	7 (1.4)
Sex work	4	0 (0.0)	11	0 (0.0)	16	0 (0.0)
p value		1.000		---		1.000
2012						
No sex work	399	7 (1.8)	141	1 (0.7)	542	8 (1.5)
Sex work	4	0 (0.0)	11	1 (9.1)	15	1 (6.7)
p value		1.000		0.140		0.219
2013						
No sex work	346	7 (2.0)	148	0 (0.0)	495	7 (1.4)
Sex work	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Non Indigenous	495	10 (2.0)	172	0 (0.0)	672	10 (1.5)
Indigenous	67	0 (0.0)	35	0 (0.0)	102	0 (0.0)
p value		0.617		---		0.375
2010						
Non Indigenous	358	10 (2.8)	103	0 (0.0)	466	10 (2.2)
Indigenous	42	1 (2.4)	19	0 (0.0)	61	1 (1.6)
p value		1.000		--		1.000
2011						
Non Indigenous	329	8 (2.4)	128	0 (0.0)	460	8 (1.8)
Indigenous	36	0 (0.0)	18	0 (0.0)	54	0 (0.0)
p value		1.000		---		1.000
2012						
Non Indigenous	357	7 (2.0)	128	1 (0.8)	487	8 (1.6)
Indigenous	52	0 (0.0)	22	0 (0.0)	74	0 (0.0)
p value		0.603		1.000		0.605
2013						
Non Indigenous	330	7 (2.1)	135	0 (0.0)	466	7 (1.5)
Indigenous	33	0 (0.0)	21	0 (0.0)	54	0 (0.0)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
English speaking	558	10 (1.8)	199	0 (0.0)	762	10 (1.3)
Non-English speaking	14	0 (0.0)	10	0 (0.0)	24	0 (0.0)
p value		1.000		---		1.000
2010						
English speaking	396	11 (2.8)	120	0 (0.0)	521	11 (2.1)
Non-English speaking	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
p value		1.000		---	0	1.000
2011						
English speaking	360	8 (2.2)	145	0 (0.0)	509	8 (1.6)
Non-English speaking	11	0 (0.0)	3	0 (0.0)	14	0 (0.0)
p value		1.000		---		1.000
2012						
English speaking	405	5 (1.2)	148	2 (1.4)	554	7 (1.3)
Non-English speaking	9	2 (22.2)	4	0 (0.0)	14	2 (14.3)
p value		0.008		1.000		0.018
2013						
English speaking	362	7 (1.9)	154	0 (0.0)	517	7 (1.4)
Non-English speaking	8	0 (0.0)	6	0 (0.0)	14	0 (0.0)
p value		1.000		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009						
Australia	504	10 (2.0)	183	0 (0.0)	692	10 (1.5)
Other Oceania	28	0 (0.0)	12	0 (0.0)	40	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	19	0 (0.0)	5	0 (0.0)	24	0 (0.0)
Other	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
p value		1.000		---		0.455
2010						
Australia	361	10 (2.8)	110	0 (0.0)	476	10 (2.1)
Other Oceania	16	0 (0.0)	4	0 (0.0)	20	0 (0.0)
Asia	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
UK & Ireland	15	0 (0.0)	2	0 (0.0)	17	0 (0.0)
Other	11	1 (9.1)	5	0 (0.0)	16	1 (6.3)
p value		0.618		--		0.689
2011						
Australia	316	8 (2.5)	126	0 (0.0)	446	8 (1.8)
Other Oceania	18	0 (0.0)	11	0 (0.0)	29	0 (0.0)
Asia	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
UK & Ireland	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
Other	18	0 (0.0)	2	0 (0.0)	20	0 (0.0)
p value		1.000		---		1.000
2012						
Australia	369	5 (1.4)	134	2 (1.5)	505	7 (1.4)
Other Oceania	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
UK & Ireland	14	1 (7.1)	5	0 (0.0)	19	1 (5.3)
Other	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
p value		0.080		1.000		0.122
2013						
Australia	334	6 (1.8)	141	0 (0.0)	476	6 (1.3)
Other Oceania	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	8	0 (0.0)	4	0 (0.0)	12	0 (0.0)
Other	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
p value		0.739		--		0.690

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 5.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009	576	244 (42)	209	94 (45)	790	339 (43)
2010	403	180 (45)	121	58 (48)	529	241 (46)
2011	368	158 (43)	146	63 (43)	518	221 (43)
2012	409	183 (45)	154	83 (54)	565	267 (47)
2013	372	167 (45)	160	79 (49)	533	247 (46)
X ² trend p value		0.739		0.213		0.155

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heterosexual	514	222 (43)	162	67 (41)	677	289 (43)
Bisexual	24	7 (29)	37	22 (59)	62	29 (47)
Homosexual	9	3 (33)	1	1 (100)	10	4 (40)
p value		0.375		0.054		0.808
2010						
Heterosexual	340	150 (44)	96	45 (47)	439	197 (45)
Bisexual	21	10 (48)	15	9 (60)	36	19 (53)
Homosexual	22	7 (32)	6	2 (33)	28	9 (32)
p value		0.486		0.490		0.267
2011						
Heterosexual	334	145 (43)	107	45 (42)	443	190 (43)
Bisexual	12	4 (33)	28	13 (46)	41	17 (41)
Homosexual	10	3 (30)	6	1 (17)	16	4 (25)
p value		0.620		0.440		0.403
2012						
Heterosexual	363	161 (44)	112	59 (53)	474	220 (46)
Bisexual	20	10 (50)	27	16 (59)	48	26 (54)
Homosexual	11	5 (45)	7	3 (43)	18	8 (44)
p value		0.916		0.736		0.604
2013						
Heterosexual	322	142 (44)	119	58 (49)	442	201 (45)
Bisexual	13	6 (46)	28	16 (57)	41	22 (54)
Homosexual	17	6 (35)	2	0 (0)	19	6 (32)
p value		0.763		0.303		0.275

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
< 25 years	75	17 (23)	39	15 (38)	116	32 (28)
25 – 34	218	75 (34)	85	39 (46)	305	114 (37)
35+ years	283	152 (54)	85	40 (47)	369	193 (52)
p value		<0.001		0.655		<0.001
2010						
< 25 years	43	7 (16)	13	3 (23)	57	10 (18)
25 – 34	154	55 (36)	50	25 (50)	204	80 (39)
35+ years	205	118 (58)	57	30 (53)	266	151 (57)
p value		<0.001		0.166		<0.001
2011						
< 25 years	45	3 (7)	9	3 (33)	56	6 (11)
25 – 34	128	44 (34)	65	24 (37)	194	68 (35)
35+ years	194	110 (57)	72	36 (50)	267	146 (55)
p value		<0.001		0.248		<0.001
2012						
< 25 years	55	6 (11)	13	4 (31)	68	10 (15)
25 – 34	129	49 (38)	64	38 (59)	194	88 (45)
35+ years	225	128 (57)	77	41 (53)	303	169 (56)
p value		<0.001		0.166		<0.001
2013						
< 25 years	43	5 (12)	20	5 (25)	63	10 (16)
25 – 34	111	38 (34)	49	24 (49)	160	62 (39)
35+ years	216	123 (57)	91	50 (55)	308	174 (56)
p value		0.000		0.056		0.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
<3 years	36	3 (8)	20	3 (15)	57	6 (11)
3 to 10 years	127	41 (32)	67	27 (40)	196	68 (35)
11 + years	400	196 (49)	116	63 (54)	518	260 (50)
p value		<0.001		0.003		<0.001
2010						
<3 years	29	2 (7)	7	0 (0)	36	2 (6)
3 to 10 years	80	25 (31)	28	9 (32)	109	34 (31)
11 + years	285	149 (52)	81	47 (58)	370	199 (54)
p value		<0.001		0.001		<0.001
2011						
<3 years	41	3 (7)	11	2 (18)	53	5 (9)
3 to 10 years	70	18 (26)	36	11 (31)	107	29 (27)
11 + years	247	136 (55)	98	50 (51)	347	186 (54)
p value		<0.001		0.023		<0.001
2012						
<3 years	52	4 (8)	11	3 (27)	63	7 (11)
3 to 10 years	76	17 (22)	31	6 (19)	107	23 (22)
11 + years	271	157 (58)	110	72 (65)	383	230 (60)
p value		<0.001		<0.001		<0.001
2013						
<3 years	51	3 (6)	10	2 (20)	61	5 (8)
3 to 10 years	74	16 (22)	34	15 (44)	108	31 (29)
11 + years	237	139 (59)	113	61 (54)	351	201 (57)
p value		0.000		0.087		0.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heroin	12	3 (25)	202	114 (56)	216	117 (54)
All other opioids	15	3 (20)	250	118 (47)	272	125 (46)
Methamphetamine	22	0 (0)	206	65 (32)	231	65 (28)
Perform/Image-enhancing drugs	4	0 (0)	4	1 (25)	9	1 (11)
Other	2	0 (0)	42	24 (57)	46	25 (54)
p value		0.128		<0.001		<0.001
2010						
Heroin	5	0 (0)	113	66 (58)	122	70 (57)
All other opioids	7	1 (14)	199	103 (52)	212	107 (50)
Methamphetamine	11	1 (9)	127	45 (35)	142	47 (33)
Perform/Image-enhancing drugs	10	0 (0)	13	0 (0)	23	0 (0)
Other	3	0 (0)	24	17 (71)	28	17 (61)
p value		0.674		<0.001		<0.001
2011						
Heroin	7	2 (29)	98	53 (54)	106	55 (52)
All other opioids	5	1 (20)	183	97 (53)	189	98 (52)
Methamphetamine	11	1 (9)	139	50 (36)	152	52 (34)
Perform/Image-enhancing drugs	26	1 (4)	8	1 (13)	39	2 (5)
Other	4	0 (0)	26	14 (54)	32	14 (44)
p value		0.285		0.003		<0.001
2012						
Heroin	3	1 (33)	113	72 (64)	118	75 (64)
All other opioids	5	2 (40)	198	113 (57)	208	118 (57)
Methamphetamine	10	3 (30)	134	51 (38)	146	56 (38)
Perform/Image-enhancing drugs	42	1 (2)	19	3 (16)	62	4 (6)
Other	2	0 (0)	25	14 (56)	29	14 (48)
p value		0.013		<0.001		<0.001
2013						
Heroin	3	1 (33)	83	51 (61)	88	53 (60)
All other opioids	10	2 (20)	178	102 (57)	194	110 (57)
Methamphetamine	12	2 (17)	137	56 (41)	153	60 (39)
Perform/Image-enhancing drugs	33	0 (0)	27	0 (0)	60	0 (0)
Other	3	0 (0)	33	22 (67)	37	23 (62)
p value		0.068		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Less than daily	22	1 (5)	268	105 (39)	294	107 (36)
Daily or more	26	5 (19)	383	186 (49)	417	194 (47)
Not last month	9	0 (0)	59	34 (58)	74	35 (47)
p value		0.136		0.010		0.019
2010						
Less than daily	19	0 (0)	216	89 (41)	237	90 (38)
Daily or more	10	2 (20)	212	116 (55)	230	122 (53)
Not last month	5	0 (0)	50	28 (56)	58	28 (48)
p value		0.098		0.011		0.004
2011						
Less than daily	29	2 (7)	187	80 (43)	220	82 (37)
Daily or more	16	3 (19)	221	118 (53)	241	122 (51)
Not last month	7	0 (0)	41	16 (39)	51	16 (31)
p value		0.396		0.055		0.003
2012						
Less than daily	25	3 (12)	193	94 (49)	219	97 (44)
Daily or more	16	2 (13)	256	138 (54)	279	146 (52)
Not last month	21	2 (10)	37	19 (51)	61	22 (36)
p value		1.000		0.551		0.035
2013						
Less than daily	39	2 (5)	203	97 (48)	249	104 (42)
Daily or more	15	3 (20)	222	121 (55)	242	129 (53)
Not last month	7	0 (0)	25	8 (32)	33	8 (24)
p value		0.185		0.066		0.001

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No receptive sharing	33	1 (3)	529	225 (43)	569	228 (40)
Receptive sharing	13	5 (38)	106	57 (54)	123	63 (51)
p value		0.005		0.042		0.027
2010						
No receptive sharing	25	2 (8)	331	149 (45)	365	156 (43)
Receptive sharing	1	0 (0)	38	24 (63)	40	24 (60)
p value		1.000		0.040		0.044
2011						
No receptive sharing	38	4 (11)	311	141 (45)	356	146 (41)
Receptive sharing	5	0 (0)	68	39 (57)	74	39 (53)
p value		1.000		0.082		0.071
2012						
No receptive sharing	37	5 (14)	376	184 (49)	417	192 (46)
Receptive sharing	3	0 (0)	64	45 (70)	71	48 (68)
p value		0.002		0.002		0.001
2013						
No receptive sharing	49	3 (6)	356	176 (49)	414	187 (45)
Receptive sharing	5	2 (40)	64	38 (59)	71	41 (58)
p value		0.062		0.143		0.050

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 5.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No imprisonment	48	2 (4)	587	250 (43)	648	254 (39)
Imprisonment	7	4 (57)	99	58 (59)	110	64 (58)
p value		0.001		0.004		<0.001
2010						
No imprisonment	35	2 (0)	351	154 (44)	397	160 (40)
Imprisonment	0	0 (0)	47	29 (62)	48	29 (60)
p value		--		0.028		0.009
2011						
No imprisonment	51	5 (10)	385	170 (44)	446	176 (39)
Imprisonment	0	0 (0)	46	31 (67)	47	31 (66)
p value		--		0.004		0.001
2012						
No imprisonment	58	7 (12)	423	207 (49)	489	219 (45)
Imprisonment	3	0 (0)	37	37 (69)	60	39 (65)
p value		1.000		0.009		0.003
2013						
No imprisonment	58	5 (9)	400	196 (49)	470	210 (45)
Imprisonment	2	0 (0)	41	27 (66)	43	27 (63)
p value		1.000		0.040		0.023

* Total includes people who did not report duration of drug injection

Table 5.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No sex work	55	5 (9)	663	294 (44)	732	302 (41)
Sex work	1	1 (100)	26	19 (73)	30	21 (70)
p value		0.107		0.005		0.002
2010						
No sex work	36	2 (6)	426	200 (47)	472	206 (44)
Sex work	0	0 (0)	12	7 (58)	13	7 (54)
p value		--		0.561		0.574
2011						
No sex work	50	5 (10)	422	199 (47)	482	205 (43)
Sex work	1	0 (0)	14	7 (50)	16	7 (44)
p value		1.000		1.000		1.000
2012						
No sex work	61	7 (11)	464	234 (50)	535	248 (46)
Sex work	1	0 (0)	13	9 (69)	16	9 (56)
p value		1.000		0.261		0.457
2013						
No sex work	55	5 (9)	428	214 (50)	495	229 (46)
Sex work	1	0 (0)	7	4 (57)	8	4 (50)
p value		1.000		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 5.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Non Indigenous	490	203 (41)	172	78 (45)	667	282 (42)
Indigenous	67	33 (49)	35	16 (46)	102	49 (48)
p value		0.237		1.000		0.284
2010						
Non Indigenous	354	159 (45)	101	52 (51)	460	214 (47)
Indigenous	42	17 (40)	19	6 (32)	61	23 (38)
p value		0.625		0.137		0.219
2011						
Non Indigenous	323	133 (41)	126	51 (40)	452	184 (41)
Indigenous	34	19 (56)	19	11 (58)	53	30 (57)
p value		0.105		0.213		0.028
2012						
Non Indigenous	352	152 (43)	129	67 (52)	483	220 (46)
Indigenous	51	28 (55)	22	14 (64)	73	42 (58)
p value		0.132		0.360		0.060
2013						
Non Indigenous	330	145 (44)	135	62 (46)	466	208 (45)
Indigenous	33	18 (55)	21	15 (71)	54	33 (61)
p value		0.243		0.030		0.022

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
English speaking	553	231 (42)	199	90 (45)	757	322 (43)
Non-English speaking	14	9 (64)	10	4 (40)	24	13 (54)
p value		0.106		1.000		0.297
2010						
English speaking	392	173 (44)	118	57 (48)	515	233 (45)
Non-English speaking	7	3 (43)	2	0 (0)	9	3 (33)
p value		1.000		0.497		0.523
2011						
English speaking	352	147 (42)	144	62 (43)	500	209 (42)
Non-English speaking	11	7 (64)	2	1 (50)	13	8 (62)
p value		0.215		1.000		0.167
2012						
English speaking	400	178 (45)	149	79 (53)	550	258 (47)
Non-English speaking	8	5 (63)	4	3 (75)	13	8 (62)
p value		0.476		0.624		0.401
2013						
English speaking	362	162 (45)	154	76 (49)	517	239 (46)
Non-English speaking	8	5 (63)	6	3 (50)	14	8 (57)
p value		0.476		1.000		0.419

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Australia	499	215 (43)	183	85 (46)	687	301 (44)
Other Oceania	28	6 (21)	12	5 (42)	40	11 (28)
Asia	4	3 (75)	1	0 (0)	5	3 (60)
UK & Ireland	19	10 (53)	5	2 (40)	24	12 (50)
Other	14	4 (29)	7	1 (14)	21	5 (24)
p value		0.057		0.459		0.071
2010						
Australia	358	157 (44)	108	49 (45)	471	209 (44)
Other Oceania	16	6 (38)	4	3 (75)	20	9 (45)
Asia	3	1 (33)	1	0 (0)	4	1 (25)
UK & Ireland	15	8 (53)	2	1 (50)	17	9 (53)
Other	10	7 (70)	5	4 (80)	15	11 (73)
p value		0.458		0.350		0.200
2011						
Australia	308	131 (43)	125	55 (44)	437	186 (43)
Other Oceania	18	5 (28)	10	4 (40)	28	9 (32)
Asia	2	0 (0)	2	0 (0)	4	0 (0)
UK & Ireland	15	8 (53)	6	2 (33)	21	10 (48)
Other	18	9 (50)	2	1 (50)	20	10 (50)
p value		0.428		0.877		0.335
2012						
Australia	362	167 (46)	135	73 (54)	499	241 (48)
Other Oceania	19	5 (26)	12	7 (58)	31	12 (39)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	14	4 (29)	5	2 (40)	19	6 (32)
Other	10	5 (50)	2	1 (50)	12	6 (50)
p value		0.235		0.923		0.406
2013						
Australia	334	149 (45)	141	71 (50)	476	221 (46)
Other Oceania	21	11 (52)	7	4 (57)	28	15 (54)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	8	4 (50)	4	1 (25)	12	5 (42)
Other	8	3 (38)	7	2 (29)	15	5 (33)
p value		0.864		0.589		0.646

* Total includes people whose gender was not reported or reported as transgender

South Australia

Table 6.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2009	2010	2011	2012	2013
Number of sites	7	7	7	7	7
N° surveyed	N=248	N=216	N=213	N=203	N=248
Response (%)	53%	41%	51%	42%	56%
Gender (%)					
Male	156 (63)	129 (60)	133 (62)	127 (63)	169 (68)
Female	92 (37)	86 (40)	78 (37)	75 (37)	78 (31)
Transgender	0 (0)	1 (<1)	2 (1)	1 (<1)	1 (<1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0(0)
Sexual identity (%)					
Heterosexual	204 (82)	185 (86)	178 (84)	155 (76)	193 (78)
Bisexual	23 (9)	11 (5)	22 (10)	18 (9)	26 (10)
Homosexual	13 (5)	12 (6)	6 (3)	12 (6)	8 (3)
Not reported	8 (3)	8 (4)	7 (3)	18 (9)	21 (8)
Age and duration of injection (years)					
<i>Median age</i>	38	38	39	40	40
Age range	16-61	18-62	17-61	18-60	17-60
<i>Age group (%)</i>					
<25 years	25 (10)	18 (8)	13 (6)	14 (7)	21 (8)
25+ years	222 (90)	198 (92)	200 (94)	189 (93)	225 (91)
Not reported	1 (<1)	0 (0)	0 (0)	0 (0)	2 (1)
<i>Median age 1stIDU</i>	18	18	19	18	18
Age range	12-46	12-44	11-45	10-55	12-48
Not reported	5	2	4	3	8
<i>Median years IDU</i>	17	17	20	20	18
Range	<1-44	<1-45	<1-37	<1-43	<1-46
<i>Duration of drug injection (%)</i>					
<3 years	15 (6)	5 (2)	12 (6)	8 (4)	13 (5)
3+ years	228 (92)	209 (97)	197 (92)	192 (95)	227 (92)
Not reported	5 (2)	2 (1)	4 (2)	3 (1)	8 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	206 (83)	185 (86)	183 (86)	183 (90)	201 (81)
Yes	31 (13)	23 (11)	29 (14)	17 (8)	35 (14)
Not reported	11 (4)	8 (4)	1 (<1)	3 (1)	12 (5)
Region/Country of birth (%)					
Australia	219 (88)	191 (88)	185 (87)	178 (88)	214 (86)
Other Oceania	5 (2)	3 (1)	4 (2)	1 (<1)	4 (2)
Asia	1 (<1)	4 (2)	4 (2)	1 (<1)	3 (1)
UK & Ireland	17 (7)	11 (5)	9 (4)	10 (5)	18 (7)
Other	5 (2)	4 (2)	9 (4)	12 (6)	9 (4)
Not reported	1 (<1)	3 (1)	2 (1)	1 (<1)	0 (0)
Main language spoken at home by parents (%)					
English speaking	224 (90)	198 (92)	193 (91)	182 (90)	230 (93)
Non-English speaking	19 (8)	16 (7)	18 (8)	21 (10)	18 (7)
Not reported	5 (2)	2 (1)	2 (1)	0 (0)	0 (0)
Imprisonment last year (%)					
No	199 (80)	168 (78)	175 (82)	184 (92)	200 (81)
Yes	37 (15)	16 (7)	19 (9)	15 (8)	25 (10)
Not reported	12 (5)	32 (15)	19 (9)	1 (<1)	23 (9)
Injected in prison (%)	N=37	N=16	N=19	N=15	N=25
Yes	5 (14)	1 (6)	4 (21)	2 (13)	4 (16)
Frequency of injection last month (%)					
Not last month	22 (9)	13 (6)	12 (6)	10 (5)	10 (4)
Less than weekly	38 (15)	42 (19)	41 (19)	41 (20)	41 (17)
Weekly not daily	59 (24)	61 (28)	49 (23)	57 (28)	70 (28)
Daily or more	127 (51)	99 (46)	108 (51)	95 (47)	121 (49)
Not reported	2 (1)	1 (<1)	3 (1)	0 (0)	6 (2)

Table 6.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2009	2010	2011	2012	2013
Last drug injected (%)	N=248	N=216	N=213	N=203	N=248
Cocaine	3 (1)	2 (1)	2 (1)	0 (0)	1 (<1)
Heroin	84 (34)	86 (40)	77 (36)	74 (36)	83 (33)
Methadone	8 (3)	7 (3)	13 (6)	9 (4)	8 (3)
Methamphetamine	91 (37)	87 (40)	75 (35)	72 (35)	93 (38)
Performance/Image-enhancing drugs	0 (0)	0 (0)	1 (<1)	4 (2)	1 (<1)
Pharmaceutical opioids	34 (14)	26 (12)	28 (13)	26 (13)	41 (17)
Suboxone®	3 (1)	3 (1)	2 (1)	1 (<1)	3 (1)
Subutex®/Buprenorphine	14 (6)	2 (1)	3 (1)	4 (2)	0 (0)
More than one	5 (2)	3 (1)	8 (4)	11 (5)	16 (6)
Other drug	3 (1)	3 (1)	4 (2)	1 (<1)	2 (1)
Not reported	6 (2)	0 (0)	0 (0)	1 (<1)	0 (0)
N° Injected last month	N=224	N=202	N=198	N=193	N=232
Places injected last month (%)*					
Any public	82 (37)	94 (47)	91 (46)	91 (47)	103 (44)
All private	141 (63)	97 (48)	98 (50)	91 (47)	128 (55)
Not reported	1 (<1)	11 (5)	9 (5)	11 (6)	1 (<1)
Use of new sterile needles & syringes last month (%)					
All injections	184 (82)	151 (75)	146 (74)	149 (77)	187 (81)
Most of the time	31 (14)	32 (16)	36 (18)	28 (15)	35 (15)
Half of the time	4 (2)	4 (2)	3 (2)	0 (0)	3 (1)
Some of the time	3 (1)	4 (2)	1 (<1)	1 (<1)	2 (1)
Not last month	0 (0)	0 (0)	1 (<1)	1 (<1)	2 (1)
Not reported	2 (1)	11 (5)	11 (6)	14 (7)	3 (1)
Re-used another's used needle & syringe last month (%)					
None	197 (88)	154 (76)	163 (82)	162 (84)	197 (85)
Once	7 (3)	8 (4)	5 (3)	12 (6)	17 (7)
Twice	7 (3)	4 (2)	6 (3)	5 (3)	6 (3)
3-5 times	3 (1)	7 (3)	6 (3)	0 (0)	5 (2)
>5 times	4 (2)	5 (2)	5 (3)	1 (<1)	6 (3)
Not reported	6 (3)	24 (12)	13 (7)	13 (7)	1 (<1)
Number of people needle & syringe was re-used after last month (%)					
None	197 (88)	154 (76)	163 (82)	162 (84)	197 (85)
One	11 (5)	7 (3)	14 (7)	7 (4)	14 (6)
Two	3 (1)	3 (1)	2 (1)	1 (<1)	3 (1)
Three to five	0 (0)	3 (1)	1 (<1)	1 (<1)	3 (1)
More than five	0 (0)	3 (1)	0 (0)	0 (0)	3 (1)
Don't know	4 (2)	4 (2)	4 (2)	2 (1)	9 (4)
Not reported	9 (4)	28 (14)	14 (7)	20 (10)	3 (1)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	9 (4)	19 (9)	18 (9)	7 (4)	18 (8)
Casual sex partner	0 (0)	2 (1)	0 (0)	0 (0)	2 (1)
Close friend	3 (1)	13 (6)	7 (4)	3 (2)	9 (4)
Acquaintance	2 (1)	2 (1)	3 (2)	2 (1)	5 (2)
Other	0 (0)	6 (3)	4 (2)	1 (<1)	5 (2)
Equipment used after someone else last month (%)*					
Spoon	36 (18)	46 (23)	33 (17)	21 (11)	51 (22)
Water	28 (14)	42 (21)	27 (14)	22 (11)	43 (19)
Filter	19 (9)	24 (12)	19 (10)	13 (7)	26 (11)
Drug mix	20 (10)	16 (8)	17 (9)	15 (8)	21 (9)
None	141 (69)	121 (60)	131 (66)	134 (69)	147 (63)
Injected by someone after that person injected themselves or others last month (%)					
No	183 (82)	148 (73)	156 (79)	164 (85)	182 (78)
Yes	34 (15)	31 (15)	32 (16)	15 (8)	39 (17)
Not reported	7 (3)	23 (11)	10 (5)	14 (7)	11 (5)
Present when someone injected for the first time in the last 12 months (%)**					
Yes	--	--	--	27 (14)	38 (16)
Overdosed in the last 12 months **					
Yes	--	--	--	--	22 (9)

* More than one option could be selected ** New question in 2012

Table 6.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2009	2010	2011	2012	2013
N° surveyed	N=248	N=216	N=213	N=203	N=248
Sex with a regular partner last month (%)					
No	112 (45)	100 (46)	96 (45)	91 (45)	124 (50)
Yes	124 (50)	106 (49)	102 (48)	108 (53)	118 (48)
Not reported	12 (5)	10 (5)	15 (7)	4 (2)	6 (2)
Condom used with regular partner last month (%)					
N° surveyed	N=124	N=106	N=102	N=108	N=118
Never	80 (64)	71 (67)	69 (68)	73 (68)	86 (73)
Sometimes	23 (19)	13 (12)	10 (10)	11 (10)	14 (12)
Every time	12 (10)	10 (9)	15 (15)	13 (12)	6 (5)
Not reported	9 (7)	12 (11)	8 (8)	11 (10)	12 (10)
Sex with other partner/s last month (%)					
No	205 (83)	170 (79)	179 (84)	176 (87)	216 (87)
Yes	31 (13)	33 (15)	22 (10)	22 (11)	23 (9)
Not reported	12 (5)	13 (6)	12 (6)	5 (2)	9 (4)
Condom used with other partner/s last month (%)					
N° surveyed	N=31	N=33	N=22	N=22	N=23
Never	9 (29)	7 (21)	6 (27)	9 (41)	11 (48)
Sometimes	9 (29)	7 (21)	6 (27)	4 (18)	5 (22)
Every time	13 (42)	16 (48)	10 (45)	8 (36)	6 (26)
Not reported	0 (0)	3 (9)	0 (0)	1 (5)	1 (4)
Sex work last month (%)					
No	229 (92)	184 (85)	194 (91)	192 (95)	217 (88)
Yes	10 (4)	20 (9)	9 (4)	6 (3)	20 (8)
Not reported	9 (4)	12 (6)	9 (4)	5 (2)	11 (4)
Condom used at last sex work last month (%)					
Yes	9 (90)	13 (68)	8 (89)	6 (100)	14

Table 6.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2009	2010	2011	2012	2013
N° surveyed	N=248	N=216	N=213	N=203	N=248
Any treatment/therapy for drug use (%)					
No	67 (27)	46 (21)	49 (23)	60 (30)	72 (29)
Yes	176 (71)	163 (75)	163 (77)	142 (70)	170 (69)
Not reported	5 (2)	7 (3)	1 (<1)	1 (<1)	6 (2)
History of methadone maintenance treatment (%)					
Currently	61 (25)	57 (26)	48 (22)	58 (29)	65 (26)
Previously	46 (19)	53 (25)	61 (29)	44 (22)	41 (17)
Never	135 (54)	92 (42)	96 (45)	100 (49)	140 (56)
Not reported	6 (2)	14 (6)	8 (4)	1 (<1)	2 (1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	40 (16)	23 (11)	13 (6)	18 (9)	19 (8)
Previously	58 (23)	60 (28)	55 (26)	46 (23)	64 (26)
Never	148 (60)	131 (61)	138 (65)	139 (68)	158 (64)
Not reported	2 (1)	2 (1)	7 (3)	0 (0)	7 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	12 (5)	7 (4)	21 (10)	26 (13)	23 (9)
Previously	36 (15)	21 (11)	37 (17)	29 (14)	57 (23)
Never	194 (78)	160 (82)	149 (70)	144 (71)	163 (66)
Not reported	6 (2)	8 (4)	6 (3)	4 (2)	5 (2)

Table.6.1.5 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2009	2010	2011	2012	2013
N° surveyed	N=248	N=216	N=213	N=203	N=248
Previous HIV test (%)					
Yes, last year	130 (52)	88 (41)	93 (44)	101 (50)	132 (53)
> 1 year ago	81 (33)	92 (43)	81 (38)	74 (36)	75 (30)
Never tested	28 (11)	25 (12)	29 (14)	21 (10)	34 (14)
Not reported	9 (4)	11 (5)	10 (5)	7 (3)	7 (3)
Previous HCV test (%)					
Yes, last year	139 (56)	99 (46)	105 (49)	112 (55)	140 (56)
> 1 year ago	67 (27)	73 (34)	77 (36)	70 (34)	74 (30)
Never tested	28 (11)	23 (11)	15 (7)	13 (6)	22 (9)
Not reported	14 (6)	21 (10)	16 (8)	8 (4)	12 (5)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=102	N=92	N=101	N=95	N=119
Interferon/Interferon+Ribavirin	14 (14)	6 (7)	12 (12)	10 (11)	17 (14)
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	0 (0)
Other	1 (1)	0 (0)	1 (1)	2 (2)	0 (0)
No treatment	81 (79)	83 (90)	80 (79)	78 (82)	89 (75)
Not reported	6 (6)	3 (3)	8 (8)	5 (5)	13 (11)
Current treatment for HCV**	N=3	N=2	N=2	N=1	N=2
Interferon/Interferon+Ribavirin	2	2	2	1	2
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	0
Other	1	0	0		0

* New treatment options added ** 'Current treatment' defined as within the previous 12 months from 2013

Table 6.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2009	2010	2011	2012	2013
N° Injected last month	N=224	N=202	N=198	N=193	N=232
Needle Syringe Program	150 (67)	183 (91)	176 (89)	159 (82)	211 (91)
Chemist/Pharmacy	36 (16)	26 (13)	30 (15)	41 (21)	41 (18)
Personal sources	39 (17)	24 (12)	19 (10)	23 (12)	27 (12)
Dispensing/Vending Machine	0 (0)	0 (0)	17 (9)	27 (14)	20 (9)
Other sources	9 (4)	5 (2)	3 (2)	2 (1)	4 (2)

* More than one option could be selected

Table 6.1.7 Number (percentage) of respondents by last drug injected and all drugs injected in the last 12 months (2013)

	Drugs injected in last 12 months*								
	N° (%)	Cocaine	Heroin	Methadone	Methamphetamine	PIEDs	Pharm. Opioids	Subutex/Suboxone	No other drugs
Last drug injected									
Cocaine	1 (<1)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)
Heroin	83 (33)	1 (1)	83 (100)	17 (20)	38 (46)	0 (0)	26 (31)	7 (8)	32 (39)
Methadone	8 (3)	0 (0)	5 (63)	8 (100)	5 (63)	0 (0)	2 (25)	0 (0)	1 (13)
Methamphetamine	93 (38)	7 (8)	11 (12)	8 (9)	93 (100)	0 (0)	12 (13)	10 (11)	61 (66)
PIEDs	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)
Pharm. opioids	41 (17)	3 (7)	24 (59)	19 (46)	23 (56)	2 (5)	41 (100)	3 (7)	0 (0)
Subutex/Suboxone	3 (1)	0 (0)	2 (67)	0 (0)	2 (67)	0 (0)	1 (33)	3 (100)	0 (0)
Other/Not reported	18 (7)	2 (11)	6 (33)	3 (17)	14 (78)	0 (0)	5 (28)	3 (17)	1 (6)
Total	248	14 (6)	131 (53)	55 (22)	175 (71)	3 (1)	88 (35)	26 (10)	95 (38)

* More than one option could be selected

HIV antibody prevalence

Table 6.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009	155	2 (1.3)	91	1 (1.1)	246	3 (1.2)
2010	129	0 (0.0)	84	1 (1.2)	214	1 (0.5)
2011	129	2 (1.6)	76	3 (4.0)	207	5 (2.4)
2012	123	2 (1.6)	73	4 (5.5)	197	6 (3.1)
2013	154	4 (2.6)	74	3 (4.1)	229	7 (3.1)
X ² trend p value		0.185		0.086		0.038

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Heterosexual	118	2 (1.7)	56	2 (3.6)	174	4 (2.3)
Bisexual	6	0 (0.0)	14	1 (7.1)	21	1 (4.8)
Homosexual	1	0 (0.0)	4	0 (0.0)	6	0 (0.0)
p value		1.000		0.572		0.518
2012						
Heterosexual	99	0 (0.0)	54	4 (7.4)	153	4 (2.6)
Bisexual	6	0 (0.0)	10	0 (0.0)	16	0 (0.0)
Homosexual	8	2 (25.0)	2	0 (0.0)	11	2 (18.2)
p value		0.007		1.000		0.072
2013						
Heterosexual	127	2 (1.6)	52	3 (5.8)	180	5 (2.8)
Bisexual	6	1 (16.7)	16	0 (0.0)	22	1 (4.6)
Homosexual	5	1 (20.0)	2	0 (0.0)	7	1 (14.3)
p value		0.032		1.000		0.141

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.3 HIV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
< 25 years	5	0 (0.0)	8	2 (25.0)	13	2 (15.4)
25 – 34	25	0 (0.0)	13	0 (0.0)	39	0 (0.0)
35+ years	99	2 (2.0)	55	1 (1.8)	155	3 (1.9)
p value		1.000		0.041		0.044
2012						
< 25 years	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
25 – 34	22	0 (0.0)	18	2 (11.1)	40	2 (5.0)
35+ years	92	2 (2.2)	50	2 (4.0)	143	4 (2.8)
p value		1.000		0.464		0.753
2013						
< 25 years	7	0 (0.0)	11	0 (0.0)	18	0 (0.0)
25 – 34	25	0 (0.0)	19	2 (10.5)	44	2 (4.6)
35+ years	120	4 (3.3)	44	1 (2.3)	165	5 (3.0)
p value		1.000		0.216		0.800

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.4 HIV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
<3 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
3 to 10 years	14	0 (0.0)	12	2 (16.7)	26	2 (7.7)
11 + years	107	2 (1.9)	56	1 (1.8)	165	3 (1.8)
p value		1.000		0.087		0.235
2012						
<3 years	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
3 to 10 years	14	1 (7.1)	17	2 (11.8)	32	3 (9.4)
11 + years	100	1 (1.0)	54	2 (3.7)	154	3 (2.0)
p value		0.307		0.322		0.113
2013						
<3 years	3	0 (0.0)	8	0 (0.0)	11	0 (0.0)
3 to 10 years	21	0 (0.0)	9	0 (0.0)	30	0 (0.0)
11 + years	123	4 (3.3)	56	3 (5.4)	180	7 (3.9)
p value		1.000		1.000		0.719

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.5 HIV antibody prevalence by last drug injected, gender and survey year

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Heroin	51	0 (0.0)	24	1 (4.2)	75	1 (1.3)
Methamphetamine	43	0 (0.0)	28	1 (3.6)	72	1 (1.4)
Other	35	2 (5.7)	24	1 (4.2)	60	3 (5.0)
p value		0.072		1.000		0.444
2012						
Heroin	42	1 (2.4)	29	2 (6.9)	72	3 (4.2)
Methamphetamine	42	1 (2.4)	27	2 (7.4)	69	3 (4.4)
Other	38	0 (0.0)	17	0 (0.0)	55	0 (0.0)
p value		1.000		0.670		0.286
2013						
Heroin						
Methamphetamine						
Other						
p value						

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Less than daily	61	0 (0.0)	28	2 (7.1)	89	2 (2.3)
Daily or more	60	2 (3.3)	42	1 (2.4)	104	3 (2.9)
Not last month	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
p value		0.325		0.643		1.000
2012						
Less than daily	60	2 (3.3)	35	4 (11.4)	95	6 (6.3)
Daily or more	60	0 (0.0)	31	0 (0.0)	92	0 (0.0)
Not last month	3	0 (0.0)	7	0 (0.0)	10	0 (0.0)
p value		0.520		0.192		0.067
2013						
Less than daily	63	2 (3.2)	38	3 (7.9)	101	5 (5.0)
Daily or more	80	1 (1.3)	33	0 (0.0)	114	1 (0.9)
Not last month	7	1 (14.3)	2	0 (0.0)	9	1 (11.1)
p value		0.136		0.304		0.061

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No receptive sharing	103	2 (1.9)	56	3 (5.4)	160	5 (3.1)
Receptive sharing	11	0 (0.0)	9	0 (0.0)	21	0 (0.0)
p value		1.000		1.000		1.000
2012						
No receptive sharing	99	1 (1.0)	56	4 (7.1)	156	5 (3.2)
Receptive sharing	14	0 (0.0)	4	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000
2013						
No receptive sharing	123	3 (2.4)	60	3 (5.0)	184	6 (3.3)
Receptive sharing	20	0 (0.0)	11	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		0.597

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 6.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No imprisonment	106	2 (1.9)	69	3 (4.4)	177	5 (2.8)
Imprisonment	13	0 (0.0)	5	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000
2012						
No imprisonment	110	2 (1.8)	68	4 (5.9)	179	6 (3.4)
Imprisonment	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)
p value		1.000		1.000		1.000
2013						
No imprisonment	122	3 (2.5)	63	3 (4.8)	186	6 (3.2)
Imprisonment	20	1 (5)	1	0 (0.0)	21	1 (4.8)
p value		0.459		1.000		0.533

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.9 HIV antibody prevalence by condom use at last sex, gender and survey year

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No condom use	40	0 (0.0)	27	1 (3.7)	67	1 (1.5)
Condom use	16	0 (0.0)	8	0 (0.0)	24	0 (0.0)
p value		---		1.000		1.000
2012						
No condom use	42	0 (0.0)	28	2 (7.1)	70	2 (2.9)
Condom use	12	1 (8.3)	11	1 (9.1)	23	2 (8.7)
p value		0.222		1.000		0.255
2013						
No condom use	43	0 (0.0)	38	1 (2.6)	82	1 (1.2)
Condom use	12	0 (0.0)	6	2 (33.3)	18	2 (11.1)
p value		--		0.045		0.083

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 6.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No sex work	124	2 (1.6)	65	3 (4.6)	191	5 (2.6)
Sex work	2	0 (0.0)	6	0 (0.0)	8	0 (0.0)
p value		1.000		1.000		1.000
2012						
No sex work	118	2 (1.7)	68	4 (5.9)	187	6 (3.2)
Sex work	1	0 (0.0)	4	0 (0.0)	5	0 (0.0)
p value		1.000		1.000		1.000
2013						
No sex work	139	3 (2.2)	60	3 (5.0)	200	6 (3.0)
Sex work	9	1 (11.1)	10	0 (0.0)	19	1 (5.3)
p value		0.224		1.000		0.475

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Non Indigenous	112	2 (1.8)	63	2 (3.2)	177	4 (2.3)
Indigenous	17	0 (0.0)	12	1 (8.3)	29	1 (3.5)
p value		1.000		0.412		0.535
2012						
Non Indigenous	113	2 (1.8)	64	4 (6.3)	178	6 (3.4)
Indigenous	9	0 (0.0)	7	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		1.000
2013						
Non Indigenous	123	3 (2.4)	62	3 (4.9)	186	6 (3.2)
Indigenous	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		0.597

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
English speaking	117	2 (1.7)	69	3 (4.4)	188	5 (2.7)
Non-English speaking	11	0 (0.0)	6	0 (0.0)	17	0 (0.0)
p value		1.000		1.000		1.000
2012						
English speaking	103	2 (1.9)	72	4 (5.6)	176	6 (3.4)
Non-English speaking	20	0 (0.0)	1	0 (0.0)	21	0 (0.0)
p value		1.000		1.000		1.000
2013						
English speaking	140	3 (2.1)	70	3 (4.3)	211	6 (2.8)
Non-English speaking	14	1 (7.1)	4	0 (0.0)	18	1 (5.6)
p value		0.320		1.000		0.441

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Australia	112	2 (1.8)	66	3 (4.6)	180	5 (2.8)
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)
UK & Ireland	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
Other	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		1.000		1.000		1.000
2012						
Australia	103	2 (1.9)	69	4 (5.8)	173	6 (3.5)
Other Oceania	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
Asia	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
UK & Ireland	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
Other	12	0 (0.0)	0	0 (0.0)	12	0 (0.0)
p value		1.000		1.000		1.000
2013						
Australia	128	4 (3.1)	68	3 (4.4)	197	7 (3.6)
Other Oceania	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
UK & Ireland	15	0 (0.0)	2	0 (0.0)	17	0 (0.0)
Other	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
p value		0.934		0.991		0.883

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 6.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009	155	65 (42)	91	36 (40)	246	101 (41)
2010	127	54 (43)	84	38 (45)	212	93 (44)
2011	128	67 (52)	75	31 (41)	205	98 (48)
2012	122	51 (42)	71	28 (39)	194	79 (41)
2013	153	78 (51)	74	32 (43)	228	111 (49)
χ^2 trend p value		0.157		0.907		0.208

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heterosexual	134	59 (44)	68	27 (40)	202	86 (43)
Bisexual	11	3 (27)	12	6 (50)	23	9 (36)
Homosexual	4	0 (0)	9	3 (33)	13	3 (23)
p value		0.138		0.756		0.410
2010						
Heterosexual	113	51 (45)	69	31 (45)	182	82 (45)
Bisexual	1	1 (100)	8	4 (50)	10	6 (60)
Homosexual	7	0 (0)	5	1 (20)	12	1 (8)
p value		0.10		0.661		0.019
2011						
Heterosexual	117	60 (51)	55	23 (42)	172	83 (48)
Bisexual	6	4 (67)	14	5 (36)	21	9 (43)
Homosexual	1	0 (0)	4	1 (25)	6	1 (17)
p value		0.553		0.756		0.325
2012						
Heterosexual	98	44 (45)	52	19 (37)	150	63 (42)
Bisexual	7	3 (43)	10	5 (50)	17	8 (47)
Homosexual	7	2 (29)	2	1 (50)	10	3 (30)
p value		0.767		0.653		0.692
2013						
Heterosexual	126	65 (52)	52	23 (44)	179	89 (50)
Bisexual	6	1 (17)	16	6 (38)	22	7 (32)
Homosexual	5	0 (0)	2	1 (50)	7	1 (14)
p value		0.021		0.888		0.055

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
< 25 years	14	1 (7)	10	4 (40)	24	5 (21)
25 – 34	37	13 (35)	30	11 (37)	67	24 (36)
35+ years	104	51 (49)	50	21 (42)	154	72 (47)
p value		0.007		0.895		0.032
2010						
< 25 years	8	0 (0)	10	2 (20)	18	2 (11)
25 – 34	30	8 (27)	23	11 (48)	53	19 (36)
35+ years	89	46 (52)	51	25 (49)	141	72 (51)
p value		0.001		0.266		0.002
2011						
< 25 years	5	0 (0)	8	1 (13)	13	1 (8)
25 – 34	25	9 (36)	13	3 (23)	39	12 (31)
35+ years	98	58 (59)	54	27 (50)	153	85 (56)
p value		0.005		0.045		<0.001
2012						
< 25 years	9	0 (0)	5	1 (20)	14	1 (7)
25 – 34	22	7 (32)	18	5 (28)	40	12 (30)
35+ years	91	44 (48)	48	22 (46)	140	66 (47)
p value		0.007		0.334		0.003
2013						
< 25 years	7	1 (14)	11	1 (9)	18	2 (11)
25 – 34	25	11 (44)	19	9 (47)	44	20 (45)
35+ years	119	66 (55)	44	22 (50)	164	89 (54)
p value		0.077		0.041		0.001

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
<3 years	4	0 (0)	10	1 (10)	14	1 (7)
3 to 10 years	26	4 (15)	20	8 (40)	46	12 (26)
11 + years	122	59 (48)	59	27 (46)	181	86 (48)
p value		0.002		0.103		0.001
2010						
<3 years	3	0 (0)	2	0 (0)	5	0 (0)
3 to 10 years	18	0 (0)	20	7 (35)	38	7 (18)
11 + years	105	54 (51)	61	31 (51)	167	86 (52)
p value		<0.001		0.242		<0.001
2011						
<3 years	5	0 (0)	7	0 (0)	12	0 (0)
3 to 10 years	14	3 (21)	12	1 (8)	26	4 (15)
11 + years	106	63 (59)	55	29 (53)	163	92 (56)
p value		0.001		0.001		<0.001
2012						
<3 years	6	0 (0)	2	1 (50)	8	1 (13)
3 to 10 years	13	3 (23)	16	4 (25)	30	7 (23)
11 + years	100	47 (47)	53	23 (43)	153	70 (46)
p value		0.023		0.361		0.016
2013						
<3 years	3	0 (0)	8	2 (25)	11	2 (18)
3 to 10 years	21	4 (19)	9	3 (33)	30	7 (23)
11 + years	122	71 (58)	56	26 (46)	179	98 (55)
p value		0.000		0.557		0.001

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heroin	3	0 (0)	79	40 (51)	83	41 (49)
All other opioids	5	0 (0)	53	26 (49)	59	27 (46)
Methamphetamine	6	1 (17)	83	28 (34)	90	29 (32)
Perform/Image-enhancing drugs	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	8	3 (38)	8	3 (38)
p value		0.488		0.131		0.121
2010						
Heroin	2	0 (0)	83	41 (49)	85	41 (48)
All other opioids	0	0 (0)	36	23 (64)	37	23 (62)
Methamphetamine	3	0 (0)	82	26 (32)	86	26 (30)
Perform/Image-enhancing drugs	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.004		0.003
2011						
Heroin	4	0 (0)	68	46 (68)	74	47 (64)
All other opioids	2	0 (0)	44	26 (59)	46	26 (57)
Methamphetamine	3	0 (0)	66	20 (30)	71	21 (30)
Perform/Image-enhancing drugs	0	0 (0)	1	0 (0)	1	0 (0)
Other	3	0 (0)	10	4 (40)	13	4 (31)
p value		--		<0.001		<0.001
2012						
Heroin	1	0 (0)	68	30 (44)	71	31 (44)
All other opioids	1	1 (100)	39	22 (56)	40	23 (58)
Methamphetamine	2	0 (0)	64	15 (23)	66	15 (23)
Perform/Image-enhancing drugs	4	0 (0)	0	0 (0)	4	0 (0)
Other	0	0 (0)	11	9 (82)	12	9 (75)
p value		0.046		<0.001		<0.001
2013						
Heroin	3	1 (33)	70	42 (60)	73	43 (59)
All other opioids	0	0 (0)	49	25 (51)	51	26 (51)
Methamphetamine	7	1 (14)	73	26 (36)	84	30 (36)
Perform/Image-enhancing drugs	0	0 (0)	1	0 (0)	1	0 (0)
Other	1	0 (0)	16	12 (75)	19	12 (63)
p value		0.685		0.008		0.023

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Less than daily	6	1 (17)	89	43 (48)	96	44 (46)
Daily or more	5	0 (0)	118	51 (43)	126	53 (42)
Not last month	3	0 (0)	18	3 (17)	22	3 (14)
p value		0.488		0.047		0.020
2010						
Less than daily	3	0 (0)	100	46 (46)	104	46 (44)
Daily or more	1	0 (0)	92	43 (47)	94	43 (46)
Not last month	1	0 (0)	12	4 (33)	13	4 (31)
p value		--		0.763		0.613
2011						
Less than daily	3	0 (0)	83	43 (52)	88	44 (50)
Daily or more	7	0 (0)	96	49 (51)	103	49 (48)
Not last month	1	0 (0)	10	4 (40)	12	4 (33)
p value		--		0.812		0.568
2012						
Less than daily	5	1 (20)	86	36 (42)	92	38 (41)
Daily or more	1	0 (0)	89	40 (45)	92	40 (43)
Not last month	2	0 (0)	8	1 (13)	10	1 (10)
p value		1.000		0.237		0.127
2013						
Less than daily	7	1 (14)	90	46 (51)	101	50 (50)
Daily or more	4	1 (25)	107	54 (50)	113	55 (49)
Not last month	0	0 (0)	8	3 (38)	9	3 (33)
p value		1.000		0.828		0.687

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No receptive sharing	10	1 (10)	181	85 (47)	195	88 (45)
Receptive sharing	0	0 (0)	21	7 (33)	21	7 (33)
p value		1.000		0.484		0.588
2010						
No receptive sharing	4	0 (0)	146	66 (45)	151	66 (44)
Receptive sharing	0	0 (0)	24	9 (38)	24	9 (38)
p value		--		0.515		0.660
2011						
No receptive sharing	8	0 (0)	149	79 (53)	159	80 (50)
Receptive sharing	1	0 (0)	19	9 (47)	20	9 (45)
p value		--		0.808		0.813
2012						
No receptive sharing	6	1 (17)	146	61 (42)	155	63 (41)
Receptive sharing	0	0 (0)	17	8 (47)	17	8 (47)
p value		--		0.797		0.614
2013						
No receptive sharing	9	1 (11)	170	83 (49)	183	87 (48)
Receptive sharing	2	1 (50)	27	17 (63)	31	18 (58)
p value		0.345		0.172		0.278

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 6.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No imprisonment	13	1 (8)	180	72 (40)	197	74 (38)
Imprisonment	1	0 (0)	35	20 (57)	37	21 (57)
p value		1.000		0.065		0.044
2010						
No imprisonment	5	0 (0)	159	62 (39)	166	62 (37)
Imprisonment	0	0 (0)	16	10 (63)	16	10 (63)
p value		--		0.107		0.062
2011						
No imprisonment	10	0 (0)	156	78 (50)	170	80 (47)
Imprisonment	1	0 (0)	16	13 (81)	17	13 (76)
p value		--		0.019		0.023
2012						
No imprisonment	7	1 (14)	169	69 (41)	178	71 (40)
Imprisonment	1	0 (0)	11	5 (45)	13	5 (38)
p value		1.000		0.762		1.000
2013						
No imprisonment	10	2 (20)	169	79 (47)	186	84 (45)
Imprisonment	0	0 (0)	19	13 (68)	20	14 (70)
p value		--		0.073		0.035

* Total includes people who did not report duration of drug injection

Table 6.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No sex work	14	1 (7)	208	93 (45)	227	96 (42)
Sex work	0	0 (0)	10	2 (20)	10	2 (20)
p value		---		0.192		0.202
2010						
No sex work	5	0 (0)	174	80 (46)	181	80 (44)
Sex work	0	0 (0)	20	5 (25)	20	5 (25)
p value		--		0.096		0.151
2011						
No sex work	10	0 (0)	176	91 (52)	189	92 (49)
Sex work	0	0 (0)	7	2 (29)	8	3 (38)
p value		--		0.273		0.722
2012						
No sex work	8	1 (13)	173	73 (42)	184	75 (41)
Sex work	0	0 (0)	5	0 (0)	5	0 (0)
p value		--		0.79		0.159
2013						
No sex work	9	0 (0)	185	93 (50)	200	97 (49)
Sex work	1	1 (100)	16	8 (50)	18	9 (50)
p value		0.100		0.983		0.903

* Total includes people who did not report duration of drug injection

Table 6.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Non Indigenous	128	50 (39)	76	28 (37)	204	78 (38)
Indigenous	20	12 (60)	11	7 (64)	31	19 (61)
p value		0.091		0.109		0.019
2010						
Non Indigenous	108	46 (43)	72	33 (46)	181	80 (44)
Indigenous	15	5 (33)	8	3 (38)	23	8 (35)
p value		0.584		0.724		0.504
2011						
Non Indigenous	112	56 (50)	62	25 (40)	176	81 (46)
Indigenous	16	11 (69)	12	5 (42)	28	16 (57)
p value		0.189		1.000		0.312
2012						
Non Indigenous	112	47 (42)	62	26 (42)	175	73 (42)
Indigenous	9	4 (44)	7	1 (14)	16	5 (31)
p value		1.000		0.233		0.596
2013						
Non Indigenous	123	59 (48)	62	26 (42)	186	86 (46)
Indigenous	21	16 (76)	10	4 (40)	31	20 (65)
p value		0.017		1.000		0.059

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
English speaking	140	63 (45)	83	33 (40)	223	96 (43)
Non-English speaking	11	1 (9)	7	2 (29)	18	3 (17)
p value		0.025		0.701		0.044
2010						
English speaking	112	46 (41)	81	37 (46)	194	84 (43)
Non-English speaking	13	6 (46)	3	1 (33)	16	7 (44)
p value		0.772		1.000		1.000
2011						
English speaking	116	59 (51)	68	28 (41)	186	87 (47)
Non-English speaking	11	7 (64)	6	2 (33)	17	9 (53)
p value		0.534		1.000		0.801
2012						
English speaking	102	47 (46)	70	28 (40)	173	75 (43)
Non-English speaking	20	4 (20)	1	0 (0)	21	4 (19)
p value		0.046		1.000		0.036
2013						
English speaking	139	73 (53)	70	30 (43)	210	104 (50)
Non-English speaking	14	5 (36)	4	2 (50)	18	7 (39)
p value		0.271		1.000		0.386

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Australia	137	60 (44)	80	29 (36)	217	89 (41)
Other Oceania	3	2 (67)	2	1 (50)	5	3 (60)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	11	3 (27)	6	5 (83)	17	8 (47)
Other	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.345		0.057		0.255
2010						
Australia	113	45 (40)	74	32 (43)	188	78 (41)
Other Oceania	0	0 (0)	3	3 (100)	3	3 (100)
Asia	3	3 (100)	1	1 (100)	4	4 (100)
UK & Ireland	6	4 (67)	5	2 (40)	11	6 (55)
Other	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.090		0.172		0.033
2011						
Australia	111	57 (51)	66	23 (35)	179	80 (45)
Other Oceania	2	0 (0)	2	2 (100)	4	2 (50)
Asia	4	4 (100)	0	0 (0)	4	4 (100)
UK & Ireland	5	2 (40)	3	3 (100)	8	5 (63)
Other	6	4 (67)	3	2 (67)	9	6 (67)
p value		0.164		0.008		0.124
2012						
Australia	102	38 (37)	68	26 (38)	171	64 (37)
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	7	5 (71)	2	2 (100)	9	7 (78)
Other	12	7 (58)	0	0 (0)	12	7 (58)
p value		0.092		0.152		0.030
2013						
Australia	127	68 (54)	68	30 (44)	196	99 (51)
Other Oceania	2	1 (50)	1	0 (0)	3	1 (33)
Asia	2	1 (50)	1	1 (100)	3	2 (67)
UK & Ireland	15	6 (40)	2	1 (50)	17	7 (41)
Other	7	2 (29)	2	0 (0)	9	2 (22)
p value		0.641		0.655		0.445

* Total includes people whose gender was not reported or reported as transgender

Tasmania

Table 7.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2009	2010	2011	2012	2013
Number of sites	4	4	4	4	4
N° surveyed	N=122	N=106	N=68	N=75	N=70
Response (%)	22%	39%	28%	28%	33%
Gender (%)					
Male	74 (61)	68 (64)	43 (63)	37 (49)	42 (60)
Female	47 (39)	38 (36)	25 (37)	38 (51)	28 (40)
Transgender	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	101 (83)	96 (91)	61 (90)	62 (83)	61 (87)
Bisexual	12 (10)	4 (4)	2 (3)	7 (9)	3 (4)
Homosexual	5 (4)	1 (1)	3 (4)	4 (5)	2 (3)
Not reported	4 (3)	5 (5)	2 (3)	2 (3)	4 (6)
Age and duration of injection (years)					
<i>Median age</i>	33	35	38	38	37
Age range	17-59	20-60	17-58	18-57	21-63
<i>Age group (%)</i>					
<25 years	13 (11)	7 (7)	4 (6)	3 (4)	3 (4)
25+ years	109 (89)	99 (93)	64 (94)	72 (96)	66 (94)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	19	19	19	18	19
Age range	11-44	12-42	13-49	13-45	12-40
Not reported	5	0	3	3	3
<i>Median years IDU</i>	13	14	15	15	16
Range	<1-39	<1-42	<1-40	<1-38	1-41
<i>Duration of drug injection (%)</i>					
<3 years	9 (7)	4 (4)	7 (10)	5 (7)	3 (4)
3+ years	108 (89)	102 (96)	58 (85)	67 (89)	31 (91)
Not reported	5 (4)	0 (0)	3 (4)	3 (4)	3 (4)
Aboriginal and Torres Strait Islander origin (%)					
No	100 (82)	94 (89)	59 (87)	64 (85)	60 (86)
Yes	15 (12)	12 (11)	8 (12)	10 (13)	9 (13)
Not reported	7 (6)	0 (0)	1 (1)	1 (1)	1 (1)
Region/Country of birth (%)					
Australia	111 (91)	98 (92)	64 (94)	69 (92)	67 (96)
Other Oceania	2 (2)	2 (2)	0 (0)	0 (0)	1 (1)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	2 (2)	4 (4)	2 (3)	1 (1)	2 (3)
Other	2 (2)	2 (2)	2 (3)	3 (4)	0 (0)
Not reported	5 (4)	0 (0)	0 (0)	2 (3)	0 (0)
Main language spoken at home by parents (%)					
English speaking	119 (98)	105 (99)	68 (100)	73 (97)	70 (100)
Non-English speaking	1 (1)	1 (1)	0 (0)	1 (1)	0 (0)
Not reported	2 (2)	0 (0)	0 (0)	1 (1)	0 (0)
Imprisonment last year (%)					
No	98 (80)	81 (76)	63 (93)	68 (94)	54 (77)
Yes	17 (14)	5 (5)	4 (6)	4 (6)	9 (13)
Not reported	7 (6)	20 (19)	1 (1)	0 (0)	7 (10)
Injected in prison (%)	N=17	N=5	N=4	N=4	N=9
Yes	6 (35)	0 (0)	1 (25)	2 (50)	1 (11)
Frequency of injection last month (%)					
Not last month	7 (6)	9 (8)	5 (7)	7 (9)	5 (7)
Less than weekly	18 (15)	21 (20)	10 (15)	14 (19)	13 (19)
Weekly not daily	47 (39)	45 (42)	27 (40)	19 (25)	26 (37)
Daily or more	46 (38)	31 (29)	26 (38)	35 (47)	24 (34)
Not reported	4 (3)	0 (0)	0 (0)	0 (0)	2 (3)

Table 7.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2009	2010	2011	2012	2013
Last drug injected (%)	N=122	N=106	N=68	N=75	N=70
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Heroin	4 (3)	1 (1)	1 (1)	1 (1)	2 (3)
Methadone	40 (33)	30 (28)	21 (31)	13 (17)	19 (27)
Methamphetamine	30 (25)	29 (27)	18 (26)	24 (32)	17 (24)
Performance/Image-enhancing drugs	1 (<1)	1 (1)	0 (0)	1 (1)	1 (1)
Pharmaceutical opioids	33 (27)	35 (33)	23 (34)	30 (40)	23 (33)
Suboxone®	4 (3)	0 (0)	0 (0)	1 (1)	1 (1)
Subutex®/Buprenorphine	2 (2)	0 (0)	1 (1)	2 (3)	3 (4)
More than one	4 (3)	8 (8)	3 (4)	0 (0)	3 (4)
Other drug	5 (4)	2 (2)	1 (1)	3 (4)	1 (1)
Not reported	3 (2)	0 (0)	0 (0)	0 (0)	0 (0)
N° Injected last month	N=111	N=97	N=63	N=68	N=63
Places injected last month (%)*					
Any public	43 (39)	32 (33)	23 (37)	17 (25)	16 (25)
All private	67 (60)	52 (54)	39 (62)	48 (71)	46 (73)
Not Reported	1 (1)	13 (13)	1 (2)	3 (4)	1 (2)
Use of new sterile needles & syringes last month (%)					
All injections	93 (84)	75 (77)	55 (87)	53 (78)	55 (87)
Most of the time	15 (14)	10 (10)	7 (11)	11 (16)	6 (10)
Half of the time	2 (2)	0 (0)	0 (0)	0 (0)	1 (2)
Some of the time	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	1 (1)	12 (12)	1 (1)	4 (6)	1 (2)
Re-used another's used needle & syringe last month (%)					
None	94 (85)	82 (85)	51 (81)	54 (79)	61 (97)
One	1 (1)	1 (1)	5 (8)	5 (7)	1 (2)
Twice	4 (4)	1 (1)	1 (1)	1 (1)	0 (0)
3-5 times	7 (6)	0 (0)	4 (6)	1 (1)	0 (0)
>5 times	2 (2)	0 (0)	0 (0)	3 (4)	1 (2)
Not reported	3 (3)	13 (13)	2 (3)	4 (6)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	94 (85)	82 (85)	51 (81)	54 (79)	61 (97)
One	3 (3)	2 (2)	3 (5)	2 (3)	0 (0)
Two	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Three to five	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
More than five	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)
Don't know	3 (3)	0 (0)	6 (10)	2 (3)	0 (0)
Not reported	9 (8)	13 (13)	3 (5)	8 (12)	2 (3)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	4 (4)	5 (5)	3 (5)	1 (1)	0 (0)
Casual sex partner	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Close friend	1 (1)	1 (1)	3 (5)	3 (4)	0 (0)
Acquaintance	1 (1)	0 (0)	3 (5)	1 (1)	0 (0)
Other	2 (2)	1 (1)	2 (3)	0 (0)	0 (0)
Equipment used after someone else last month (%)*					
Spoon	6 (6)	9 (9)	9 (14)	9 (13)	6 (10)
Water	7 (7)	12 (12)	5 (8)	5 (7)	10 (16)
Filter	6 (6)	6 (6)	2 (3)	3 (4)	8 (13)
Drug mix	3 (3)	4 (4)	3 (5)	4 (6)	2 (3)
None	86 (84)	67 (69)	51 (81)	54 (79)	46 (73)
Injected by someone after that person injected themselves or others last month (%)					
No	83 (75)	76 (78)	54 (86)	53 (78)	50 (79)
Yes	27 (24)	8 (8)	7 (11)	10 (15)	9 (14)
Not reported	1 (1)	13 (13)	2 (3)	5 (7)	4 (6)
Present when someone injected for the first time in the last 12 months (%)**					
Yes	--	--	--	8 (12)	6 (10)
Overdosed in the last 12 months **					
Yes	--	--	--	--	6 (9)

* More than one option could be selected ** New question in 2012

Table 7.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2009	2010	2011	2012	2013
N° surveyed	N=122	N=106	N=68	N=75	N=70
Sex with a regular partner last month (%)					
No	52 (43)	59 (56)	28 (41)	34 (45)	23 (33)
Yes	59 (48)	43 (41)	37 (54)	37 (49)	41 (59)
Not reported	11 (9)	4 (4)	3 (4)	4 (5)	6 (9)
Condom used with regular partner last month (%)					
N° surveyed	N=59	N=59	N=37	N=37	N=41
Never	51 (86)	44 (75)	24 (65)	27 (73)	27 (66)
Sometimes	1 (2)	7 (12)	9 (24)	4 (11)	2 (5)
Every time	4 (7)	6 (10)	4 (11)	6 (16)	7 (17)
Not reported	3 (5)	2 (3)	0 (0)	0 (0)	5 (12)
Sex with other partner/s last month (%)					
No	86 (70)	94 (89)	57 (84)	58 (77)	59 (84)
Yes	19 (16)	7 (7)	8 (12)	8 (11)	5 (7)
Not reported	17 (14)	5 (5)	3 (4)	9 (12)	6 (9)
Condom used with other partner/s last month (%)					
N° surveyed	N=19	N=7	N=8	N=8	N=5
Never	4 (21)	4 (57)	3 (28)	3 (38)	3 (60)
Sometimes	5 (26)	1 (14)	2 (25)	2 (25)	1 (20)
Every time	9 (47)	2 (29)	3 (38)	2 (25)	1 (20)
Not reported	1 (5)	0 (0)	0 (0)	1 (13)	0 (0)
Sex work last month (%)					
No	107 (88)	101 (95)	64 (94)	68 (91)	58 (83)
Yes	2 (2)	2 (2)	1 (1)	2 (3)	1 (1)
Not reported	13 (11)	3 (3)	3 (4)	5 (7)	11 (16)
Condom used at last sex work last month (%)					
Yes	1 (50)	1 (50)	1 (100)	2 (100)	1 (100)

Table 7.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2009	2010	2011	2012	2013
N° surveyed	N=122	N=106	N=68	N=75	N=70
Any treatment/therapy for drug use (%)					
No	31 (25)	28 (26)	13 (19)	19 (25)	13 (19)
Yes	88 (72)	77 (73)	53 (78)	55 (73)	56 (80)
Not reported	3 (2)	1 (1)	2 (3)	1 (1)	1 (1)
History of methadone maintenance treatment (%)					
Currently	47 (39)	44 (42)	20 (30)	22 (29)	27 (39)
Previously	24 (20)	19 (18)	18 (26)	21 (28)	14 (20)
Never	46 (38)	40 (38)	25 (37)	31 (41)	29 (41)
Not reported	5 (4)	3 (3)	5 (7)	1 (1)	0 (0)
History of buprenorphine (Subutex®) treatment (%)					
Currently	7 (6)	5 (5)	5 (7)	7 (9)	5 (7)
Previously	27 (22)	25 (24)	19 (28)	18 (24)	18 (26)
Never	85 (70)	75 (71)	42 (62)	47 (63)	46 (66)
Not reported	3 (2)	1 (1)	2 (3)	3 (4)	1 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	5 (4)	4 (4)	1 (1)	6 (8)	3 (4)
Previously	14 (11)	13 (12)	13 (19)	12 (16)	12 (17)
Never	99 (81)	88 (83)	53 (78)	54 (72)	51 (73)
Not reported	4 (3)	1 (1)	1 (1)	3 (4)	4 (6)

Table 7.1.5 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2009	2010	2011	2012	2013
N° surveyed	N=122	N=106	N=68	N=75	N=70
Previous HIV test (%)					
Yes, last year	50 (41)	43 (41)	24 (35)	29 (39)	33 (47)
> 1 year ago	41 (34)	42 (40)	30 (44)	26 (35)	28 (40)
Never tested	18 (15)	15 (14)	12 (18)	15 (20)	5 (7)
Not reported	13 (11)	6 (6)	2 (3)	5 (7)	4 (6)
Previous HCV test (%)					
Yes, last year	71 (58)	56 (53)	30 (44)	36 (48)	33 (47)
> 1 year ago	37 (30)	36 (34)	27 (40)	27 (36)	23 (33)
Never tested	8 (7)	10 (9)	7 (10)	7 (9)	6 (9)
Not reported	6 (5)	4 (4)	4 (6)	5 (7)	8 (11)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=68	N=48	N=32	N=34	N=34
Interferon/Interferon+Ribavirin	6 (9)	2 (4)	2 (6)	6 (18)	3 (9)
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	0 (0)
Other	1 (1)	1 (2)	0 (0)	0 (0)	0 (0)
No treatment	61 (90)	40 (83)	29 (91)	26 (76)	30 (88)
Not reported	0 (0)	1 (1)	1 (3)	2 (6)	1 (3)
Current treatment for HCV					
	N=0	N=0	N=0	N=3	N=0
Interferon/Interferon+Ribavirin	0	0	0	3	0
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	0
Other	0	0	0	0	0

* New treatment options added ** 'Current treatment' defined as within the previous 12 months from 2013

Table 7.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2009	2010	2011	2012	2013
N° Injected last month	N=111	N=97	N=63	N=68	N=63
Needle Syringe Program	73 (66)	96 (99)	58 (92)	61 (90)	63 (100)
Chemist/Pharmacy	21 (19)	9 (9)	10 (16)	18 (26)	6 (10)
Personal sources	15 (14)	3 (3)	2 (3)	4 (6)	2 (3)
Dispensing/Vending Machine	3 (3)	0 (0)	1 (2)	5 (7)	5 (8)
Other sources	1 (1)	0 (0)	1 (2)	0 (0)	0 (0)

* More than one option could be selected

Table 7.1.7 Number (percentage) of respondents by last drug injected and all drugs injected in the last 12 months (2013)

	Drugs injected in last 12 months*								
	N° (%)	Cocaine	Heroin	Methadone	Methamphetamine	PIEDs	Pharm. Opioids	Subutex/Suboxone	No other drugs
Last drug injected									
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Heroin	2 (3)	1 (50)	2 (100)	0 (0)	1 (50)	0 (0)	1 (50)	0 (0)	1 (50)
Methadone	19 (27)	0 (0)	1 (5)	19 (100)	7 (37)	1 (5)	8 (42)	0 (0)	7 (37)
Methamphetamine	17 (24)	0 (0)	1 (6)	5 (29)	17 (100)	0 (0)	4 (24)	0 (0)	10 (59)
PIEDs	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)
Pharm. opioids	23 (33)	0 (0)	1 (4)	8 (35)	8 (35)	1 (4)	23 (100)	3 (13)	0 (0)
Subutex/Suboxone	4 (6)	0 (0)	0 (0)	1 (25)	4 (100)	0 (0)	2 (50)	4 (100)	0 (0)
Other/Not reported	4 (6)	1 (25)	2 (50)	2 (50)	4 (100)	0 (0)	4 (100)	1 (25)	1 (6)
Total	70	2 (3)	7 (10)	35 (50)	41 (59)	3 (4)	42 (60)	8 (11)	19 (27)

* More than one option could be selected

HIV antibody prevalence

Table 7.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009	73	0 (0.0)	47	0 (0.0)	121	0 (0.0)
2010	68	0 (0.0)	38	0 (0.0)	106	0 (0.0)
2011	43	0 (0.0)	25	0 (0.0)	68	0 (0.0)
2012	36	0 (0.0)	38	0 (0.0)	74	0 (0.0)
2013	41	0 (0.0)	28	0 (0.0)	69	0 (0.0)
X ² trend p value		--		--		--

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 7.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009	73	38 (52)	45	24 (53)	119	63 (53)
2010	68	30 (44)	38	18 (47)	106	48 (45)
2011	42	17 (40)	25	14 (56)	67	31 (46)
2012	36	17 (47)	37	17 (46)	73	34 (47)
2013	41	19 (46)	28	18 (64)	69	37 (54)
X ² trend p value		0.580		0.568		0.961

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heterosexual	64	33 (52)	33	18 (55)	98	52 (53)
Bisexual	4	3 (75)	8	5 (63)	12	8 (67)
Homosexual	4	2 (50)	1	0 (0)	5	2 (40)
p value		0.853		0.691		0.602
2010						
Heterosexual	66	28 (42)	30	15 (50)	96	43 (45)
Bisexual	0	0 (0)	4	2 (50)	4	2 (50)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2011						
Heterosexual	38	15 (39)	22	11 (50)	60	26 (43)
Bisexual	0	0 (0)	2	2 (100)	2	2 (100)
Homosexual	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.560		0.482		0.236
2012						
Heterosexual	30	15 (50)	30	16 (53)	60	31 (52)
Bisexual	2	1 (50)	5	1 (20)	7	2 (29)
Homosexual	3	0 (0)	1	0 (0)	4	0 (0)
p value		0.298		0.252		0.100
2013						
Heterosexual	36	17 (47)	24	15 (63)	60	32 (53)
Bisexual	1	1 (100)	2	2 (100)	3	3 (100)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.730		0.283		0.081

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
< 25 years	9	4 (44)	3	0 (0)	12	4 (33)
25 – 34	29	12 (41)	30	18 (60)	59	30 (51)
35+ years	35	22 (63)	12	6 (50)	48	29 (60)
p value		0.205		0.134		0.220
2010						
< 25 years	2	0 (0)	5	2 (40)	7	2 (29)
25 – 34	30	12 (40)	13	7 (54)	43	19 (44)
35+ years	36	18 (50)	20	9 (45)	56	27 (48)
p value		0.442		0.906		0.677
2011						
< 25 years	2	0 (0)	2	1 (50)	4	1 (25)
25 – 34	12	3 (25)	10	6 (60)	22	9 (41)
35+ years	28	14 (50)	13	7 (54)	41	21 (51)
p value		0.177		1.000		0.616
2012						
< 25 years	1	0 (0)	2	0 (0)	3	0 (0)
25 – 34	11	5 (45)	13	7 (54)	24	12 (50)
35+ years	24	12 (50)	22	10 (45)	46	22 (48)
p value		1.000		0.563		0.369
2013						
< 25 years	2	0 (0)	1	1 (100)	3	1 (33)
25 – 34	11	3 (27)	9	4 (44)	20	7 (35)
35+ years	28	16 (57)	17	12 (71)	45	28 (62)
p value		0.114		0.395		0.076

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
<3 years	5	0 (0)	4	1 (25)	9	1 (11)
3 to 10 years	16	8 (50)	15	6 (40)	31	14 (45)
11 + years	51	29 (57)	22	15 (68)	74	45 (61)
p value		0.052		0.116		0.012
2010						
<3 years	4	0 (0)	0	0 (0)	4	0 (0)
3 to 10 years	13	5 (38)	12	4 (33)	25	9 (36)
11 + years	51	25 (49)	26	14 (54)	77	39 (51)
p value		0.181		0.307		0.108
2011						
<3 years	3	1 (33)	4	1 (25)	7	2 (29)
3 to 10 years	5	0 (0)	7	5 (71)	12	5 (42)
11 + years	32	15 (47)	13	8 (62)	45	23 (51)
p value		0.156		0.388		0.535
2012						
<3 years	1	0 (0)	4	1 (25)	5	1 (20)
3 to 10 years	5	2 (40)	5	2 (40)	10	4 (40)
11 + years	29	15 (52)	26	14 (54)	55	29 (53)
p value		1.000		0.643		0.356
2013						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	5	2 (40)	8	3 (38)	13	5 (38)
11 + years	34	16 (47)	16	13 (81)	50	29 (58)
p value		1.000		0.022		0.086

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heroin	0	0 (0)	4	3 (75)	4	3 (75)
All other opioids	2	1 (50)	70	40 (57)	77	44 (57)
Methamphetamine	7	0 (0)	23	9 (39)	30	9 (30)
Perform/Image-enhancing drugs	0	0 (0)	1	1 (100)	1	1 (100)
Other	0	0 (0)	4	3 (75)	4	3 (75)
p value		0.047		0.333		0.055
2010						
Heroin	0	0 (0)	1	1 (100)	1	1 (100)
All other opioids	1	0 (0)	63	33 (52)	65	33 (51)
Methamphetamine	2	0 (0)	27	9 (33)	29	9 (31)
Perform/Image-enhancing drugs	1	0 (0)	0	0 (0)	1	0 (0)
Other	0	0 (0)	10	5 (50)	10	5 (50)
p value		--		0.272		0.259
2011						
Heroin	0	0 (0)	1	1 (100)	1	1 (100)
All other opioids	2	0 (0)	41	20 (49)	44	21 (48)
Methamphetamine	3	1 (33)	13	6 (46)	18	7 (39)
Perform/Image-enhancing drugs	0	0 (0)	0	0 (0)	0	0 (0)
Other	2	1 (50)	2	1 (50)	4	2 (50)
p value		0.526		0.781		0.656
2012						
Heroin	1	0 (0)	0	0 (0)	1	0 (0)
All other opioids	1	0 (0)	43	24 (56)	46	24 (52)
Methamphetamine	2	1 (50)	19	8 (42)	22	9 (41)
Perform/Image-enhancing drugs	1	0 (0)	0	0 (0)	1	0 (0)
Other	0	0 (0)	3	1 (33)	3	1 (33)
p value		0.599		0.503		0.589
2013						
Heroin	0	0 (0)	2	1 (50)	2	1 (50)
All other opioids	0	0 (0)	44	24 (55)	46	26 (56)
Methamphetamine	1	0 (0)	14	7 (50)	16	8 (50)
Perform/Image-enhancing drugs	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	0 (0)	3	2 (67)	4	2 (50)
p value		--		0.960		0.839

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Less than daily	6	1 (17)	57	34 (60)	65	37 (57)
Daily or more	1	0 (0)	40	23 (58)	44	24 (55)
Not last month	2	0 (0)	5	1 (20)	7	1 (14)
p value		0.755		0.228		0.098
2010						
Less than daily	1	0 (0)	67	30 (45)	68	30 (44)
Daily or more	1	0 (0)	28	16 (57)	29	16 (55)
Not last month	2	0 (0)	7	2 (29)	9	2 (22)
p value		--		0.356		0.220
2011						
Less than daily	4	1 (25)	31	14 (45)	37	15 (41)
Daily or more	2	1 (50)	22	13 (59)	25	15 (60)
Not last month	1	0 (0)	4	1 (25)	5	1 (20)
p value		1.000		0.345		0.162
2012						
Less than daily	2	1 (50)	31	14 (45)	33	15 (45)
Daily or more	2	0 (0)	29	16 (55)	34	16 (47)
Not last month	1	0 (0)	5	3 (60)	6	3 (50)
p value		1.000		0.693		1.000
2013						
Less than daily	1	0 (0)	35	19 (54)	38	21 (55)
Daily or more	1	0 (0)	22	11 (50)	24	12 (50)
Not last month	1	0 (0)	4	2 (50)	5	2 (40)
p value		--		0.919		0.804

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No receptive sharing	6	1 (17)	82	49 (60)	93	53 (57)
Receptive sharing	1	0 (0)	12	8 (67)	13	8 (62)
p value		1.000		0.759		1.000
2010						
No receptive sharing	1	0 (0)	81	38 (47)	82	38 (46)
Receptive sharing	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.229		0.224
2011						
No receptive sharing	1	0 (0)	47	26 (55)	50	27 (54)
Receptive sharing	5	2 (40)	4	1 (25)	10	3 (30)
p value		1.000		0.331		0.299
2012						
No receptive sharing	3	1 (33)	47	25 (53)	53	26 (49)
Receptive sharing	0	0 (0)	10	5 (50)	10	5 (50)
p value		--		1.000		1.000
2013						
No receptive sharing	2	0 (0)	56	30 (54)	60	32 (53)
Receptive sharing	0	0 (0)	1	0 (0)	2	1 (50)
p value		--		0.474		1.000

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 7.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No imprisonment	8	1 (13)	85	48 (56)	96	51 (53)
Imprisonment	0	0 (0)	15	10 (67)	16	10 (63)
p value		---		0.575		0.592
2010						
No imprisonment	3	0 (0)	78	29 (37)	81	29 (36)
Imprisonment	0	0 (0)	5	5 (100)	5	5 (100)
p value		--		0.010		0.008
2011						
No imprisonment	7	2 (29)	54	26 (48)	62	28 (45)
Imprisonment	0	0 (0)	2	2 (100)	4	3 (75)
p value		--		0.491		0.335
2012						
No imprisonment	5	1 (20)	58	31 (53)	66	32 (48)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		1.000		1.000
2013						
No imprisonment	3	0 (0)	49	24 (49)	54	26 (48)
Imprisonment	0	0 (0)	9	8 (89)	9	8 (89)
p value		--		0.033		0.031

* Total includes people who did not report duration of drug injection

Table 7.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No sex work	9	1 (11)	92	54 (59)	104	57 (55)
Sex work	0	0 (0)	1	1 (100)	2	2 (100)
p value		---		1.000		0.502
2010						
No sex work	3	0 (0)	98	47 (48)	101	47 (47)
Sex work	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.497		0.499
2011						
No sex work	7	2 (29)	54	27 (50)	63	30 (48)
Sex work	0	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		1.000
2012						
No sex work	5	1 (20)	59	31 (53)	66	32 (48)
Sex work	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
2013						
No sex work	3	0 (0)	52	26 (50)	57	28 (49)
Sex work	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 7.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Non Indigenous	61	30 (49)	36	20 (56)	98	51 (52)
Indigenous	9	6 (67)	6	3 (50)	15	9 (60)
p value		0.479		1.000		0.593
2010						
Non Indigenous	61	27 (44)	33	15 (45)	94	42 (45)
Indigenous	7	3 (43)	5	3 (60)	12	6 (50)
p value		1.000		0.653		0.766
2011						
Non Indigenous	38	16 (42)	20	10 (50)	58	26 (45)
Indigenous	3	1 (33)	5	4 (80)	8	5 (63)
p value		1.000		0.341		0.459
2012						
Non Indigenous	33	17 (52)	29	12 (41)	62	29 (47)
Indigenous	2	0 (0)	8	5 (63)	10	5 (50)
p value		0.486		0.428		1.000
2013						
Non Indigenous	36	17 (47)	23	13 (57)	59	30 (51)
Indigenous	5	2 (40)	4	4 (100)	9	6 (67)
p value		1.000		0.264		0.484

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
English speaking	70	37 (53)	44	24 (55)	117	63 (54)
Non-English speaking	0	0 (0)	1	0 (0)	1	0 (0)
p value		---		0.467		0.466
2010						
English speaking	67	30 (45)	38	18 (47)	105	48 (46)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
2011						
English speaking	42	17 (40)	25	14 (56)	67	31 (46)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2012						
English speaking	34	16 (47)	37	17 (46)	71	33 (46)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.486		--		0.472
2013						
English speaking	41	19 (46)	28	18 (64)	69	37 (54)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Australia	68	36 (53)	40	21 (53)	109	58 (53)
Other Oceania	1	0 (0)	1	1 (100)	2	1 (50)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	0	0 (0)	2	1 (50)	2	1 (50)
p value		0.724		1.000		0.874
2010						
Australia	65	28 (43)	33	15 (45)	98	43 (44)
Other Oceania	0	0 (0)	2	2 (100)	2	2 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	2 (100)	2	1 (50)	4	3 (75)
Other	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.187		0.365		0.134
2011						
Australia	39	14 (36)	24	13 (54)	63	27 (43)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	2	2 (100)	0	0 (0)	2	2 (100)
p value		0.059		1.000		0.041
2012						
Australia	33	15 (45)	34	15 (44)	67	30 (45)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	1	1 (100)	1	1 (100)
Other	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.471		0.723		0.403
2013						
Australia	39	17 (44)	27	17 (63)	66	34 (52)
Other Oceania	0	0 (0)	1	1 (100)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	2 (100)	0	0 (0)	2	2 (100)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.209		1.000		0.495

* Total includes people whose gender was not reported or reported as transgender

Victoria

Table 8.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2009	2010	2011	2012	2013
Number of sites	6	5	6	6	6
N° surveyed	N=334	N=445	N=506	N=463	N=448
Response (%)	--	58%	55%	52%	61%
Gender (%)					
Male	216 (65)	310 (70)	341 (67)	322 (70)	302 (67)
Female	116 (35)	133 (30)	163 (32)	140 (30)	139 (31)
Transgender	2 (<1)	1 (<1)	1 (<1)	1 (<1)	4 (<1)
Not reported	0 (0)	1 (<1)	1 (<1)	0 (0)	3 (<1)
Sexual identity (%)					
Heterosexual	273 (82)	373 (84)	415 (82)	367 (79)	338 (75)
Bisexual	34 (10)	36 (8)	45 (9)	46 (10)	31 (7)
Homosexual	8 (2)	8 (2)	14 (3)	17 (4)	25 (6)
Not reported	19 (6)	28 (6)	32 (6)	33 (7)	54 (12)
Age and duration of injection (years)					
<i>Median age</i>	34	35	37	37	38
Age range	17-61	18-62	18-63	17-64	15-66
<i>Age group (%)</i>					
<25 years	29 (9)	46 (10)	38 (8)	21 (5)	18 (4)
25+ years	305 (91)	399 (90)	464 (92)	440 (95)	429 (96)
Not reported	0 (0)	0 (0)	4 (1)	2 (<1)	1 (<1)
<i>Median age 1st IDU</i>	18	17	18	18	18
Age range	11-51	10-50	10-50	10-59	10-52
Not reported	9	9	11	17	23
<i>Median years IDU</i>	14	15	17	18	18
Range	<1-40	<1-42	<1-47	<1-43	<1-40
<i>Duration of drug injection (%)</i>					
<3 years	13 (91)	15 (3)	13 (3)	14 (3)	13 (3)
3+ years	312 (93)	421 (95)	481 (95)	431 (93)	412 (92)
Not reported	9 (3)	9 (2)	12 (2)	18 (4)	23 (5)
Aboriginal and Torres Strait Islander origin (%)					
No	304 (91)	405 (91)	442 (87)	389 (84)	380 (85)
Yes	23 (7)	36 (8)	55 (11)	67 (14)	52 (12)
Not reported	7 (2)	4 (1)	9 (2)	7 (2)	16 (4)
Region/Country of birth (%)					
Australia	285 (85)	392 (88)	444 (88)	388 (84)	364 (81)
Other Oceania	8 (2)	9 (2)	11 (2)	14 (3)	10 (2)
Asia	7 (2)	7 (2)	6 (1)	14 (3)	20 (4)
UK & Ireland	12 (4)	13 (3)	20 (4)	21 (5)	22 (5)
Other	20 (6)	15 (3)	24 (5)	24 (5)	30 (7)
Not reported	2 (<1)	9 (2)	1 (<1)	2 (<1)	2 (<1)
Main language spoken at home by parents (%)					
English speaking	303 (91)	412 (93)	457 (90)	417 (90)	393 (88)
Non-English speaking	23 (7)	26 (6)	45 (9)	45 (10)	54 (12)
Not reported	8 (2)	7 (2)	4 (1)	1 (<1)	1 (<1)
Imprisonment last year (%)					
No	285 (85)	319 (72)	403 (80)	368 (80)	354 (79)
Yes	39 (12)	45 (10)	59 (12)	75 (16)	48 (11)
Not reported	10 (3)	81 (18)	44 (9)	15 (3)	46 (10)
Injected in prison (%)					
Yes	N=39	N=45	N=59	N=75	N=48
Yes	12 (31)	15 (33)	19 (32)	22 (29)	14 (29)
Frequency of injection last month (%)					
Not last month	21 (6)	30 (7)	46 (9)	26 (6)	33 (7)
Less than weekly	44 (13)	72 (16)	68 (13)	93 (20)	84 (19)
Weekly not daily	69 (21)	101 (23)	109 (22)	99 (21)	102 (23)
Daily or more	196 (59)	235 (53)	278 (55)	236 (51)	210 (47)
Not reported	4 (1)	7 (2)	5 (1)	9 (2)	19 (4)

Table 8.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2009	2010	2011	2012	2013
Last drug injected (%)	N=334	N=445	N=506	N=463	N=448
Cocaine	0 (0)	4 (1)	2 (<1)	0 (0)	1 (<1)
Heroin	205 (61)	265 (60)	307 (61)	299 (65)	241 (54)
Methadone	9 (3)	13 (3)	12 (2)	7 (2)	5 (2)
Methamphetamine	45 (13)	57 (13)	91 (18)	82 (18)	96 (21)
Performance/Image-enhancing drugs	1 (<1)	1 (<1)	1 (<1)	2 (<1)	3 (<1)
Pharmaceutical opioids	21 (6)	34 (8)	26 (5)	15 (3)	19 (4)
Suboxone®	3 (1)	13 (3)	16 (3)	10 (2)	10 (2)
Subutex®/Buprenorphine	26 (8)	31 (7)	20 (4)	13 (3)	22 (5)
More than one	10 (3)	23 (5)	26 (5)	32 (7)	43 (10)
Other drug	8 (2)	4 (1)	2 (<1)	2 (<1)	4 (<1)
Not reported	6 (2)	0 (0)	3 (<1)	1 (<1)	1 (<1)
N° Injected last month	N=309	N=409	N=455	N=428	N=396
Places injected last month (%)*					
Any public	195 (63)	257 (63)	292 (64)	259 (61)	224 (57)
All private	113 (37)	126 (31)	149 (33)	148 (35)	164 (41)
Not reported	1 (<1)	26 (6)	14 (3)	21 (5)	8 (2)
Use of new sterile needles & syringes last month (%)					
All injections	224 (72)	289 (71)	327 (72)	319 (75)	296 (68)
Most of the time	69 (22)	76 (19)	87 (19)	70 (16)	103 (26)
Half of the time	7 (2)	5 (1)	13 (3)	9 (2)	2 (<1)
Some of the time	5 (2)	6 (1)	5 (1)	4 (1)	8 (2)
Not last month	0 (0)	0 (0)	0 (0)	2 (<1)	2 (<1)
Not reported	4 (1)	33 (8)	23 (5)	24 (6)	12 (3)
Re-used another's used needle & syringe last month (%)					
None	252 (82)	307 (75)	330 (73)	316 (74)	313 (79)
Once	16 (5)	20 (5)	30 (7)	43 (10)	19 (5)
Twice	13 (4)	16 (4)	25 (5)	18 (4)	18 (5)
3-5 times	9 (3)	16 (4)	21 (5)	17 (4)	20 (5)
>5 times	11 (4)	11 (3)	16 (4)	16 (4)	16 (4)
Not reported	8 (3)	39 (10)	33 (7)	18 (4)	10 (3)
Number of people needle & syringe was re-used after last month (%)					
None	252 (82)	307 (75)	330 (73)	316 (74)	313 (79)
One	26 (8)	33 (8)	49 (11)	50 (12)	30 (8)
Two	1 (<1)	4 (1)	9 (2)	5 (1)	8 (2)
Three to five	2 (<1)	4 (1)	5 (1)	5 (1)	2 (<1)
More than five	1 (<1)	7 (2)	5 (1)	3 (1)	6 (2)
Don't know	7 (2)	8 (2)	20 (4)	16 (4)	18 (5)
Not reported	20 (6)	46 (11)	37 (8)	33 (8)	19 (5)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	24 (8)	41 (10)	47 (10)	28 (7)	28 (7)
Casual sex partner	0 (0)	4 (1)	3 (1)	3 (1)	5 (1)
Close friend	8 (3)	33 (8)	50 (11)	29 (7)	18 (5)
Acquaintance	2 (<1)	8 (2)	23 (5)	13 (3)	14 (4)
Other	4 (1)	6 (1)	13 (3)	10 (2)	6 (2)
Equipment used after someone else last month (%)*					
Spoon	105 (36)	128 (31)	163 (36)	143 (33)	128 (32)
Water	55 (19)	76 (19)	100 (22)	90 (21)	83 (21)
Filter	49 (17)	52 (13)	76 (17)	68 (16)	56 (14)
Drug mix	31 (11)	51 (12)	53 (12)	60 (14)	43 (11)
None	167 (58)	220 (54)	246 (54)	228 (53)	238 (60)
Injected by someone after that person injected themselves or others last month (%)					
No	246 (80)	314 (77)	359 (79)	336 (79)	315 (80)
Yes	57 (18)	64 (16)	72 (16)	65 (15)	58 (15)
Not reported	6 (2)	31 (8)	24 (5)	27 (6)	23 (6)
Present when someone injected for the first time in the last 12 months (%)**					
Yes	--	--	--	63 (15)	44 (11)
Overdosed in the last 12 months **					
Yes	--	--	--	--	78 (17)

* More than one option could be selected ** New question in 2012 or 2013

Table 8.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2009	2010	2011	2012	2013
N° surveyed	N=334	N=445	N=506	N=463	N=448
Sex with a regular partner last month (%)					
No	140 (42)	216 (49)	249 (49)	256 (55)	244 (54)
Yes	179 (54)	215 (48)	209 (41)	196 (42)	182 (41)
Not reported	15 (4)	14 (3)	48 (9)	11 (2)	22 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=179	N=215	N=209	N=196	N=182
Never	126 (70)	138 (64)	146 (70)	124 (63)	117 (64)
Sometimes	23 (13)	31 (14)	29 (14)	28 (14)	30 (16)
Every time	24 (13)	36 (17)	25 (12)	25 (13)	20 (11)
Not reported	6 (3)	10 (5)	9 (4)	19 (10)	15 (8)
Sex with other partner/s last month (%)					
No	273 (82)	353 (79)	406 (80)	359 (78)	351 (78)
Yes	45 (13)	65 (15)	81 (16)	86 (19)	70 (16)
Not reported	16 (5)	27 (6)	19 (4)	18 (4)	27 (6)
Condom used with other partner/s last month (%)					
N° surveyed	N=45	N=65	N=81	N=86	N=70
Never	14 (31)	21 (32)	28 (35)	30 (35)	17 (24)
Sometimes	10 (22)	17 (26)	16 (20)	24 (28)	24 (34)
Every time	20 (44)	23 (35)	32 (40)	30 (35)	24 (34)
Not reported	1 (2)	4 (6)	5 (6)	2 (2)	5 (7)
Sex work last month (%)					
No	308 (92)	393 (88)	454 (90)	418 (90)	390 (87)
Yes	17 (5)	28 (6)	31 (6)	34 (7)	19 (4)
Not reported	9 (3)	24 (5)	21 (4)	11 (2)	39 (9)
Condom used at last sex work last month (%)					
Yes	15 (88)	21 (78)	25 (89)	29 (85)	12 (75)

Table 8.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2009	2010	2011	2012	2013
N° surveyed	N=334	N=445	N=506	N=463	N=448
Any treatment/therapy for drug use (%)					
No	29 (9)	36 (8)	58 (11)	38 (8)	39 (9)
Yes	304 (91)	404 (91)	441 (87)	423 (91)	406 (91)
Not reported	1 (<1)	5 (1)	7 (1)	2 (<1)	3 (<1)
History of methadone maintenance treatment (%)					
Currently	88 (26)	140 (31)	169 (33)	162 (35)	171 (38)
Previously	125 (37)	155 (35)	157 (31)	176 (38)	142 (32)
Never	114 (34)	133 (30)	162 (32)	123 (27)	133 (30)
Not reported	7 (2)	17 (4)	18 (4)	2 (<1)	2 (<1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	52 (16)	69 (16)	57 (11)	55 (12)	44 (10)
Previously	136 (41)	169 (38)	197 (39)	198 (43)	197 (44)
Never	141 (42)	200 (45)	234 (46)	203 (44)	200 (45)
Not reported	5 (2)	7 (2)	18 (4)	7 (2)	7 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	54 (16)	66 (15)	69 (14)	53 (11)	61 (14)
Previously	94 (28)	123 (28)	137 (27)	165 (36)	156 (35)
Never	181 (54)	248 (56)	281 (56)	238 (51)	225 (50)
Not reported	5 (2)	8 (2)	19 (4)	7 (2)	6 (1)

Table 8.1.5 Number and (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2009	2010	2011	2012	2013
N° surveyed	N=334	N=445	N=506	N=463	N=448
Previous HIV test (%)					
Yes, last year	174 (52)	233 (52)	264 (52)	274 (59)	253 (56)
> 1 year ago	121 (36)	144 (32)	166 (33)	130 (28)	128 (29)
Never tested	29 (9)	40 (9)	52 (10)	44 (10)	42 (9)
Not reported	10 (3)	28 (6)	24 (5)	15 (3)	25 (6)
Previous HCV test (%)					
Yes, last year	194 (58)	268 (60)	305 (60)	295 (64)	268 (60)
> 1 year ago	110 (33)	125 (28)	153 (30)	122 (26)	125 (28)
Never tested	14 (4)	24 (5)	18 (4)	22 (5)	13 (3)
Not reported	16 (5)	28 (6)	30 (6)	24 (5)	42 (9)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=201	N=280	N=321	N=313	N=263
Interferon/Interferon+Ribavirin	14 (7)	16 (9)	23 (7)	22 (7)	20 (8)
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	1 (<1)
Other	5 (2)	5 (2)	2 (<1)	4 (1)	5 (2)
No treatment	176 (88)	238 (85)	278 (87)	272 (87)	224 (85)
Not reported	6 (3)	11 (4)	18 (6)	15 (5)	13 (5)
Current treatment for HCV**	N=2	N=4	N=6	N=6	N=11
Interferon/Interferon+Ribavirin	2	1	6	2	7
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	2
Other	0	3	0	4	2

* New treatment options added ** 'Current treatment' defined as within the previous 12 months from 2013

Table 8.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2009	2010	2011	2012	2013
N° Injected last month	N=309	N=409	N=455	N=428	N=396
Needle Syringe Program	229 (74)	385 (94)	425 (93)	394 (92)	374 (94)
Chemist/Pharmacy	62 (20)	75 (18)	92 (20)	88 (21)	90 (23)
Personal sources	64 (21)	58 (14)	46 (10)	65 (15)	29 (7)
Dispensing/Vending Machine	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Other sources	13 (4)	13 (3)	4 (1)	7 (2)	7 (2)

* More than one option could be selected

Table 8.1.7 Number (percentage) of respondents by last drug injected and all drugs injected in the last 12 months (2013)

	N° (%)	Drugs injected in last 12 months*							
		Cocaine	Heroin	Methadone	Methamphetamine	PIEDs	Pharm. Opioids	Subutex/Suboxone	No other drugs
Last drug injected									
Cocaine	1 (<1)	1 (100)	1 (100)	1 (100)	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)
Heroin	241 (54)	24 (10)	214 (100)	18 (7)	119 (49)	1 (<1)	40 (17)	19 (8)	99 (41)
Methadone	8 (2)	1 (13)	5 (63)	8 (100)	4 (50)	1 (13)	3 (38)	1 (13)	3 (38)
Methamphetamine	96 (21)	12 (13)	48 (50)	10 (10)	96 (100)	4 (4)	19 (20)	17 (18)	32 (33)
PIEDs	3 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	0 (0)	0 (0)	1 (33)
Pharm. opioids	19 (4)	3 (16)	13 (68)	3 (16)	11 (58)	2 (11)	19 (100)	4 (21)	0 (0)
Subutex/Suboxone	32 (7)	1 (3)	12 (38)	4 (13)	19 (59)	1 (3)	8 (25)	32 (100)	9 (28)
Other/Not reported	48 (11)	6 (13)	32 (67)	10 (21)	31 (65)	3 (6)	12 (25)	9 (18)	5 (10)
Total	448	48 (11)	352 (79)	54 (12)	281 (63)	15 (3)	102 (23)	82 (18)	149 (33)

* More than one option could be selected

HIV antibody prevalence

Table 8.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009	215	3 (1.4)	116	0 (0.0)	333	3 (0.9)
2010	305	2 (0.7)	131	0 (0.0)	438	2 (0.5)
2011	335	4 (1.2)	162	0 (0.0)	499	4 (0.8)
2012	304	1 (0.3)	128	0 (0.0)	433	1 (0.2)
2013	300	5 (1.7)	139	1 (0.7)	446	6 (1.3)
X ² trend p value		0.809		0.158		0.536

* Total includes people whose gender was not reported or reported as transgender

Table 8.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heterosexual	243	2 (0.8)	91	1 (1.1)	337	3 (0.9)
Bisexual	8	0 (0.0)	22	0 (0.0)	31	0 (0.0)
Homosexual	13	2 (15.4)	8	0 (0.0)	24	2 (8.3)
p value		<0.001		1.000		0.006

* Total includes people whose gender was not reported or reported as transgender

Table 8.2.3 HIV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
< 25 years	8	0 (0.0)	10	0 (0.0)	18	0 (0.0)
25 – 34	80	2 (2.5)	48	0 (0.0)	132	2 (1.5)
35+ years	211	3 (1.4)	81	1 (1.2)	295	4 (1.4)
p value		0.667		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 8.2.4 HIV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<3 years	5	0 (0.0)	6	0 (0.0)	13	0 (0.0)
3 to 10 years	39	2 (5.1)	26	0 (0.0)	66	2 (3.0)
11 + years	239	3 (1.3)	102	1 (1.0)	344	4 (1.2)
p value		0.219		1.000		0.378

* Total includes people whose gender was not reported or reported as transgender

Table 8.2.5 HIV antibody prevalence by last drug injected, gender and survey year

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heroin	160	2 (1.3)	76	1 (1.3)	239	3 (1.3)
Methamphetamine	61	3 (4.9)	34	0 (0.0)	96	3 (3.1)
Other	78	0 (0.0)	29	0 (0.0)	110	0 (0.0)
p value		0.084		1.000		0.156

* Total includes people whose gender was not reported or reported as transgender

Table 8.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Less than daily	119	1 (0.8)	65	1 (1.5)	185	2 (1.1)
Daily or more	147	3 (2.0)	58	0 (0.0)	209	3 (1.5)
Not last month	24	1 (4.2)	9	0 (0.0)	33	1 (3.0)
p value		0.357		1.000		

* Total includes people whose gender was not reported or reported as transgender

Table 8.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No receptive sharing	207	4 (1.9)	99	1 (1.0)	311	5 (1.6)
Receptive sharing	55	0 (0.0)	18	0 (0.0)	73	0 (0.0)
p value		0.582		1.000		0.588

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 8.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No imprisonment	115	1 (0.9)	32	1 (3.1)	147	2 (1.4)
Imprisonment	38	1 (2.6)	10	0 (0.0)	48	1 (2.1)
p value		0.436		1.000		0.574

* Total includes people whose gender was not reported or reported as transgender

Table 8.2.9 HIV antibody prevalence by condom use at last sex, gender and survey year

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No condom use	65	1 (1.6)	51	0 (0.0)	117	1 (0.9)
Condom use	32	2 (6.3)	16	0 (0.0)	50	2 (4.0)
p value		0.252		---		0.214

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 8.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No sex work	268	5 (1.9)	115	1 (0.9)	388	6 (1.6)
Sex work	7	0 (0.0)	11	0 (0.0)	19	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 8.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Non Indigenous	256	4 (1.6)	119	1 (0.8)	379	5 (1.3)
Indigenous	32	1 (3.1)	17	0 (0.0)	51	1 (2.0)
p value		0.448		1.000		0.533

* Total includes people whose gender was not reported or reported as transgender

Table 8.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
English speaking	254	4 (1.6)	130	1 (0.8)	391	5 (1.3)
Non-English speaking	45	1 (2.2)	9	0 (0.0)	54	1 (1.9)
p value		0.560		1.000		0.542

* Total includes people whose gender was not reported or reported as transgender

Table 8.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Australia	235	3 (1.3)	121	1 (0.8)	363	4 (1.1)
Other Oceania	10	0 (0.0)	0	0 (0.0)	10	0 (0.0)
Asia	17	1 (5.9)	3	0 (0.0)	20	1 (5.0)
UK & Ireland	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
Other	22	1 (4.6)	8	0 (0.0)	30	1 (3.3)
p value		0.486		1.000		0.258

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 8.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009	212	120 (57)	115	60 (52)	329	182 (55)
2010	303	204 (67)	130	72 (55)	435	278 (64)
2011	332	229 (69)	158	93 (59)	492	324 (66)
2012	301	214 (71)	127	83 (65)	429	297 (69)
2013	299	199 (67)	138	94 (68)	444	296 (67)
X ² trend p value		0.028		0.002		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heterosexual	186	108 (58)	82	40 (49)	270	150 (56)
Bisexual	11	5 (45)	22	14 (64)	33	19 (58)
Homosexual	4	1 (25)	4	2 (50)	8	3 (38)
p value		0.344		0.412		0.637
2010						
Heterosexual	269	183 (68)	97	52 (54)	367	236 (64)
Bisexual	13	10 (77)	21	13 (62)	34	23 (68)
Homosexual	3	2 (67)	4	1 (25)	7	3 (43)
p value		0.893		0.409		0.442
2011						
Heterosexual	300	212 (71)	102	60 (59)	403	273 (68)
Bisexual	10	5 (50)	35	18 (51)	45	23 (51)
Homosexual	9	5 (56)	5	2 (40)	14	7 (50)
p value		0.893		0.409		0.442
2012						
Heterosexual	259	182 (70)	80	50 (63)	339	232 (68)
Bisexual	16	12 (75)	28	19 (68)	44	31 (70)
Homosexual	5	2 (40)	9	7 (78)	15	9 (60)
p value		0.308		0.665		0.717
2013						
Heterosexual	242	166 (69)	90	63 (70)	335	231 (69)
Bisexual	8	6 (75)	22	12 (55)	31	18 (58)
Homosexual	13	4 (31)	8	6 (75)	24	11 (46)
p value		0.019		0.350		0.040

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
< 25 years	15	2 (13)	14	1 (7)	29	3 (10)
25 – 34	95	49 (52)	49	27 (55)	145	77 (53)
35+ years	102	69 (68)	52	32 (62)	155	102 (66)
p value		<0.001		0.001		<0.001
2010						
< 25 years	14	3 (21)	29	7 (24)	43	10 (23)
25 – 34	112	69 (62)	44	26 (59)	157	96 (61)
35+ years	177	132 (75)	57	39 (68)	235	172 (73)
p value		<0.001		<0.001		<0.001
2011						
< 25 years	18	8 (44)	20	5 (25)	38	13 (34)
25 – 34	102	68 (67)	60	40 (67)	163	109 (67)
35+ years	210	152 (72)	77	48 (62)	287	200 (70)
p value		0.046		0.004		<0.001
2012						
< 25 years	14	3 (21)	7	2 (29)	21	5 (24)
25 – 34	91	63 (69)	50	32 (64)	142	95 (67)
35+ years	195	147 (75)	70	49 (70)	265	196 (74)
p value		<0.001		0.101		<0.001
2013						
< 25 years	8	1 (13)	10	4 (40)	18	5 (28)
25 – 34	79	37 (47)	48	28 (58)	131	67 (51)
35+ years	211	160 (76)	80	62 (78)	294	223 (76)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
<3 years	6	2 (33)	6	0 (0)	12	2 (17)
3 to 10 years	44	16 (36)	36	13 (36)	81	30 (37)
11 + years	159	101 (64)	68	43 (63)	227	144 (63)
p value		0.003		0.001		<0.001
2010						
<3 years	10	4 (40)	4	2 (50)	14	6 (43)
3 to 10 years	40	18 (45)	44	15 (34)	84	33 (39)
11 + years	247	177 (71)	81	54 (67)	329	323 (71)
p value		0.001		0.001		<0.001
2011						
<3 years	5	0 (0)	8	3 (38)	13	3 (23)
3 to 10 years	49	29 (59)	37	15 (41)	86	44 (51)
11 + years	274	198 (72)	107	71 (66)	382	270 (71)
p value		0.001		0.008		<0.001
2012						
<3 years	9	2 (22)	4	1 (25)	13	3 (23)
3 to 10 years	46	27 (59)	18	7 (39)	64	34 (53)
11 + years	236	175 (74)	99	70 (71)	336	245 (73)
p value		0.001		0.008		<0.001
2013						
<3 years	5	2 (40)	6	1 (17)	13	4 (31)
3 to 10 years	38	13 (34)	26	18 (69)	65	31 (48)
11 + years	239	170 (71)	101	74 (73)	343	245 (71)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heroin	4	0 (0)	194	117 (60)	201	119 (59)
All other opioids	4	1 (25)	51	24 (47)	58	26 (45)
Methamphetamine	1	0 (0)	41	18 (44)	45	21 (47)
Perform/Image-enhancing drugs	0	0 (0)	1	1 (100)	1	1 (100)
Other	2	1 (50)	16	11 (69)	18	12 (67)
p value		0.428		0.117		0.140
2010						
Heroin	8	4 (50)	245	168 (69)	257	176 (68)
All other opioids	3	2 (67)	86	56 (65)	91	59 (65)
Methamphetamine	1	0 (0)	52	22 (42)	56	25 (45)
Perform/Image-enhancing drugs	0	0 (0)	1	1 (100)	1	1 (100)
Other	1	0 (0)	27	16 (59)	30	17 (58)
p value		0.518		0.008		0.013
2011						
Heroin	8	1 (13)	283	202 (71)	297	208 (70)
All other opioids	4	1 (25)	68	45 (66)	74	46 (62)
Methamphetamine	1	1 (100)	87	49 (56)	89	50 (56)
Perform/Image-enhancing drugs	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	26	16 (62)	28	18 (64)
p value		0.146		0.053		0.077
2012						
Heroin	9	2 (22)	268	188 (70)	287	199 (69)
All other opioids	2	1 (50)	34	28 (82)	39	32 (69)
Methamphetamine	1	0 (0)	68	45 (66)	69	45 (65)
Perform/Image-enhancing drugs	0	0 (0)	2	1 (50)	2	1 (50)
Other	1	1 (0)	28	17 (61)	31	19 (61)
p value		0.701		0.349		0.310
2013						
Heroin	4	1 (25)	225	161 (72)	237	170 (72)
All other opioids	1	0 (0)	54	36 (67)	59	38 (64)
Methamphetamine	4	1 (25)	86	53 (62)	96	58 (60)
Perform/Image-enhancing drugs	2	1 (50)	1	0 (0)	3	1 (33)
Other	2	1 (50)	42	26 (62)	48	28 (58)
p value		0.867		0.219		0.110

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Less than daily	5	0 (0)	104	62 (60)	111	64 (58)
Daily or more	7	2 (29)	182	100 (55)	193	104 (54)
Not last month	0	0 (0)	19	9 (47)	21	10 (48)
p value		0.190		0.547		0.648
2010						
Less than daily	2	1 (50)	189	127 (67)	195	132 (68)
Daily or more	11	5 (45)	193	123 (64)	206	129 (63)
Not last month	1	0 (0)	26	13 (50)	29	15 (52)
p value		1.000		0.225		0.204
2011						
Less than daily	3	0 (0)	168	106 (63)	173	106 (61)
Daily or more	10	3 (30)	251	176 (70)	269	186 (69)
Not last month	0	0 (0)	44	28 (64)	45	28 (62)
p value		0.528		0.276		0.206
2012						
Less than daily	6	1 (17)	167	116 (69)	179	123 (69)
Daily or more	6	2 (33)	206	146 (71)	219	154 (70)
Not last month	1	0 (0)	21	14 (67)	24	16 (67)
p value		1.000		0.901		0.900
2013						
Less than daily	6	1 (17)	168	117 (70)	185	122 (66)
Daily or more	4	2 (50)	193	126 (65)	207	138 (67)
Not last month	2	1 (50)	30	20 (67)	33	22 (67)
p value		0.414		0.688		0.987

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No receptive sharing	11	2 (18)	234	135 (58)	249	140 (56)
Receptive sharing	1	0 (0)	44	23 (52)	47	24 (51)
p value		1.000		0.512		0.526
2010						
No receptive sharing	11	5 (45)	287	184 (64)	303	193 (64)
Receptive sharing	2	1 (50)	57	37 (65)	59	38 (64)
p value		1.000		1.000		1.000
2011						
No receptive sharing	10	2 (20)	306	197 (64)	323	203 (63)
Receptive sharing	1	0 (0)	84	64 (76)	87	66 (76)
p value		1.000		0.049		0.030
2012						
No receptive sharing	10	2 (20)	282	195 (69)	299	203 (68)
Receptive sharing	2	1 (50)	76	57 (75)	84	64 (76)
p value		0.455		0.321		0.179
2013						
No receptive sharing	9	3 (33)	288	192 (67)	309	203 (66)
Receptive sharing	1	0 (0)	65	45 (69)	73	50 (68)
p value		1.000		0.771		0.682

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 8.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No imprisonment	12	2 (17)	261	140 (54)	282	148 (52)
Imprisonment	0	0 (0)	38	28 (74)	38	28 (74)
p value		---		0.023		0.015
2010						
No imprisonment	10	3 (30)	299	183 (61)	315	192 (61)
Imprisonment	1	1 (100)	40	27 (68)	42	28 (67)
p value		0.364		0.492		0.505
2011						
No imprisonment	12	3 (25)	372	238 (64)	392	248 (63)
Imprisonment	1	0 (0)	53	42 (79)	56	42 (75)
p value		1.000		0.030		0.100
2012						
No imprisonment	12	3 (25)	315	210 (67)	341	226 (66)
Imprisonment	1	0 (0)	66	52 (79)	69	54 (78)
p value		1.000		0.058		0.065
2013						
No imprisonment	10	4 (40)	325	212 (65)	351	227 (65)
Imprisonment	1	0 (0)	44	34 (77)	47	35 (74)
p value		1.000		0.127		0.184

* Total includes people who did not report duration of drug injection

Table 8.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No sex work	11	2 (18)	284	160 (56)	303	168 (55)
Sex work	1	0 (0)	15	8 (53)	17	8 (47)
p value		1.000		1.000		0.618
2010						
No sex work	11	5 (45)	366	239 (65)	384	250 (65)
Sex work	3	1 (33)	24	12 (50)	28	14 (50)
p value		1.000		0.185		0.152
2011						
No sex work	12	3 (23)	421	274 (65)	442	283 (64)
Sex work	0	0 (0)	28	23 (82)	29	23 (79)
p value		--		0.097		0.110
2012						
No sex work	11	3 (27)	359	249 (69)	384	265 (69)
Sex work	2	0 (0)	31	24 (77)	34	25 (74)
p value		1.000		0.418		0.584
2013						
No sex work	11	3 (27)	358	237 (66)	386	251 (65)
Sex work	2	1 (50)	16	10 (63)	19	12 (63)
p value		1.000		0.790		1.000

* Total includes people who did not report duration of drug injection

Table 8.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Non Indigenous	195	52 (51)	102	52 (51)	299	164 (55)
Indigenous	12	8 (73)	11	8 (73)	23	15 (65)
p value		1.000		0.213		0.389
2010						
Non Indigenous	281	192 (68)	113	66 (58)	396	260 (66)
Indigenous	18	10 (56)	17	6 (35)	35	16 (46)
p value		0.301		0.115		0.026
2011						
Non Indigenous	292	201 (69)	136	82 (60)	429	284 (66)
Indigenous	33	25 (76)	20	9 (45)	54	35 (65)
p value		0.550		0.229		0.879
2012						
Non Indigenous	251	173 (69)	109	75 (69)	361	248 (69)
Indigenous	46	39 (85)	16	6 (38)	62	45 (73)
p value		0.029		0.014		0.540
2013						
Non Indigenous	255	167 (65)	118	79 (67)	377	247 (66)
Indigenous	32	21 (66)	17	13 (76)	51	35 (69)
p value		0.988		0.431		0.660

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
English speaking	193	107 (55)	103	54 (52)	298	163 (55)
Non-English speaking	16	11 (69)	7	3 (43)	23	14 (61)
p value		0.432		0.702		0.666
2010						
English speaking	277	188 (68)	126	69 (55)	404	258 (64)
Non-English speaking	23	13 (57)	2	2 (100)	25	15 (60)
p value		0.356		0.502		0.675
2011						
English speaking	293	200 (68)	150	88 (59)	444	289 (65)
Non-English speaking	36	27 (75)	7	4 (57)	44	32 (73)
p value		0.452		1.000		0.405
2012						
English speaking	266	186 (70)	117	75 (64)	384	261 (68)
Non-English speaking	35	28 (80)	9	7 (78)	44	35 (80)
p value		0.216		0.493		0.115
2013						
English speaking	253	163 (64)	129	87 (67)	389	253 (65)
Non-English speaking	45	35 (78)	9	7 (78)	54	42 (78)
p value		0.081		0.719		0.063

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Australia	180	105 (58)	99	51 (52)	281	158 (56)
Other Oceania	5	3 (60)	2	1 (50)	7	4 (57)
Asia	5	2 (40)	2	1 (50)	7	3 (43)
UK & Ireland	7	3 (43)	5	4 (80)	12	7 (58)
Other	14	6 (43)	6	3 (50)	20	9 (45)
p value		0.650		0.873		0.832
2010						
Australia	260	178 (68)	122	65 (53)	383	244 (64)
Other Oceania	8	7 (88)	1	0 (0)	9	7 (78)
Asia	5	3 (60)	1	1 (100)	6	4 (67)
UK & Ireland	11	6 (55)	2	2 (100)	13	8 (62)
Other	15	7 (47)	1	1 (100)	18	10 (56)
p value		0.242		0.179		0.855
2011						
Australia	283	198 (70)	148	87 (59)	431	287 (66)
Other Oceania	10	6 (60)	1	1 (100)	11	7 (64)
Asia	6	4 (67)	0	0 (0)	6	4 (67)
UK & Ireland	15	9 (60)	4	2 (50)	19	11 (58)
Other	17	11 (65)	5	3 (60)	22	14 (64)
p value		0.808		1.000		0.939
2012						
Australia	245	169 (69)	110	71 (65)	355	240 (67)
Other Oceania	9	6 (67)	4	2 (50)	13	8 (62)
Asia	13	13 (100)	1	1 (100)	14	14 (100)
UK & Ireland	15	11 (73)	5	4 (80)	20	15 (75)
Other	17	14 (82)	7	5 (71)	24	19 (79)
p value		0.090		0.881		0.042
2013						
Australia	235	154 (66)	120	82 (68)	355	239 (66)
Other Oceania	10	4 (40)	0	0 (0)	10	4 (40)
Asia	16	15 (94)	3	3 (100)	19	18 (95)
UK & Ireland	14	9 (64)	7	4 (57)	21	13 (62)
Other	22	15 (68)	8	5 (63)	30	20 (67)
p value		0.055		0.673		0.022

* Total includes people whose gender was not reported or reported as transgender

Western Australia

Table 9.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Demographic characteristics	2009	2010	2011	2012	2013
Number of sites	2	3	3	3	3
N° surveyed	N=222	N=219	N=192	N=186	N=220
Response (%)	80%	56%	77%	79%	77%
Gender (%)					
Male	134 (60)	127 (58)	114 (59)	121 (65)	135 (61)
Female	87 (39)	92 (42)	77 (40)	64 (34)	83 (38)
Transgender	1 (<1)	0 (0)	1 (<1)	1 (<1)	1 (<1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Sexual identity (%)					
Heterosexual	185 (83)	183 (84)	159 (83)	150 (81)	177 (80)
Bisexual	15 (7)	14 (6)	17 (9)	17 (9)	19 (9)
Homosexual	10 (5)	8 (4)	9 (5)	4 (2)	7 (3)
Not reported	12 (5)	14 (6)	7 (4)	15 (8)	17 (8)
Age and duration of injection (years)					
<i>Median age</i>	36	40	40	40	39
Age range	15-62	18-63	16-64	20-65	15-66
<i>Age group (%)</i>					
<25 years	16 (7)	8 (4)	8 (4)	4 (2)	13 (6)
25+ years	206 (93)	211 (96)	183 (95)	181 (97)	204 (93)
Not reported	0 (0)	0 (0)	1 (<1)	1 (<1)	3 (1)
<i>Median age 1st IDU</i>	18	18	19	19	19
Age range	11-52	11-50	11-47	10-53	12-50
Not reported	7	3	5	6	9
<i>Median years IDU</i>	16	18	18	19	17
Range	<1-44	<1-47	<1-45	<1-47	<1-49
<i>Duration of drug injection (%)</i>					
<3 years	9 (4)	11 (5)	6 (3)	4 (2)	18 (8)
3+ years	206 (93)	205 (94)	180 (94)	176 (95)	193 (88)
Not reported	7 (3)	3 (1)	6 (3)	6 (3)	0 (4)
Aboriginal and Torres Strait Islander origin (%)					
No	208 (94)	200 (91)	177 (92)	166 (89)	191 (87)
Yes	12 (5)	11 (5)	13 (7)	16 (9)	15 (7)
Not reported	2 (1)	8 (4)	2 (1)	4 (2)	14 (6)
Region/Country of birth (%)					
Australia	179 (81)	176 (80)	150 (78)	150 (95)	172 (78)
Other Oceania	8 (4)	13 (6)	11 (6)	12 (6)	10 (5)
Asia	5 (2)	3 (1)	3 (2)	1 (<1)	1 (<1)
UK & Ireland	18 (8)	16 (7)	19 (10)	14 (8)	19 (9)
Other	7 (3)	7 (3)	9 (5)	8 (4)	14 (6)
Not reported	5 (2)	4 (2)	0 (0)	1 (<1)	4 (2)
Main language spoken at home by parents (%)					
English speaking	216 (97)	208 (95)	186 (97)	176 (95)	205 (93)
Non-English speaking	5 (2)	7 (3)	6 (3)	9 (5)	11 (5)
Not reported	1 (<1)	4 (2)	0 (0)	1 (<1)	4 (2)
Imprisonment last year (%)					
No	193 (87)	160 (73)	162 (84)	159 (87)	178 (81)
Yes	21 (9)	16 (7)	16 (8)	20 (11)	17 (8)
Not reported	8 (4)	43 (20)	14 (7)	4 (2)	25 (11)
Injected in prison (%)	N=21	N=16	N=16	N=20	N=17
Yes	7 (33)	3 (19)	4 (25)	4 (20)	2 (12)
Frequency of injection last month (%)					
Not last month	6 (3)	11 (5)	11 (6)	8 (4)	19 (9)
Less than weekly	22 (10)	29 (13)	27 (14)	27 (15)	28 (13)
Weekly not daily	43 (19)	48 (22)	46 (24)	36 (19)	38 (17)
Daily or more	150 (68)	131 (60)	106 (55)	112 (60)	124 (56)
Not reported	1 (<1)	0 (0)	2 (1)	3 (2)	11 (5)

Table 9.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2009	2010	2011	2012	2013
Last drug injected (%)	N=222	N=219	N=192	N=186	N=220
Cocaine	2 (1)	0 (0)	1 (<1)	1 (<1)	3 (1)
Heroin	74 (33)	66 (30)	48 (25)	48 (26)	51 (23)
Methadone	12 (5)	13 (6)	12 (6)	6 (3)	10 (5)
Methamphetamine	43 (19)	58 (26)	65 (34)	59 (32)	79 (36)
Performance/Image-enhancing drugs	1 (<1)	1 (<1)	0 (0)	1 (<1)	5 (2)
Pharmaceutical opioids	37 (17)	31 (14)	34 (18)	28 (15)	28 (13)
Suboxone®	4 (2)	10 (5)	11 (6)	9 (5)	13 (6)
Subutex®/Buprenorphine	16 (7)	8 (4)	8 (4)	11 (6)	9 (4)
More than one	11 (5)	22 (10)	12 (6)	19 (10)	18 (8)
Other drug	18 (8)	14 (6)	0 (0)	1 (<1)	1 (<1)
Not reported	8 (4)	6 (3)	1 (<1)	3 (2)	3 (1)
N° Injected last month	N=215	N=208	N=179	N=175	N=190
Places injected last month (%)*					
Any public	105 (49)	88 (42)	75 (42)	61 (35)	95 (50)
All private	110 (51)	97 (47)	91 (51)	105 (60)	92 (48)
Not reported	0 (0)	23 (11)	13 (7)	9 (5)	3 (2)
Use of new sterile needles & syringes last month (%)					
All injections	148 (69)	131 (63)	126 (70)	118 (67)	128 (67)
Most of the time	56 (26)	47 (23)	33 (18)	34 (19)	50 (26)
Half of the time	4 (2)	5 (2)	2 (1)	5 (3)	3 (2)
Some of the time	3 (1)	2 (1)	6 (3)	6 (3)	4 (2)
Not last month	1 (<1)	0 (0)	0 (0)	1 (<1)	2 (1)
Not reported	3 (1)	23 (11)	12 (7)	11 (6)	3 (2)
Re-used another's used needle & syringe last month (%)					
None	168 (78)	151 (73)	131 (73)	128 (73)	148 (78)
Once	13 (6)	8 (4)	7 (4)	15 (9)	11 (6)
Twice	12 (6)	13 (6)	9 (5)	7 (4)	7 (4)
3-5 times	12 (6)	4 (2)	9 (5)	9 (5)	10 (5)
>5 times	6 (3)	4 (2)	9 (5)	6 (3)	8 (4)
Not reported	4 (2)	28 (13)	14 (8)	10 (6)	6 (3)
Number of people needle & syringe was re-used after last month (%)					
None	168 (78)	151 (73)	131 (73)	128 (73)	148 (78)
One	23 (11)	16 (8)	20 (11)	14 (8)	18 (9)
Two	5 (2)	4 (2)	1 (<1)	3 (2)	4 (2)
Three to five	1 (<1)	1 (<1)	2 (1)	1 (<1)	2 (1)
More than five	1 (<1)	1 (<1)	3 (2)	5 (3)	2 (1)
Don't know	6 (3)	5 (2)	4 (2)	5 (3)	6 (3)
Not reported	11 (5)	30 (14)	18 (10)	19 (11)	10 (5)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	18 (8)	21 (10)	19 (11)	10 (6)	17 (9)
Casual sex partner	0 (0)	2 (1)	2 (1)	1 (<1)	3 (2)
Close friend	13 (6)	11 (5)	8 (4)	13 (7)	11 (6)
Acquaintance	5 (2)	6 (3)	5 (3)	7 (4)	9 (5)
Other	5 (2)	3 (1)	5 (3)	3 (2)	7 (4)
Equipment used after someone else last month (%)*					
Spoon	48 (24)	36 (17)	42 (23)	39 (22)	49 (26)
Water	37 (19)	28 (13)	15 (8)	30 (17)	43 (23)
Filter	35 (18)	23 (11)	17 (10)	27 (15)	24 (13)
Drug mix	20 (10)	19 (9)	11 (6)	18 (10)	16 (8)
None	131 (66)	126 (61)	107 (60)	107 (61)	116 (61)
Injected by someone after that person injected themselves or others last month (%)					
No	172 (80)	160 (77)	140 (78)	135 (77)	143 (75)
Yes	39 (18)	23 (11)	140 (78)	26 (15)	35 (18)
Not reported	4 (2)	25 (12)	12 (7)	14 (8)	12 (6)
Present when someone injected for the first time in the last 12 months (%)**					
Yes	--	--	--	23 (13)	19 (10)
Overdosed in the last 12 months **					
Yes	--	--	--	--	25 (11)

* More than one option could be selected ** New question in 2012 or 2013

Table 9.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2009	2010	2011	2012	2013
N° surveyed	N=222	N=219	N=192	N=186	N=220
Sex with a regular partner last month (%)					
No	103 (46)	99 (45)	86 (45)	105 (56)	108 (49)
Yes	113 (51)	109 (50)	93 (48)	74 (40)	96 (44)
Not reported	6 (3)	11 (5)	13 (7)	7 (4)	16 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=113	N=109	N=93	N=74	N=96
Never	89 (79)	77 (71)	70 (75)	56 (76)	70 (73)
Sometimes	12 (11)	12 (11)	10 (11)	8 (11)	13 (14)
Every time	5 (4)	12 (11)	10 (11)	6 (8)	8 (8)
Not reported	7 (6)	8 (7)	3 (3)	4 (5)	5 (5)
Sex with other partner/s last month (%)					
No	180 (81)	187 (85)	163 (85)	147 (79)	159 (72)
Yes	32 (14)	22 (10)	24 (13)	28 (15)	39 (18)
Not reported	10(5)	10 (5)	5 (3)	11 (6)	22 (10)
Condom used with other partner/s last month (%)					
N° surveyed	N=32	N=22	N=24	N=28	N=39
Never	12 (38)	8 (36)	11 (46)	14 (50)	12 (31)
Sometimes	9 (28)	6 (27)	5 (21)	8 (29)	12 (31)
Every time	11 (34)	8 (36)	7 (29)	5 (18)	14 (36)
Not reported	0 (0)	0 (0)	1 (4)	1 (4)	1 (3)
Sex work last month (%)					
No	203 (91)	200 (91)	173 (90)	169 (91)	188 (85)
Yes	11 (5)	6 (3)	10 (5)	11 (6)	11 (5)
Not reported	8 (4)	13 (6)	9 (5)	6 (3)	21 (10)
Condom used at last sex work last month (%)					
Yes	8 (73)	5 (83)	8 (80)	8 (80)	9 (90)

Table 9.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Treatment for drug use	2009	2010	2011	2012	2013
N° surveyed	N=222	N=219	N=192	N=186	N=220
Any treatment/therapy for drug use (%)					
No	57 (26)	50 (23)	43 (22)	49 (26)	67 (30)
Yes	158 (71)	165 (75)	147 (77)	133 (72)	148 (67)
Not reported	7 (3)	4 (2)	2 (1)	4 (2)	5 (2)
History of methadone maintenance treatment (%)					
Currently	53 (24)	53 (25)	41 (21)	35 (19)	39 (18)
Previously	52 (23)	56 (26)	59 (31)	49 (26)	53 (24)
Never	112 (50)	97 (44)	84 (44)	101 (54)	125 (57)
Not reported	5 (2)	11 (5)	8 (4)	1 (<1)	3 (1)
History of buprenorphine (Subutex®) treatment (%)					
Currently	27 (12)	21 (10)	19 (10)	21 (11)	19 (9)
Previously	43 (19)	44 (20)	39 (20)	39 (21)	51 (23)
Never	149 (67)	152 (69)	124 (65)	125 (67)	144 (65)
Not reported	3 (1)	2 (1)	10 (5)	1 (<1)	6 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	25 (11)	25 (11)	32 (17)	23 (12)	23 (10)
Previously	28 (13)	30 (14)	25 (13)	23 (12)	37 (17)
Never	164 (74)	160 (73)	129 (67)	136 (73)	150 (68)
Not reported	5 (2)	4 (2)	6 (3)	4 (2)	10 (5)

Table 9.1.5 Number and (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year

HIV/HCV testing and HCV treatment	2009	2010	2011	2012	2013
N° surveyed	N=222	N=219	N=192	N=186	N=220
Previous HIV test (%)					
Yes, last year	111 (50)	113 (52)	104 (54)	81 (44)	95 (43)
> 1 year ago	78 (35)	60 (27)	63 (33)	67 (36)	72 (33)
Never tested	26 (12)	33 (15)	19 (10)	28 (15)	39 (18)
Not reported	7 (3)	13 (6)	6 (3)	10 (5)	14 (6)
Previous HCV test (%)					
Yes, last year	128 (58)	124 (57)	115 (60)	96 (52)	106 (48)
> 1 year ago	71 (32)	63 (29)	58 (30)	69 (37)	61 (28)
Never tested	15 (7)	13 (6)	8 (4)	10 (5)	25 (11)
Not reported	8 (4)	19 (9)	11 (6)	11 (6)	28 (13)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=92	N=120	N=106	N=93	N=95
Interferon/Interferon+Ribavirin	13 (14)	19 (16)	21 (20)	12 (8)	19 (20)
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	1 (1)
Other	1 (1)	2 (2)	3 (3)	2 (2)	1 (1)
No treatment	72 (78)	92 (77)	77 (73)	77 (83)	69 (73)
Not reported	6 (7)	7 (6)	5 (5)	2 (2)	5 (5)
Current treatment for HCV**	N=5	N=5	N=8	N=4	N=6
Interferon/Interferon+Ribavirin	5	4	6	2	6
Teleprevir/Boceprevir&INF-RBV*	--	--	--	--	0
Other	0	1	2	2	0

* New treatment options added ** 'Current treatment' defined as within the previous 12 months from 2013

Table 9.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2009	2010	2011	2012	2013
N° Injected last month	N=215	N=208	N=179	N=175	N=190
Needle Syringe Program	102 (47)	175 (84)	154 (86)	134 (77)	160 (84)
Chemist/Pharmacy	72 (33)	55 (26)	44 (25)	60 (34)	58 (31)
Personal sources	46 (21)	32 (15)	24 (13)	24 (14)	24 (13)
Dispensing/Vending Machine	0 (0)	1 (1)	4 (2)	3 (2)	2 (1)
Other sources	5 (2)	4 (2)	3 (2)	0 (0)	9 (5)

* More than one option could be selected

Table 9.1.7 Number (percentage) of respondents by last drug injected and all drugs injected in the last 12 months (2013)

	Drugs injected in last 12 months*								
	N° (%)	Cocaine	Heroin	Methadone	Methamphetamine	PIEDs	Pharm. Opioids	Subutex/Suboxone	No other drugs
Last drug injected									
Cocaine	3 (1)	3 (100)	0 (0)	0 (0)	1 (33)	0 (0)	0 (0)	0 (0)	2 (67)
Heroin	51 (23)	1 (2)	51 (100)	8 (16)	18 (35)	0 (0)	16 (31)	11 (22)	23 (45)
Methadone	10 (5)	0 (0)	2 (20)	10 (100)	6 (60)	0 (0)	2 (20)	3 (30)	3 (30)
Methamphetamine	79 (36)	4 (5)	20 (25)	6 (8)	79 (100)	2 (3)	15 (19)	19 (24)	42 (53)
PIEDs	5 (2)	0 (0)	0 (0)	0 (0)	0 (0)	5 (100)	0 (0)	0 (0)	0 (0)
Pharm. opioids	28 (13)	0 (0)	12 (43)	5 (18)	12 (43)	1 (4)	28 (100)	5 (18)	0 (0)
Subutex/Suboxone	22 (10)	0 (0)	9 (41)	2 (9)	14 (64)	0 (0)	6 (27)	22 (100)	7 (32)
Other/Not reported	22 (10)	1 (5)	12 (55)	5 (23)	17 (77)	1 (5)	12 (55)	12 (55)	4 (18)
Total	220	9 (4)	106 (48)	36 (16)	147 (67)	9 (4)	79 (36)	72 (33)	81 (37)

* More than one option could be selected

HIV antibody prevalence

Table 9.2.1 HIV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2009	126	1 (0.8)	85	1 (1.2)	212	2 (0.9)
2010	121	0 (0.0)	92	1 (1.1)	213	1 (0.5)
2011	112	1 (0.9)	77	3 (3.9)	190	4 (2.1)
2012	120	0 (0.0)	63	3 (4.8)	184	3 (1.6)
2013	126	3 (2.4)	71	2 (2.8)	199	5 (2.5)
X ² trend p value		0.210		0.214		0.108

* Total includes people whose gender was not reported or reported as transgender

Table 9.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heterosexual	110	2 (1.8)	49	2 (4.1)	159	4 (2.5)
Bisexual	4	1 (25.0)	15	0 (0.0)	19	1 (5.3)
Homosexual	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
p value		0.191		1.000		0.522

* Total includes people whose gender was not reported or reported as transgender

Table 9.2.3 HIV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
< 25 years	8	1 (12.5)	5	0 (0.0)	13	1 (7.7)
25 – 34	41	1 (2.4)	22	0 (0.0)	63	1 (1.6)
35+ years	75	1 (1.3)	44	2 (4.6)	120	3 (2.5)
p value		0.217		0.610		0.411

* Total includes people whose gender was not reported or reported as transgender

Table 9.2.4 HIV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
<3 years	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)
3 to 10 years	16	1 (6.3)	11	0 (0.0)	27	1 (3.7)
11 + years	97	2 (2.1)	51	2 (3.9)	149	4 (2.7)
p value		0.475		1.000		0.708

* Total includes people whose gender was not reported or reported as transgender

Table 9.2.5 HIV antibody prevalence by last drug injected, gender and survey year

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Heroin	35	1 (2.9)	14	2 (14.3)	49	3 (6.1)
Methamphetamine	35	2 (5.7)	34	0 (0.0)	70	2 (2.9)
Other	55	0 (0.0)	22	0 (0.0)	77	0 (0.0)
p value		0.172		0.038		0.048

* Total includes people whose gender was not reported or reported as transgender

Table 9.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Less than daily	33	1 (3.0)	25	1 (4.0)	58	2 (3.5)
Daily or more	78	2 (2.6)	37	1 (2.7)	115	3 (2.6)
Not last month	10	0 (0.0)	5	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		

* Total includes people whose gender was not reported or reported as transgender

Table 9.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No receptive sharing	89	3 (3.4)	45	2 (4.4)	314	5 (3.7)
Receptive sharing	18	0 (0.0)	16	0 (0.0)	34	0 (0.0)
p value		1.000		1.000		0.584

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 9.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No imprisonment	100	3 (3.0)	63	2 (3.2)	163	5 (3.1)
Imprisonment	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 9.2.9 HIV antibody prevalence by condom use at last sex, gender and survey year

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No condom use	29	0 (0.0)	33	0 (0.0)	62	0 (0.0)
Condom use	13	1 (7.7)	7	0 (0.0)	20	1 (5.0)
p value		0.310		---		0.244

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 9.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
No sex work	110	3 (2.7)	60	2 (3.3)	171	5 (2.9)
Sex work	4	0 (0.0)	6	0 (0.0)	10	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 9.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Non Indigenous	109	3 (2.8)	63	2 (3.2)	173	5 (2.9)
Indigenous	7	0 (0.0)	8	0 (0.0)	15	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 9.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
English speaking	117	2 (1.7)	66	2 (3.0)	184	4 (2.2)
Non-English speaking	6	1 (16.7)	5	0 (0.0)	11	1 (9.1)
p value		0.140		1.000		0.254

* Total includes people whose gender was not reported or reported as transgender

Table 9.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2013						
Australia	98	2 (2.0)	55	2 (3.6)	154	4 (2.6)
Other Oceania	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)
Asia	1	1 (100.0)	0	0 (0.0)	1	1 (100.0)
UK & Ireland	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)
Other	8	0 (0.0)	5	0 (0.0)	13	0 (0.0)
p value		0.068		1.000		0.072

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 9.3.1 HCV antibody prevalence by gender and survey year

Survey year	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009	125	60 (48)	85	42 (49)	211	102 (48)
2010	119	65 (55)	92	54 (59)	211	119 (56)
2011	110	69 (63)	73	34 (47)	184	104 (57)
2012	120	71 (59)	64	31 (48)	185	103 (56)
2013	123	66 (54)	71	23 (32)	196	90 (46)
X ² trend p value		0.260		0.014		0.637

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heterosexual	109	52 (48)	68	32 (47)	177	84 (47)
Bisexual	3	2 (67)	9	7 (78)	12	9 (75)
Homosexual	4	2 (50)	6	2 (17)	10	4 (40)
p value		0.851		0.143		0.162
2010						
Heterosexual	110	62 (56)	65	40 (62)	175	102 (58)
Bisexual	3	1 (33)	11	5 (45)	14	6 (43)
Homosexual	0	0 (0)	8	3 (38)	8	3 (38)
p value		0.583		0.316		0.316
2011						
Heterosexual	98	64 (65)	55	27 (49)	153	91 (59)
Bisexual	4	0 (0)	11	5 (45)	16	6 (38)
Homosexual	3	1 (33)	6	2 (33)	9	3 (33)
p value		0.006		0.845		0.090
2012						
Heterosexual	106	64 (60)	43	24 (56)	149	88 (59)
Bisexual	6	2 (33)	10	3 (30)	17	6 (35)
Homosexual	0	0 (0)	4	2 (50)	4	2 (50)
p value		0.226		0.329		0.151
2013						
Heterosexual	107	56 (52)	49	17 (35)	156	73 (47)
Bisexual	4	3 (75)	15	5 (33)	19	8 (42)
Homosexual	4	2 (50)	2	0 (0)	6	2 (33)
p value		0.857		0.890		0.832

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.3 HCV antibody prevalence by age group, gender and survey year

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
< 25 years	8	2 (25)	6	0 (0)	14	2 (14)
25 – 34	36	17 (47)	33	18 (55)	70	35 (50)
35+ years	81	41 (51)	46	24 (52)	127	65 (51)
p value		0.382		0.042		0.030
2010						
< 25 years	2	0 (0)	6	3 (50)	8	3 (38)
25 – 34	31	16 (52)	30	14 (47)	61	30 (49)
35+ years	86	49 (57)	56	37 (66)	142	86 (61)
p value		0.296		0.197		0.174
2011						
< 25 years	6	1 (17)	2	1 (50)	8	2 (25)
25 – 34	25	13 (52)	24	8 (33)	49	21 (43)
35+ years	78	54 (69)	47	25 (53)	126	80 (63)
p value		0.017		0.254		0.007
2012						
< 25 years	3	1 (33)	1	0 (0)	4	1 (25)
25 – 34	29	18 (62)	19	7 (37)	48	25 (52)
35+ years	88	52 (59)	43	23 (53)	132	76 (58)
p value		0.685		0.278		0.408
2013						
< 25 years	7	1 (14)	5	0 (0)	12	1 (8)
25 – 34	40	17 (43)	22	7 (32)	62	24 (39)
35+ years	74	47 (64)	44	16 (36)	119	64 (54)
p value		0.010		0.339		0.003

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.4 HCV antibody prevalence by duration of drug injection, gender and survey year

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
<3 years	4	0 (0)	5	1 (20)	9	1 (11)
3 to 10 years	20	6 (30)	22	7 (32)	42	13 (31)
11 + years	95	52 (55)	58	34 (59)	154	86 (56)
p value		0.018		0.040		0.001
2010						
<3 years	6	0 (0)	4	2 (50)	10	2 (20)
3 to 10 years	13	4 (31)	21	11 (52)	34	15 (44)
11 + years	98	60 (61)	66	40 (61)	164	100 (61)
p value		0.001		0.733		0.014
2011						
<3 years	2	0 (0)	4	3 (75)	6	3 (50)
3 to 10 years	19	6 (32)	15	7 (47)	34	13 (38)
11 + years	83	57 (69)	54	24 (44)	138	82 (59)
p value		0.002		0.588		0.073
2012						
<3 years	2	2 (100)	2	1 (50)	4	3 (75)
3 to 10 years	16	9 (56)	10	4 (40)	26	13 (50)
11 + years	98	59 (60)	50	24 (48)	149	84 (56)
p value		0.640		0.867		0.674
2013						
<3 years	7	0 (0)	7	1 (14)	14	1 (7)
3 to 10 years	14	6 (43)	11	1 (9)	25	7 (28)
11 + years	96	57 (59)	51	21 (41)	148	79 (53)
p value		0.004		0.072		0.000

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and survey year

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Heroin	1	1 (100)	70	38 (54)	71	39 (55)
All other opioids	4	0 (0)	60	36 (60)	65	36 (55)
Methamphetamine	3	0 (0)	36	7 (19)	41	7 (17)
Perform/Image-enhancing drugs	0	0 (0)	1	1 (100)	1	1 (100)
Other	1	0 (0)	26	15 (58)	27	15 (56)
p value		0.029		0.001		<0.001
2010						
Heroin	3	1 (33)	61	42 (69)	66	45 (68)
All other opioids	1	1 (100)	59	41 (69)	60	42 (70)
Methamphetamine	22	0 (0)	53	17 (32)	55	17 (31)
Perform/Image-enhancing drugs	1	0 (0)	0	0 (0)	1	0 (0)
Other	3	0 (0)	20	12 (60)	23	12 (52)
p value		0.212		0.041		<0.001
2011						
Heroin	2	2 (100)	42	26 (62)	46	30 (65)
All other opioids	2	1 (50)	59	37 (63)	63	40 (63)
Methamphetamine	2	0 (0)	57	23 (40)	61	25 (41)
Perform/Image-enhancing drugs	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	13	9 (69)	13	9 (69)
p value		0.135		0.041		0.023
2012						
Heroin	0	0 (0)	48	32 (67)	48	32 (67)
All other opioids	0	0 (0)	51	34 (67)	54	36 (67)
Methamphetamine	3	2 (67)	54	16 (30)	58	18 (31)
Perform/Image-enhancing drugs	0	0 (0)	1	0 (0)	1	0 (0)
Other	1	1 (100)	19	13 (68)	21	15 (71)
p value		0.505		<0.001		<0.001
2013						
Heroin	0	0 (0)	49	29 (59)	49	29 (59)
All other opioids	0	0 (0)	48	32 (67)	50	32 (64)
Methamphetamine	10	1 (10)	56	14 (25)	68	17 (25)
Perform/Image-enhancing drugs	3	0 (0)	2	0 (0)	5	0 (0)
Other	1	0 (0)	17	10 (59)	21	11 (52)
p value		0.806		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and survey year

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Less than daily	5	0 (0)	56	23 (41)	62	23 (37)
Daily or more	3	1 (33)	138	76 (55)	144	79 (55)
Not last month	1	0 (0)	2	0 (0)	4	0 (0)
p value						
2010						
Less than daily	4	1 (25)	80	46 (58)	84	47 (56)
Daily or more	5	1 (20)	110	67 (61)	117	70 (60)
Not last month	1	0 (0)	8	2 (25)	10	2 (20)
p value		1.000		0.147		0.051
2011						
Less than daily	2	1 (50)	68	36 (53)	70	37 (53)
Daily or more	4	2 (50)	94	55 (59)	102	61 (60)
Not last month	0	0 (0)	8	3 (38)	10	5 (50)
p value		1.000		0.453		0.639
2012						
Less than daily	2	1 (50)	60	30 (50)	63	32 (51)
Daily or more	2	2 (100)	106	64 (60)	111	68 (61)
Not last month	0	0 (0)	6	1 (17)	8	1 (13)
p value		1.000		0.074		0.018
2013						
Less than daily	8	0 (0)	48	23 (48)	56	23 (41)
Daily or more	3	0 (0)	107	56 (52)	114	59 (52)
Not last month	3	1 (33)	12	4 (33)	16	5 (31)
p value		0.429		0.461		0.181

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No receptive sharing	7	1 (14)	150	73 (49)	160	75 (47)
Receptive sharing	1	0 (0)	40	24 (60)	42	25 (60)
p value		1.000		0.218		0.167
2010						
No receptive sharing	9	2 (22)	136	78 (57)	147	82 (56)
Receptive sharing	0	0 (0)	28	18 (64)	28	18 (64)
p value		--		0.535		0.533
2011						
No receptive sharing	5	2 (40)	118	68 (58)	125	72 (58)
Receptive sharing	1	1 (100)	30	13 (43)	33	16 (48)
p value		1.000		0.218		0.431
2012						
No receptive sharing	4	3 (75)	121	64 (53)	127	69 (54)
Receptive sharing	0	0 (0)	36	24 (67)	37	24 (65)
p value		--		0.144		0.255
2013						
No receptive sharing	9	0 (0)	121	67 (55)	132	69 (52)
Receptive sharing	1	0 (0)	31	11 (35)	34	12 (35)
p value		--		0.048		0.077

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 9.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No imprisonment	9	1 (11)	172	82 (48)	185	85 (46)
Imprisonment	0	0 (0)	19	15 (79)	20	15 (75)
p value		---		0.014		0.018
2010						
No imprisonment	10	2 (20)	143	77 (54)	156	81 (52)
Imprisonment	0	0 (0)	15	11 (73)	15	11 (73)
p value		--		0.179		0.174
2011						
No imprisonment	3	2 (67)	146	79 (54)	154	86 (56)
Imprisonment	2	0 (0)	13	10 (77)	16	11 (69)
p value		0.400		0.148		0.429
2012						
No imprisonment	4	3 (75)	150	78 (52)	158	83 (53)
Imprisonment	0	0 (0)	19	16 (84)	20	16 (80)
p value		--		0.012		0.020
2013						
No imprisonment	12	1 (8)	143	69 (48)	161	71 (44)
Imprisonment	1	0 (0)	14	10 (71)	16	11 (69)
p value		1.000		0.160		0.059

* Total includes people who did not report duration of drug injection

Table 9.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and survey year

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
No sex work	9	1 (11)	178	90 (51)	193	93 (48)
Sex work	0	0 (0)	10	5 (50)	10	5 (50)
p value		---		1.000		1.000
2010						
No sex work	9	2 (22)	182	106 (58)	194	110 (57)
Sex work	1	0 (0)	5	3 (60)	6	3 (50)
p value		1.000		1.000		1.000
2011						
No sex work	6	3 (50)	156	84 (54)	166	91 (55)
Sex work	0	0 (0)	8	4 (50)	9	5 (56)
p value		--		1.000		1.000
2012						
No sex work	4	3 (75)	159	89 (56)	168	95 (57)
Sex work	0	0 (0)	10	7 (70)	11	7 (64)
p value		--		0.517		0.760
2013						
No sex work	10	0 (0)	152	77 (51)	169	79 (47)
Sex work	3	1 (33)	6	4 (67)	10	6 (60)
p value		0.231		0.682		0.521

* Total includes people who did not report duration of drug injection

Table 9.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Non Indigenous	122	57 (47)	78	39 (50)	201	96 (48)
Indigenous	1	1 (100)	7	3 (43)	8	4 (50)
p value		0.472		1.000		1.000
2010						
Non Indigenous	113	61 (54)	80	46 (58)	193	107 (55)
Indigenous	3	1 (33)	7	6 (86)	10	7 (70)
p value		0.597		0.234		0.518
2011						
Non Indigenous	101	64 (63)	68	33 (49)	170	98 (58)
Indigenous	7	4 (57)	5	1 (20)	12	5 (42)
p value		0.708		0.363		0.369
2012						
Non Indigenous	109	63 (58)	55	27 (49)	165	91 (55)
Indigenous	8	5 (63)	8	3 (38)	16	8 (50)
p value		1.000		0.710		0.795
2013						
Non Indigenous	106	59 (56)	63	22 (35)	170	82 (48)
Indigenous	7	2 (29)	8	1 (13)	15	3 (20)
p value		0.245		0.261		0.056

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
English speaking	120	55 (46)	85	42 (49)	205	97 (47)
Non-English speaking	4	4 (100)	0	0 (0)	5	4 (80)
p value		0.049		---		0.198
2010						
English speaking	111	58 (52)	89	51 (57)	200	109 (55)
Non-English speaking	6	5 (83)	1	1 (100)	7	6 (86)
p value		0.215		1.000		0.135
2011						
English speaking	105	65 (62)	72	34 (47)	178	100 (56)
Non-English speaking	5	4 (80)	1	0 (0)	6	4 (67)
p value		0.649		1.000		0.699
2012						
English speaking	113	69 (61)	61	28 (46)	175	98 (56)
Non-English speaking	7	2 (29)	2	2 (100)	9	4 (44)
p value		0.120		0.223		0.515
2013						
English speaking	114	62 (54)	66	22 (33)	181	85 (47)
Non-English speaking	6	2 (33)	5	1 (20)	11	3 (27)
p value		0.416		1.000		0.231

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.12 HCV antibody prevalence by region/country of birth, gender and survey year

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2009						
Australia	102	46 (45)	67	34 (51)	169	80 (47)
Other Oceania	3	1 (33)	5	3 (60)	8	4 (50)
Asia	4	3 (75)	0	0 (0)	5	3 (60)
UK & Ireland	9	7 (78)	9	2 (22)	18	9 (50)
Other	4	2 (50)	3	2 (67)	7	4 (57)
p value				0.364		0.972
2010						
Australia	95	52 (55)	74	43 (58)	169	95 (56)
Other Oceania	7	1 (14)	6	2 (33)	13	2 (23)
Asia	2	2 (100)	1	1 (100)	3	3 (100)
UK & Ireland	9	6 (67)	7	5 (71)	16	11 (69)
Other	4	2 (50)	2	1 (50)	6	3 (50)
p value		0.148		0.594		0.057
2011						
Australia	90	55 (61)	51	23 (45)	142	79 (56)
Other Oceania	4	3 (75)	7	5 (71)	11	8 (73)
Asia	2	2 (100)	1	1 (100)	3	3 (100)
UK & Ireland	11	7 (64)	8	4 (50)	19	11 (58)
Other	3	2 (67)	6	1 (17)	9	3 (33)
p value		0.945				0.287
2012						
Australia	99	60 (61)	50	22 (44)	150	83 (55)
Other Oceania	5	4 (80)	7	5 (71)	12	9 (75)
Asia	0	0 (0)	1	1 (100)	1	1 (100)
UK & Ireland	10	5 (50)	3	2 (67)	13	7 (54)
Other	5	2 (40)	3	1 (33)	8	3 (38)
p value		0.543		0.516		0.453
2013						
Australia	95	51 (54)	55	16 (29)	151	68 (45)
Other Oceania	4	2 (50)	5	3 (60)	9	5 (56)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	12	6 (50)	6	3 (50)	18	9 (50)
Other	8	5 (63)	5	1 (20)	13	6 (46)
p value		0.929		0.395		0.956

* Total includes people whose gender was not reported or reported as transgender

Participating NSP services

Year		'09	'10	'11	'12	'13
Number of NSP sites		51	52	52	52	50
Australian Capital Territory		1	1	1	1	1
Canberra	Directions ACT	✓	✓	✓	✓	✓
New South Wales		20	21	20	20	19
Albury	Albury Community Health Centre	✓	✓	✓	✓	✓
Ballina/Byron	Harm Reduction Services	✓	✓	✓	✓	✓
Blacktown	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Coffs Harbour/Grafton	Harm Reduction Services	✓	✓	✓	✓	✓
Canterbury	Resource and Education Program for IDUs	✓	✓			
Central Coast	Gosford, Long Jetty and Woy Woy Harm Reduction	✓	✓	✓	✓	✓
Liverpool	Health ConneXions	✓	✓	✓	✓	✓
Kings Cross	Clinic 180 (formerly K2)	✓	✓	✓	✓	✓
Kings Cross	Kirketon Road Centre	✓	✓	✓	✓	✓
Kogarah/Sutherland	Central Access Service	✓	✓	✓	✓	✓
Mt Drutt	Kelly Close Needle Syringe Program	✓	✓	✓	✓	✓
Murwillumbah/Tweed	Harm Reduction Services	✓	✓	✓	✓	✓
Nepean	South Court Primary Care NSP	✓	✓	✓	✓	
Newcastle	Hunter Harm Reduction Services	✓	✓	✓	✓	✓
Newcastle	AIDS Council of NSW Hunter	✓	✓	✓	✓	✓
Nimbin/Lismore	Harm Reduction Services	✓	✓	✓	✓	✓
Parramatta	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Illawarra	First Step Program, SEIAHS (Port Kembla and Nowra)	✓	✓	✓	✓	✓
Redfern	Resource and Education Program for IDU	✓	✓	✓	✓	✓
Surry Hills	NSW Users and AIDS Association	✓	✓	✓	✓	✓
Wagga Wagga	Wagga Wagga Community Health Centre		✓	✓	✓	✓
Northern Territory		3	3	3	3	3
Alice Springs	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Darwin	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Palmerston	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Queensland		8	8	8	8	8
Brisbane	Biala Community Alcohol and Drug Services	✓	✓	✓	✓	✓
Brisbane	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Cairns	Cairns ATODS NSP	✓	✓	✓	✓	✓
Gold Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Ipswich	West Moreton Sexual Health Service	✓	✓	✓	✓	✓
Sunshine Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Toowoomba	Kobi House	✓	✓	✓	✓	✓
Townsville	Townsville ATODS NSP	✓	✓	✓	✓	✓

Year		'09	'10	'11	'12	'13
Number of NSP sites		51	52	52	52	50
South Australia		7	7	7	7	7
Adelaide	Nunkuwarrin Yunti Community Health Centre	✓	✓	✓	✓	✓
Adelaide	Streetlink Youth Health					✓
Angle Park	SAVIVE - Central Northern Adelaide Health Service	✓	✓	✓	✓	✓
Hindmarsh	Hindmarsh Centre	✓	✓	✓	✓	✓
Keswick	SAVIVE, Clean Needle Program	✓	✓	✓	✓	
Noarlunga	Noarlunga Primary Health	✓	✓	✓	✓	✓
Port Adelaide	SAVIVE, Central Northern Adelaide Health Service	✓	✓	✓	✓	✓
Salisbury	SAVIVE, Shopfront Youth Health Service	✓	✓	✓	✓	✓
Tasmania		4	4	4	4	3
Clarence	Clarence Community Health Centre	✓	✓	✓	✓	✓
Glenorchy	Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart	Hobart NSP Service	✓	✓	✓	✓	
Launceston	Salvation Army Launceston	✓	✓	✓	✓	✓
Victoria		6	5	6	6	6
Barwon	Barwon Health Drug and Alcohol Services	✓	✓	✓	✓	✓
Collingwood	InnerSpace NSP	✓	✓	✓	✓	✓
Footscray	Health Works			✓	✓	✓
Frankston	Southern Hepatitis/HIV/AIDS Resource & Prevention Service	✓	✓	✓	✓	✓
North Richmond	North Richmond NSP Services	✓	✓	✓	✓	✓
Northcote	Northcote NSP Services	✓				
St Kilda	Health Information Exchange	✓	✓	✓	✓	✓
Western Australia		2	3	3	3	3
South West Coast	Western Australia Substance Users Association (WASUA)		✓	✓	✓	✓
Northbridge	Western Australia Substance Users Association (WASUA)	✓	✓	✓	✓	✓
Perth	WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

Methodological notes

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using the Murex 1.2.0 ELISA (Diasorin). Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France). A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 2 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Data presented in this report were analysed using Stata, Version 12 (Stata Corporation, College Station TX). Changes in HIV and HCV antibody prevalence overtime were assessed using the X^2 test for linear trend. Associations between demographic and behavioural variables and HIV and HCV antibody prevalence were assessed using the X^2 test or Fisher's exact test where expected frequencies were less than five.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as transgender. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection.

Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5. Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. The vast majority of survey questions were consistent over all survey years. In 2012, one new core question was added to the questionnaire and this will be included in future surveys ("In the last 12 months, have you been present when someone injected for the first time?").

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to assess response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator. Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. Verbal rather than written informed consent was obtained to assure the anonymity of participants.

List of Tables

1. Demographic characteristics and drug use

Table 1.1.1	Number (%) of respondents by demographic characteristics and survey year
Table 1.1.2	Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey
Table 1.1.3	Number (%) of respondents by sexual behaviour in the month prior to survey and year of survey
Table 1.1.4	Number (%) of respondents by treatment for drug use and survey year
Table 1.1.5	Number (%) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by survey year
Table 1.1.6	Number (%) of respondents by source of needle and syringe acquisition in the last month
Table 1.1.7	Number (%) of respondents by last drug injected and all drugs injected in the last 12 months (2013)

2. HIV prevalence

Table 1.2.1	HIV antibody prevalence by gender and survey year
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and survey year
Table 1.2.3	HIV antibody prevalence by age group, gender and survey year
Table 1.2.4	HIV antibody prevalence by duration of drug injection, gender and survey year
Table 1.2.5	HIV antibody prevalence by last drug injected, gender and survey year
Table 1.2.6	HIV antibody prevalence by frequency of drug injection last month, gender and survey year
Table 1.2.7	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and survey year
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and survey year
Table 1.2.11	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.2.12	HIV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.2.13	HIV antibody prevalence by region/country of birth, gender and survey year

3. Hepatitis C prevalence

Table 1.3.1	HCV antibody prevalence by gender and survey year
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and survey year
Table 1.3.3	HCV antibody prevalence by age group, gender and survey year
Table 1.3.4	HCV antibody prevalence by duration of drug injection, gender and survey year
Table 1.3.5	HCV antibody prevalence by last drug injected, duration of drug injection and survey year
Table 1.3.6	HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year
Table 1.3.7	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year
Table 1.3.8	HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year
Table 1.3.9	HCV antibody prevalence by sex work last month, duration of drug injection and survey year
Table 1.3.10	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.3.11	HCV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.3.12	HCV antibody prevalence by region/country of birth, gender and survey year

Directions ACT, Canberra. Albury Community Health Centre. Wagga Wagga Community Health Centre. Harm Reduction Services Ballina/Byron, Nimbin/Lismore, Murwillumbah/Tweed Coffs Harbour/Grafton. HIV/Hepatitis C Prevention Services, Blacktown, Parramatta, Mt Drutt. South Court Primary Care NSP, Nepean. Resource and Education Program for IDUs (REPIDU), Redfern. Gosford Needle and Syringe Program. Long Jetty Needle and Syringe Program. Health ConneXions, Liverpool. Kirketon Road Centre, K2, Kings Cross. St George NSP, Hunter Harm Reduction Services, ACON Hunter. First Step Program Illawarra, Nowra. NSW Users and AIDS Association (NUAA). Northern Territory AIDS Council, Alice Springs, Darwin, Palmerston. Biala Community Alcohol and Drug Services, Townsville ATODS. QUIHN Brisbane, Gold Coast, Sunshine Coast. West Moreton Sexual Health Service, Ipswich. Cairns Base Hospital, Kobi House, Toowoomba. SAVIVE, Norwood, Parks, Port Adelaide, Northern Metropolitan, Shopfront. Hindmarsh Centre. Nunkuwarrin Yunti Community Health Centre, Noarlunga Community Health Centre. Clarence Community Health Centre, Anglicare Hobart, Glenorchy. Salvation Army Launceston. Barwon Health Drug and Alcohol Services. Bendigo NSP. InnerSpace, Collingwood. Health Works, Gray. North Richmond NSP Services. Health Information Exchange, St Kilda. Western Australia Substance Users Association (WASUA), Northbridge, South West Coast. WA AIDS Council Mobile NSP Directions ACT, Canberra. Albury Community Health Centre. Wagga Wagga Community Health Centre. Harm Reduction Services Ballina/Byron, Nimbin/Lismore, Murwillumbah/Tweed Coffs Harbour/Grafton. HIV/Hepatitis C Prevention Services, Blacktown, Parramatta, Mt Drutt. South Court Primary Care NSP, Nepean. Resource and Education Program for IDUs (REPIDU), Redfern. Gosford Needle and Syringe Program. Long Jetty Needle and Syringe Program. Health ConneXions, Liverpool. Kirketon Road Centre, K2, Kings Cross. St George NSP, Hunter Harm Reduction Services, ACON Hunter. First Step Program Illawarra, Nowra. NSW Users and AIDS Association (NUAA). Northern Territory AIDS Council, Alice Springs, Darwin, Palmerston. Biala Community Alcohol and Drug Services, Townsville ATODS. QUIHN Brisbane, Gold Coast, Sunshine Coast. West Moreton Sexual Health Service, Ipswich. Cairns Base Hospital, Kobi House, Toowoomba. SAVIVE, Norwood, Parks, Port Adelaide, Northern Metropolitan, Shopfront. Hindmarsh Centre. Nunkuwarrin Yunti Community Health Centre, Noarlunga Community Health Centre. Clarence Community Health Centre, Anglicare Hobart, Glenorchy. Salvation Army Launceston. Barwon Health Drug and Alcohol Services. Bendigo NSP. InnerSpace,